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Abstract 
 
Ovarian cancer (OC) accounts for 4% of all cancer cases and 4.2% of all cancer deaths 
worldwide. OC is the most lethal gynecological cancer because it lacks early disease symptoms 
and does not have a specific diagnostic marker. As a result, more than 70% of OC patients are 
diagnosed in later stages when the disease has already metastasized and the 5-year survival rate 
has decreased to less than 20% compared with approximately 90% survival for women diagnosed 
with early stage disease. Therefore, I initiated my studies with a computational analysis of the 27 
most commonly reported literature-derived ovarian cancer (LDOC) protein biomarkers. I found 
that LDOC protein biomarkers share many biochemical features including a preponderance for a 
stable protein structure, the ability to be secreted, and functionality related to extracellular matrix 
(ECM) modification, immune response and/or energy production. Subsequently, I analyzed the 
human proteome to identify proteins that also share these biochemical features. Of the 70,616 
proteins in the human proteome, 683 proteins were found to have similar biochemical features to 
the 27 LDOC proteins. I also identified a subset of 21 potential additional protein regulators of 
ovarian cancer (APROC) that interact with LDOCs. Three of the APROCs identified were amylase 
proteins AMY1A, AMY2A, and AMY2B which cleaves alpha 1, 4-glycosidic bonds in 
polysaccharides. Amylase is reportedly overexpressed in and secreted by ovarian tumors but its 
functional contribution to OC remains unknown[1]. In this thesis, I posit that amylase contributes 
xiv 
  
to OC invasion. I initiated my studies by computational characterizing the different amylase 
isozymes to predict which amylase isozyme(s) is most likely overexpressed in and contributory to 
OC invasion. I found that AMY1 and AMY2B have unique regions of disorder and unique 
phosphorylation sites indicating that AMY1 and AMY2B would be more likely to interact with 
other proteins, and to be easily secreted. Using OC patient serum samples, I was able to validate 
AMY1 and AMY2B overexpression by western immunoblotting.  
I then developed an in vitro model system to study the molecular contribution of amylase 
to OC invasion using normal ovarian surface epithelial (IOSE) and OC cell lines. I showed that 
OC cells generally overexpress and secrete metabolically active amylase isozymes AMY1 and 
AMY2B. Abrogating amylase activity using siRNA silencing technology decreased the capacity 
of OC cells to invade collagen coated Boyden chambers and increased sulfated 
glycosaminoglycans (sGAG) production. Since a survey of OC cell lines indicated that cancer cells 
have a bulkier glycocalyx compared to IOSE cells and immunogold labeling studies indicated the 
presence of amylase within the immediate OC microenvironment, my data suggest that, by 
cleaving alpha 1, 4-glycosidic bonds in glycoconjugates present within ECM, amylase may 
remodel the ECM to promote an invasive cancer phenotype. Amylase is therefore a target for 
therapeutic intervention in OC patients with hyperamylasemia. I established Spirulina, a dietary 
supplement, as a novel transcriptional inhibitor of amylase. Spirulina inhibited amylase expression 
in OC cell lines at both the message and protein levels. Spirulina reduced OC cell invasion and 
migration in vitro, putatively by decreasing amylase expression.  
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Chapter 1 
Overview of Ovarian Cancer Biomarkers  
 
Ovarian Cancer 
Ovarian cancer (OC) is the 5th leading cause of cancer death in women in the US after lung, 
bronchial, breast, colorectal, and pancreatic cancers [2]. OC represents the most lethal 
gynecological cancer [3].  Approximately 22,000 new cases are diagnosed each year and 
approximately 14,000 women die from OC each year [2]. While the causes of OC remain 
unknown, risk factors for OC include Caucasian race, age, increased number of ovulatory cycles 
associated with early menarche, late menopause, nulliparity [4], family history of breast and/or 
ovarian cancer, and BReast CAncer genes 1 and 2 (BRCA1/2) mutations [5–7].  
A precursor of epithelial OC has not been identified [8,9] and the site of origin of OC remains 
unknown [10]. OC is thought to arise from the ovarian surface epithelium [11,12], a specialized 
mesothelial layer of cells derived from the coelomic epithelium [10] that covers and protects the 
ovary [13]. The coelomic epithelium also gives rise to the epithelia of the peritoneum, the fallopian 
tubes (FTs) and the uterus and expresses mesenchymal markers Vimentin and N-Cadherin [14]. 
Further, the common embryonic origin of the epithelia lining the majority of the female 
reproductive tract is reflected in histologic subtypes of OC [15] such that serous, mucinous and 
endometrioid OCs histologically mimic the epithelium lining the FT, cervix and uterus, 
respectively [16]. Recent studies suggest the FT is an alternate source of OC [10], because serous 
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carcinoma, the most frequent OC subtype, resembles the FT [17]. High grade serous OCs account 
for much of the mortality associated with OC due to their aggressive phenotype evidenced by 
disease relapse following initial treatment and emergence of drug-resistant disease. [18–20]. 
Lastly, some OC may arise from extra-ovarian origins, i.e. clear cell OC mimics renal clear cell 
carcinoma and mucinous OC bears a resemblance to the gastrointestinal tract [20,21]. 
Symptoms of OC are generally vague and unspecific; symptoms include bloating, pelvic 
discomfort, gas pains and a change in urinary frequency. OC symptoms appear during early disease 
stages, but the symptoms are usually mistaken for benign intestinal, musculoskeletal, or 
gynecologic conditions. Eighty-nine percent of OC patients experience symptoms during the first 
stages of disease and 97% of OC patients experience symptoms in the later stages of disease. 
Unfortunately, the non-specific nature of symptoms and a lack of a specific screening test results 
in OC generally being diagnosed when it has already metastasized [5]. 
Current modalities for the detection of OC include pelvic examination, transvaginal ultrasound, 
transabdominal ultrasound, and serum CA125 levels (see below). Other imaging methods include 
computed tomography, magnetic resonance imaging, and positron emission tomography. 
However, none of these modalities is sufficiently sensitive or specific to identify OC, especially 
in early stage disease when the 5-year survival rate can be as high as 90% [4,22]. As a result, the 
5-year survival for OC patients diagnosed at late stages is generally no better than 30% [23]. 
Consequently, identifying new screening and detection methods as well as further elucidating the 
etiology of OC remains imperative to improving OC patient survival [24]. 
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Literature-derived OC protein biomarkers 
A number of OC biomarkers has been reported to date and include biomarkers found elevated  
in the serum, urine and/or tissues of OC patients [25]. These biomarkers may have not only 
diagnostic and prognostic clinical value as indicators of survival time, drug resistance and 
recurrent disease, but also serve as possible therapeutic targets. OC biomarkers have been 
associated with molecular and cellular processes that include inflammation, cellular movement, 
proliferation and cell death. Many OC biomarkers also play a role in cancer development by 
regulating metastasis, angiogenesis, immune responses, cell cycle regulation and inflammation 
[26].  
In order to identify the most prominent protein biomarkers associated with OC, a review of the 
literature was carried out and monomer protein OC biomarkers with more than 100 publications 
in Pubmed or proteins explored by the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening 
trial and/or the National Academy of Clinical Biochemistry (NACB) due to their potential 
diagnostic and prognostic utility were selected for further review by computational analyses. The 
resulting set of 27 biomarkers identified are typically overexpressed in OC patient serum and tissue 
and are associated with poor clinical outcome (Table 1). These biomarkers fell within the following 
categories:  
(1) Cytokines and growth factors: interleukin-6 (IL-6), interleukin-8 (IL-8/ CXCL8), interleukin-
10 (IL-10), prolactin (PRL), transforming growth factor beta 1 (TGF-β1), tumor necrosis factor 
alpha (TNFα) and vascular endothelial growth factor (VEGF);  
(2) Structural and Extracellular matrix (ECM) related proteins: claudin 3,4 (CLDN3,4), 
collagen1A1, 11A1 (COL1A1 and COL11A1), human plasminogen activator inhibitor-1 
(SERPINE1), kallikreins-10, -11 (KLK-10, -11), metalloproteinase-2, -9 (MMP-2, -9), mucin 1 
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(MUC1), mucin 4 (MUC4), mucin 16 (MUC16), osteopontin (SPP1) and phosphoprotein 1 
(STIP1); 
(3) Metabolic regulators: apolipoprotein E (ApoE) and fatty acid synthase (FASN);  
(4) Receptors: folate receptor-α (FOLR1); 
(5) Proteins of unknown functions in cancer: human epididymis protein 4 (WFDC2/HE4), 
mesothelin (MSLN), and tumor stress-induced prostasin (PRSS8). 
Table 1.1: Functional and clinical characteristics of OC biomarkers 
Protein 
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Cytokines and growth factors 
IL-6              [27–34] 
IL-8              [35–37] 
IL-10              [30,38,39] 
PRL              [40–44] 
TGF-β1              [30,45–48] 
TNFα              [49–53] 
VEGF              [54–57] 
Adhesion proteins/proteases/ receptors 
CLDN3              [58–66] 
CLDN4              [58–66] 
COL1A1              [67–69] 
COL11A1              [69–71] 
FOLR1              [72] 
 SERPINE
1 
             [73–76] 
KLK10              [77–91] 
 KLK11              [77–91] 
MMP2              [92–95] 
MMP9              [92–95] 
MUC1              [96–98] 
MUC4              [99–101] 
MUC16              [102–104] 
SPP1              [87,105–109] 
STIP1              [110–117] 
Metabolic Regulators 
ApoE              [89,118] 
 FASN              [119–126] 
Proteins of unknown function 
WFDC2              [87,127,128] 
MSLN              [129–132] 
PRSS8              [133] 
Grey shading indicates notable protein expression or reported clinical outcome. 
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Herein follows a brief review of these 27 proteins describing their diagnostic, prognostic, 
and clinical use as well as their potential contribution and function in the etiology of OC.  
Cytokines and growth factors 
While both cytokines and growth factors regulate the immune response, cytokines are small 
polypeptides secreted from cells that stimulate proliferation, survival and differentiation of other 
cells through cytokine receptors. Chemokines, a subtype of cytokines, attract cells to sites of 
inflammation, thereby influencing cell migration. Cytokines overexpressed in OC enhance cancer 
progression through increased cell survival, migration and chemoresistance [134].  
Interleukin-6 (IL-6) 
IL-6 is predominately a pro-inflammatory cytokine secreted by T-cells and macrophages to 
stimulate the immune response [135]. However, in cancer cells, IL-6 may also promote metastasis 
through down-regulation of E-cadherin, thereby inducing epithelial-mesenchymal transition 
(EMT) [136]. IL-6 overexpression in OC cells results in an upregulation of anti-apoptotic 
regulators and matrix metalloproteinase-9 leading to increased cancer cell proliferation and 
invasion, respectively [31,34]. Elevated serum IL-6 is also associated with higher OC stage and 
reduced chemotherapeutic responsiveness [32,33]. 
Interleukin-8 (IL-8) 
IL-8 is a chemokine produced by macrophages, endothelial cells and a number of epithelial 
cells [137]. IL-8 overexpression increases OC cell proliferation [35] by activating the PI3K/Akt 
and Raf/MEK/ERK pathways and altering cell cycle regulating proteins. In addition, IL-8 
overexpression appears to enhance OC invasion through an upregulation of matrix 
metalloproteinase (MMP2/9 – see below) expression and activity [36]. 
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Interleukin-10 (IL-10) 
IL-10 is an anti-inflammatory cytokine that mediates the immune response through signal 
transducer and activator of transcription 3 (STAT3) signaling [138] and effectively inhibits 
bacterial-mediated induction of pro-inflammatory cytokines [139,140]. IL-10 levels are elevated 
in the serum and ascites fluid of OC patients where it is thought to serve as a useful prognostic 
biomarker indicative of disease recurrence [30,39] and worse overall survival [38] by diminishing 
the immune response in OC patients.   
Prolactin (PRL) 
Secreted by the pituitary, PRL is best known for its role to stimulate milk production [141]. 
However, specific PRL isoforms secreted by monocytes have been shown to enhance the 
inflammatory response [142]. Further, by promoting endothelial cell migration and angiogenesis 
via enhanced ERK1/2 and STAT5 signaling as well as enhancing breast cancer cell migration 
through modulation of the actin cytoskeleton, PRL is believed to promote breast cancer 
progression [40,41]. Prolactin is a circulating cytokine/hormone secreted by ovarian follicular cells 
[42]. PRL is significantly elevated in OC patient serum [43] where it is believed that increased 
PRL expression increases OC PRL receptor expression leading to enhanced OC proliferation via 
activation of the MAPK/ERK1 pathway [42]. Further, PRL acts as a tumorigenic agent by 
activating Ras in normal ovarian epithelial cells while also protecting these cells from apoptosis 
following chemotherapeutic treatment [42]. Lastly, PRL overexpression can enhance OC 
migration via reduction of E-cadherin expression [44].  
Transforming growth factor beta 1 (TGF-β1) 
TGF-β1, a member of the transforming growth factor beta family, is a highly pleiotropic 
cytokine involved in cell growth, proliferation, differentiation and apoptosis through Mothers 
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against decapentaplegic homolog 3 (SMAD3) signaling in OC [143–145]. TGF-β1 promotes 
tumor cell-mediated ECM remodeling. TGF-β1 increases proteinase and plasmin expression by 
tumor cells which creates a positive regulatory feedback loop that increases TGF-β1 activation and 
release with subsequent ECM degradation. TGF-β1 expression also upregulates MMP expression 
leading to increased ECM remodeling [146]. Elevated TGF-β1 serum levels parallel OC stage and 
correlate with metastatic disease [30]. Likewise, OC patients with drug resistant disease also 
demonstrate elevated serum TGF-β1 [45] so that OC patients with TGF-β1 overexpression have 
poor prognosis [46]. Overexpressed TGF-β1 stimulates tumor growth and angiogenesis in 
xenograft OC models [47] and OC metastasis through MMP-2 activation [48]. 
Tumor necrosis factor alpha (TNFα) 
TNFα is typically produced by macrophages and lymphocytes to control immune cells during 
the immune response [137]. However, TNFα is a multifunctional cytokine mediating diverse 
cellular effects including apoptosis, angiogenesis and cell migration [50,51]. Consequently, TNFα 
has been implicated in both anti- and pro-tumorigenic roles [147]. TNFα is overexpressed in OC 
tissue [49]. Since TNFα overexpression modulates the expression of other cytokines, including IL-
6 and IL-8, TNFα may mediate inflammatory stimuli that contribute to OC tumorigenesis [52]. 
TNFα can also act as an endogenous tumor promoter contributing to cellular transformation, 
invasion, dissemination and angiogenesis in OC [50,53].   
Vascular endothelial growth factor (VEGF)  
The VEGF family consists of endothelial cell mitogens that enhance endothelial cell growth 
and migration following binding to cell surface receptors that trigger activation of receptor tyrosine 
kinases [148]. Secreted VEGF recruits and promotes progenitor endothelial cell growth and 
migration that create leaky and permeable cancer vasculature for nutrient transportation and waste 
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removal necessary to the survival, proliferation, invasion and metastasis of cancer cells. VEGF 
also acts as an anti-apoptotic factor for recruited endothelial cells [54]. VEGF released by and 
sequestered in the ECM can be activated by extracellular cleavage by MMPs. Active VEGF then 
binds to ECM collagens and proteoglycans in the ECM that then remodel the ECM to enhance 
vascular branching and capillary density [149]. Overexpression of VEGF in OC tissue and patient 
serum is associated with poor overall survival and can be indicative of tumor recurrence [55]. 
Serum VEGF levels have been used to predict patients’ response to anti-angiogenic treatment [56]. 
VEGF levels in the ovarian cyst fluids are elevated in malignant OC tumors compared with benign 
or borderline cysts and tumors and inhibiting VEGF expression can lead to suppression of tumor 
growth [57].  
Structural and extracellular matrix (ECM) related proteins 
Transmembrane proteins 
Claudin-3 and -4  
Claudins (20-27 kDa), a family of transmembrane proteins, play a central role in tight junction 
formation, thereby maintaining epithelial integrity  [58]. Both claudin-3 and claudin-4 have been 
reported to be overexpressed in OC cells [58–65] and associated with increased cancer cell 
survival, invasion and motility which may be mediated, in part, through increased MMP-2 activity 
(see below). Claudins also play a role in drug resistance since claudin-4 is overexpressed in 
cisplatin-resistant OC cells [66]. Claudin-3 and claudin-4 also act as specific receptors of 
Clostridium perfringens enterotoxin (CPE) by mediating endotoxin-dependent cell lysis 
[150,151]. Treatment of xenograft ovarian tumors with CPE-based therapies results in inhibited 
tumor growth suggesting that claudin-3 and claudin-4 may serve as potential targets for therapeutic 
intervention in OC [89,152].  
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Mucin 1 (MUC1)  
MUC1, also known as CA15-3, is a highly glycosylated transmembrane glycoprotein that 
facilitates invasion, metastasis, immune system evasion, drug resistance, and survival via the ErbB 
and β-catenin-Wnt pathways [96–98]. MUC1 is overexpressed on OC cell surfaces and in OC 
patient serum. Compared with normal cells, MUC1 expressed by cancer cells is structurally 
different – it is attached to shorter and less dense O-glycan moieties, thereby unmasking novel 
protein core epitopes that can be exploited to create antibodies differentiating between normal and 
diseased cells. MUC1 is overexpressed in over 90% of OC, but only 5% of normal ovarian tissue.  
Mucin 4 (MUC4) 
MUC4 is a highly glycosylated glycoprotein that lubricates epithelial cell surfaces. MUC4 is 
also a signal modulator that can alter tumor phenotype by reorganizing actin indirectly by HER2-
mediated pathways [153]. MUC4 expression was reported to be upregulated in 100% and 88% of 
early (stage I and II) and advanced (stage III and IV) OC samples, respectively – with an overall 
incidence of 92% in OC samples. Though MUC4 plays a diagnostic role, there is no prognostic 
correlation of MUC4 expression with prolonged patient survival [99]. OC cells in effusions have 
higher MUC4 expression when compared with solid OC primary tumors and metastases [100]. 
MUC4-expressing OC cells demonstrate an enhanced motility due to the formation of 
lamellipodia, filopodia and microspikes [101]. 
Mucin 16 (CA125) 
Mucin16, a transmembrane mucin known as CA125, is a widely used serum marker of OC 
[102]. However, CA125 can be elevated in benign conditions, including menstruation, 
endometriosis and pregnancy as well as in malignancies of the liver, lung, bladder and pancreas 
contributing to false positive results. In healthy adults, CA125 can be expressed in coelomic and 
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Mullerian epithelium, as well as the pancreas, colon, gall bladder, lung, kidney, and stomach 
epithelia. While CA125 values below 35U/L are considered normal, CA125 is only elevated in 
50% of stage I OC patients leading to many false negative results. CA125 is elevated in 75-90% 
of advanced stage ovarian disease and CA125 is elevated in approximately 80% of epithelial OCs. 
[103,104]. CA125 plays a role in OC peritoneal metastasis by interacting with mesothelin. CA125 
also plays an immunosuppressive role in OC by inhibiting natural killer cells’ cytotoxic responses 
[98].  
Structural and matrix-related proteins 
Collagen (COL1A1 and COL11A1)  
Collagens are abundant fibrous proteins found in the ECM. Collagen I (COL1A1) is the most 
abundant structural constituent of the ECM of OC and has been shown to enhance OC adhesion 
and proliferation by interacting with integrin receptors α3β1 and α6β1 that then activate the Ras, 
Erk and Akt pathways in OC cell lines [154]. Collagen XI (COL11A1), which is absent in most 
tissues, is overexpressed in OC ECM and OC patient serum potentially serving as one of the 
earliest indications of cancer initiation and progression [67,69]. COL11A1 overexpression, as 
triggered by TGF-β1 activation and SMAD2 signaling, promotes MMP3 activation in OC [68]. 
COL11A1 overexpression enhances OC migration and invasion [70]. The overexpression of 
collagen by OC also serves to reduce chemotherapeutic drug efficacy by inhibiting drug 
penetration/access to OC cells, therefore, contributing to drug resistance and OC tissue survival 
[71]. 
Human plasminogen activator inhibitor-1 (PAI-1) 
PAI-1, also known as SERPINE1, is a serine protease inhibitor that plays a role in tissue 
remodeling [75]. Inactive plasminogen is converted to broad spectrum serine protease plasmin by 
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urinary (uPA) or tissue-type (tPA) plasminogen activators (PAs) which then cleave ECM 
components such as fibronectin, laminin, vitronectin, proteoglycans, and fibrins. PAs are regulated 
by plasminogen activator inhibitors (PAI) which curb plasmin generation [155]. PAIs prevent the 
cleavage of plasminogen by binding to the active site of PA [156]. PAI is overexpressed in OC 
patient serum [73] and tissue [74]. PAI-1 overexpression is associated with proliferation and PAI-
1 inhibitors can act as anticancer agents. PAI-1 expression is associated with poor prognosis [75] 
and lower overall survival [73]. Overexpressed PAI-1 has been correlated with higher grade OC 
tumors and a higher probability of disease recurrence [76].  
Kallikrein (KLK-10, -11) 
Kallikriens (KLKs) comprise a family of 15 secreted serine proteases that are dependent upon 
a serine in their catalytic site. Secreted into the tumor microenvironment, KLKs, which are thought 
to be stimulated by a steroid hormone–driven cascade [84], are involved in tissue remodeling and 
neoplastic disease progression [77–79] by promoting ECM degradation, cellular invasion and 
metastasis [80–83]. Kallikrein-4, -5, -6, -7, -8, -10, -11, -13, -14, and -15 are overexpressed in OC 
tissues, serum, and cell lines at the mRNA and protein levels. Kallikrein-4, -6, and -10 are highly 
expressed in serous epithelial ovarian tumors, and kallikrein-5, -11, and -13 are found in non-
serous ovarian tumors. Kallikrein–8, -10, -11, -13 and -14 have also been found in ascites fluid of 
OC patients [84]. Further, kallikrein-10 and -11, which are promising OC serum biomarkers are, 
respectively, elevated in approximately 56% and 70% of OC patients serum and tissue [85–88]. 
Upregulation of KLKs in OC has been associated with worse overall survival, although conflicting 
reports indicate that further research is required [89–91].  
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Matrix metalloproteinases (MMP-2 and -9) 
MMPs consist of a group of 23 proteins that play an important role in tumor progression by 
degrading the basement membrane and ECM components; MMP2 cleaves fibronectin, vitronectin 
and collagen I [157] into smaller fragments that enhance adhesion of OC cells via α5β1 (fibronectin 
receptor) and αVβ3 (vitronectin receptor) integrin binding [158] and MMP9 degrades E-cadherin 
which is involved in cell-cell adhesion and differentiation [93]. MMP-2 and -9 play a role in tumor 
metastasis, migration, angiogenesis, cell proliferation and cell–cell interactions [92,93], therefore, 
MMP-2 and -9 expression has been associated with poor survival [94]. Differential MMP 
expression in OC tissue can be used to distinguish different OC subtypes and determine prognosis; 
MMP-2 and -9 are more highly expressed in serous OC than mucinous OC tumors. MMP-2 
expression is higher in benign tumors versus borderline and malignant tumors, but MMP-9 
expression is higher in malignant tumors versus borderline tumors [95].  
Osteopontin (SPP1) 
Osteopontin, a glycophosphoprotein found in all body fluids and expressed in the ECM, is 
involved in embryonic development, wound healing and tumor development. Osteopontin appears 
to promote tumor growth, survival, angiogenesis and metastasis by upregulation of the PI3K/Akt 
pathway [105] and MMP-9 activity [87,106,107]. Of clinical significance, osteopontin expression 
is higher in OC cells, ovarian tumor tissue and serum of OC patients when compared with healthy 
control patients. Osteopontin expression is higher in borderline and invasive tumors than in benign 
tumors and normal ovaries, which suggests that osteopontin may be effective to detect early stage 
OC [108,109].  
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Stress induced phosphoprotein 1 (STIP1)  
Stress induced phosphoprotein 1 (STIP1) forms nuclear scaffolds supporting formation of 
protein complexes that participate in transcription, protein folding, signal transduction and cell 
cycle regulation [159,160]. STIP1 is elevated in melanoma, glioma, hepatocellular carcinoma and 
pancreatic cancer and is believed to induce survival and invasion in cancer by modulating the 
SMAD pathway and MMP-2 expression [110–115]. STIP1 is significantly higher in OC patients 
tissue and serum versus normal age-matched patients [116,117]. Analysis of STIP1 levels in OC 
patients with low CA125 levels revealed that STIP1 levels can be used to detect invasive OC as 
an alternative diagnostic marker of OC [161].  
Metabolic regulators 
Apolipoprotein E (ApoE) 
ApoE is an essential component of the plasma lipoproteins responsible for cholesterol 
transportation and metabolism. ApoE is mostly found in the liver, brain, adrenal glands, kidney, 
and macrophages and is associated with cholesterol-rich proteins [162]. ApoE expression has been 
associated with serous OC, but not with borderline serous tumors or normal ovarian surface 
epithelial. Inhibiting ApoE expression leads to G2 cell-cycle arrest and apoptosis in ApoE-
expressing OC cells, indicating ApoE is important for OC proliferation and survival [89,118]. 
Fatty acid synthase (FASN) 
FASN, a cytoplasmic enzyme, is involved in de novo fatty acid synthesis via Nicotinamide 
adenine dinucleotide phosphate (NADPH)-dependent condensation of malonyl-CoA and acetyl-
CoA into palmitate [119]. Normal adult tissues minimally express FASN, however, FASN 
overexpression has been reported in breast, colon, ovarian and prostate cancer [120,163–168] and 
is associated with metabolic dysregulation in cancer cells. FASN levels are elevated in OC 
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development, in serous carcinoma [119–121], and especially in recurrent serous carcinomas [122]. 
Elevated FASN levels parallel cancer aggressiveness, predict poorer overall survival as well as 
disease recurrence [119,120,122–126]. FASN-based therapies have been developed for recurrent 
OC patients; FASN can be successfully targeted by C93, a FASN inhibitor, to induce apoptosis in 
drug resistant OC cells [89,169]. Since FASN is elevated in >75% of OC, the use of therapies 
targeting FASN has great potential, but current inhibitors of FASN have limited efficacy due to 
cell impermeability and solubility as well as lack of cell selectivity [170,171].  
Receptors 
Folate receptor-α (FLOR1)  
FOLR1, a 38–40 kDa [172] glycosylphosphatidyl-inositol-membrane anchored protein, is 
found in the kidneys where it reabsorbs folate (vitamin B9) from the urine filtrate back into the 
blood. FOLR1 is normally expressed in the apical surface of epithelial cells [72], especially in the 
lung and kidney [172]. FOLR1 is overexpressed in epithelial cancer, including ovarian, renal, lung, 
and breast cancers, though its function in cancer is unknown. Overexpressed FOLR1 can be used 
to target cancer with therapeutic drugs or imaging agents. FOLR1 is overexpressed in 72% in 
primary OC and 81.5% in recurrent tumors and FOLR1 expression is equal in primary, metastatic 
and recurrent tumors. Over 90% of non-mucinous OCs overexpress FOLR1, and the level of 
FOLR1 correlates with aggressiveness of the malignancy [72]. Secreted functional FOLR1 in the 
blood serves as an OC biomarker [172]. While FOLR1 is not a prognostic marker since levels of 
FOLR1 do not correlate with survival or tumor response to treatment [173], FOLR1 could deliver 
therapeutic drugs to OC tumors. For example, BGC 945, a thymidylate synthase inhibitor, is 
transported into the cell via FOLR1 and, therefore, targets cells that overexpress FOLR1 [89,174]. 
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Proteins of unknown function in OC  
Human epididymis protein 4 (HE4) 
The WAP Four-Disulfide Core Domain 2 (WFDC2) gene encodes HE4, a secreted “four-
disulfide core” protein of unknown function. The four-disulfide core protein family is a varied 
group of acid- and heat-stable proteins that have many proposed functions including aiding in 
sperm maturation and storage [127,175]. HE4 is expressed at low levels in the female reproductive 
tract, breast and respiratory system. HE4 is a 13KDa protein that is secreted as a 25kDa 
glycosylated protein [176]. The WFDC2 gene is amplified in epithelial OC (EOC) tissue and this 
is associated with increased HE4 in OC serum while HE4 expression remains low in normal tissue. 
In comparison with CA125, serum HE4 levels have greater specificity in discriminating malignant 
disease from benign ovarian disease and between early and late stage disease [127]. Likewise, 
preoperative HE4 levels may be used to predict the extent and success of cytoreductive surgery 
needed for optimal debulking [87,128]. Overexpression of HE4 in OC patients correlates with 
lower overall survival and increased cisplatin resistance. Lastly, in vitro and in vivo HE4 
overexpression increases tumor growth and cisplatin resistance in OC cells and tumors such that 
targeting HE4 suppresses OC cells and tumor growth. HE4 may function by interacting with 
EGFR, IGF1R, and TF HIF1α [176].   
Mesothelin (MSLN) 
The soluble mesothelin-related peptide (SMRP) gene encodes MSLN, a 40 kDa 
glycosylphosphatidylinositol-anchored cell surface molecule, found on the cell surface of 
mesothelial cells and overexpressed in the serum and urine of patients with mesotheliomas and 
OC [129–131]. MSLN is highly expressed in non-mucinous OCs, including endometrioid, clear 
cell, and transitional cell carcinoma as well as pancreatic adenocarcinomas, endometrium 
16 
  
carcinoma and lung carcinoma [177]. While the function of MSLN has not been fully elucidated, 
MSLN binds to CA125 on tumor cell surfaces which may alter cell-to-cell adhesion and increase 
metastasis to the peritoneum [178]. The development of m912, a human monoclonal antibody to 
MSLN, imparts tumor cell toxicity [179]. In contrast, other reports suggest that presence of MSLN 
after treatment in advanced-stage OC disease patients is associated with prolonged survival 
[130,132].  
Prostasin (PRSS8) 
PRSS8, first isolated from seminal fluid, is expressed at low concentrations in a variety of 
tissues including salivary gland, lung, bronchus, kidney, liver, pancreas, and colon, but is absent 
in normal testis and ovary [180]. PRSS8 is a secreted prostatic serine protease and potential OC 
biomarker [181]. The function of PRSS8 is not completely understood, however, it is thought to 
play a role in fertilization [133,182]. Elevated PRSS8 levels in the serum of OC patients have been 
detected with the highest level of PRSS8 detected in stage II of the disease [133].  
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*The protein sequences for the OC biomarkers isolated from the literature were retrieved from 
Uniprot for bioinformatics analysis. The distribution of intrinsic protein disorder was analyzed 
using disorder predictors PONDR® VLXT [183] and PONDR® VSL2 [184,185] which identify 
regions of protein disorder and hydropathy. Amylpred 2 [186] was used to find protein sequences 
prone to form protein aggregates. Uniprot  [187] was used to determine regions of protein 
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instability, signal localization, and binding sites. The predicted post-translational modifications of 
each protein was elucidated using different programs. Phosphorylation was predicted using 
PhosphoSitePlus (PSP) which provides phosphorylation, ubiquitination, acetylation and 
methylation information pertaining to each protein as curated from literature and low- and high-
throughput data sources [188]. N-linked glycosylation was predicted using NetNGlyc 1.0 Server 
which predicts the acceptor sites of N-linked glycosylation at Asn-Xaa-Ser/Thr (where Xaa is not 
Pro) residues. NetNGlyc 1.0 Server predicts glycosylation with 76% overall accuracy [189]. O-
linked glycosylation was predicted using NetOGlyc 4.0 Server which predicts the addition of a 
glycan moiety on Ser, Thr and Tyr residues. The NetOGlyc 4.0 determined glycosylated proteins 
from mapping the proteome of different human cell lines [190]. Sumoylation was predicted by 
SUMOplot Analysis Program. Sumoylation is the reversible attachment of a SUMO protein (11 
kDa). SUMO protein is added to a peptide sequence of a hydrophobic residue bound to a lysine 
bound to any amino acid followed by an acidic residue [191]. Palmitoylation, the reversible 
attachment of a 16-carbon saturated fatty acid to a cysteine reside via a thioester linkage was 
predicted vis NBA-Palm [192]. Acetylation was predicted to by NetAcet 1.0 Server which predicts 
the addition of acetyl moiety by N-acetyltransferase A [193]. Tyrosine sulfation sites were 
predicted by the Sulfinator which uses four different models to recognize sulfated tyrosine residues 
located in the N- and C- terminals [194]. Myristoylation was predicted using Myristoylator which 
looks for sequences that accept the addition  of a myristate to a N-terminal glycine [195]. 
Prenylation was predicted using PrePS which determines protein farnesylation (15 carbon 
polyisopren) as carried out by farnesyltransferases and geranylgeranylation (20 carbon 
polyisopren) as carried out by geranylgeranyltransferase 1 and Geranylgeranyltransferase 2. PrePS 
recognizes the motifs recognized by prenyltransfeases (the CaaX box and Rab escort protein in the 
C-terminal of proteins. Therefore, PrePS recognizes CaaX Farnesylation, CaaX 
Geranylgeranylation and Rab Geranylgeranylation [196]. Methylation was predicted using MeMo, 
the methylation Modification Prediction Server 2.0 which predicts methylation on lysine and 
arginine residues [197].  
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Shared computational characteristics among OC protein biomarkers 
All these OC biomarkers have limited diagnostic usefulness. While none are effective at 
detecting all OCs, these OC biomarkers may contribute to malignant transformation and/or disease 
progression in OC. Therefore, in order to better understand the molecular mechanisms involved in 
OC it would be useful to identify other proteins that may also contribute to OC based on similar 
biochemical protein characteristics. Therefore, to identify common biochemical features among 
the 27 OC biomarkers derived from literature review, computational analyses for measurements 
of protein order, hydropathy, posttranslational modifications, aggregation prone regions and 
subcellular localization were performed (Table 1.2). As outlined below, computational analyses 
indicated that these reported 27 OC protein biomarkers share characteristics of secreted (presence 
of export signal sequence, hydrophilic) and stable (ordered, aggregation prone, glycosylated, 
sumoylated) proteins. 
Characteristics of secreted proteins - (presence of export signal sequence, hydrophilic) 
The majority (22/27) of OC biomarkers examined (ApoE, COL1A1, COL11A1, FOLR1, 
IL-6, IL-8, IL-10, KLK10, KLK11, MMP2, MMP9, MSLN, MUC1, MUC4, MUC16, PRL, 
PRSS8, SERPINE1, SPP1, TGF-β1, VEGF, WFDC2) are secreted proteins based on the presence 
of an export signal sequence while 5/27 (CLDN3, CLDN4, FASN, TNF-α) and only 1/27 (STIP1) 
were predicted to be localized at cell membranes or within the cytoplasm, respectively.  
Likewise, the vast majority (24/27) of these OC biomarkers (ApoE, COL1A1, CLDN3, 
CLDN4, FASN, FOLR1, IL-6, IL-8, IL-10, KLK10, KLK11,  MMP2, MMP9,  MSLN, MUC1, 
MUC4, MUC16, PRL, PRSS8, SERPINE1, TNF-α, TGF-β1, VEGF, WFDC2) were determined 
to be hydrophilic in keeping with a secretory protein profile or function within hydrophilic 
cytoplasmic environments. Similarly, almost half, 11/27, (COL11A1, IL-10, MUC1, MUC4, 
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MUC16, MMP2, SPP1, STIP1, TGF-β1, TNF-α, VEGF) of the OC biomarkers were predicted to 
be sulfated. Sulfation, the enzyme-catalyzed conjugation of a sulfo group, often to tyrosine 
residues, is required by many secreted proteins that traverse the Golgi apparatus for export [198]. 
Consequently, it is not unexpected that many of the OC biomarkers should be sulfated.  
In contrast, only 8/27 (ACTH, ALB, COL1A1, COL11A1, FASN, IL-10, MMP9, TGF-β1) 
were predicted to be methylated. Since methylation increases protein hydrophobicity [199–201] 
and the vast majority of OC biomarkers are hydrophilic, it is not surprising that few are predicted 
to be methylated. In addition, only 4/27 biomarkers (ApoE, COL1A1, FASN, STIP1) were 
predicted to be succinylated. While protein succinylation at lysine residues plays a significant role 
in protein structure, folding and function due to the addition of  a large structural moiety, 
succinylation also typically changes protein charge from +1 to −1 [202]. Since secreted proteins 
contain a positively charged amino terminal necessary for the export process, low levels of OC 
biomarker succinylation (4/27) are consistent with characteristics of secreted proteins [203].  
Lastly, only 3/27 (CLDN3, CLDN4, PRL) are predicted to be palmitoylated and none of the 
OC biomarkers are predicted to be myristoylated or prenylated. Since palmitoylation, 
myristoylation and prenylation anchor proteins to the membrane with potential for increased 
interaction with the endoplasmic reticulum [204], the few OC biomarkers predicted to undergo 
these posttranslational modifications suggests that they mostly operate without membrane 
anchorage.   
Characteristics of stable proteins - (ordered, aggregation prone, glycosylated, sumoylated)   
In addition to a secretory protein profile, the majority (19/27) of reported OC biomarkers 
(CLDN3, CLDN4, FASN, FOLR1,  IL-6, IL-8, IL-10, KLK10, KLK11, MMP2, MMP9, MSLN, 
PRL, PRSS8, SERPINE1, TNF-α, TGF-β1, VEGF, WFDC2) were determined to be ordered 
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proteins with over 65% ordered content. Since highly ordered proteins have stable secondary 
and/or tertiary structures with low physical binding potential to other proteins, these OC 
biomarkers are unlikely to form  larger multi-protein complexes [205]. Interestingly, 17/27 
(CLDN3, CLDN4, FOLR1, IL-6, IL-8, IL-10, KLK10, KLK11, MMP2, MMP9, PRL, PRSS8,  
SERPINE1, TGF-β1, TNF-α, VEGF, WFDC2) of the OC biomarkers contain amino acid 
sequences of which, greater than 30% are considered aggregation prone regions (APR). APRs are 
more likely to represent conserved regions and occur in ordered regions within close structural 
proximity to catalytic residues and have, therefore, been theorized to stabilize proteins and 
contribute to protein function [206].  
With regards to possible post-translational modifications in support of stable protein structures, 
most (23/27) of the OC biomarkers studied (ApoE, COL1A1,  COL11A1, CLDN3, FOLR1, IL-
10, KLK10, KLK11, MMP2, MMP9,  MSLN, MUC1, MUC4, MUC16, PRL, PRSS8, SERPINE1, 
SPP1, STIP1, TNF-α, TGF-β1, VEGF, WFDC2) are predicted to be glycosylated. Glycosylation 
can increase protein stability and modify protein function by increasing thermal stability that 
destabilizes the unfolded state of proteins [207], thereby playing a role in many cellular functions 
including intercellular communication, adhesion and migration, all of which are important in 
cancer progression. Consequently, in addition to an ordered and aggregation prone protein 
structure imparting a stable protein confirmation, additional protein stability would be conferred 
by glycosylation.  
Many of the OC biomarkers (20/27) (ApoE, COL1A1,  COL11A1, CLDN3, CLDN4, IL-6, 
KLK10, KLK11,  MMP2, MMP9, MSLN, MUC1, MUC4, MUC16, SERPINE1, SPP1, STIP1, 
TNF-α, TGF-β1, VEGF) are predicted to be phosphorylated. Phosphorylation can alter protein 
activity, stability, function by changing serine, threonine or tyrosine residues from 0 to −2 [202] 
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as well as protein interactions [208] by activating intracellular signaling cascades [209]. 
Phosphorylation is predicted to be a common posttranslational modification in OC biomarkers 
because it affects many oncogenic processes, including transcriptional regulation, proliferation and 
kinase signaling [210]. 
Further, the vast majority (22/27) of OC biomarkers (ApoE, COL1A1,  COL11A1,CLDN3, 
CLDN4, FASN, FOLR1, IL-10, KLK11, MMP2, MMP9,  MSLN, MUC4, MUC16, PRL, PRSS8, 
SERPINE1, STIP1, TNF-α, TGF-β1, VEGF, WFDC2) are also predicted to be sumoylated. 
Sumoylation is a posttranslational modification resulting from the conjugation of  Small Ubiquitin-
related MOdifiers (SUMO) to proteins; sumoylated proteins appear to take a part in transcription 
[211,212], apoptosis [213], and signal transduction [214]. While the mechanisms that regulate 
sumoylation are not well understood, conjugation of SUMO to proteins can alter protein 
configuration potentially leading to new protein-protein interactions, inhibition of existing protein-
protein interactions and/or changes to existing protein functions and activity [215], thereby 
enhancing functional diversity. In this way, sumoylation can increase protein stability by 
promoting the formation of multimeric protein complexes as well as by inhibition of ubiquitination 
[216]. 
In contrast, only 12/27 (ApoE, CLDN3, CLDN4, COL1A1, COL11A1, FASN, MMP9, 
MUC1, MUC4, MUC16, STIP1, VEGF) of OC biomarkers were predicted to be acetylated. While 
certain forms of protein acetylation can increase protein stability by reducing protein degradation 
[217], the principal function of acetylation involves regulation of gene expression. Since the group 
of OC biomarkers examined do not typically include transcriptional proteins, it is not surprising 
that few might be acetylated. Likewise, only 10/27 (ApoE, CLDN3, CLDN4, COL11A1, FASN, 
IL-6, KLK11, PRL, STIP1, TGF-β1) of OC biomarkers were predicted to be ubiquitinated. 
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Ubiquitination marks proteins for degradation. Ordered proteins have fewer ubiquitination and 
microRNA targeting sites, and lower mRNA decay rates. Therefore, ordered proteins can persist 
within cells at higher levels for longer periods before facing decay [218]. This is consistent with 
the prediction that most biomarkers (17/27) are not ubiquitinated.  
As might be expected for disease biomarkers, computational biochemical analyses indicated 
that the set of published OC protein biomarkers share characteristics of secreted (export signal 
sequence, high hydrophilic, low hydrophobicity, low palmitoylation, myristoylation and 
prenylation) and stable (ordered, aggregation prone, sumoylated, glycosylated, but not acetylated 
or ubiquinated) proteins. However, given the functional diversity of  these biomarkers as indicated 
above, String [219] analysis was also performed to identify a network of functional interactions 
among these established OC biomarkers (Figure 1.1). Interestingly, interactions among these 
diverse biomarkers appear functionally related to: ECM/microenvironment modifications (CLDN-
3, CLDN-4, COL1A1, COL11A1, KLK10, KLK11, MMP2, MMP9, MUC1, MUC4, MUC16, 
SERPINE1, SPP1); regulation/modulation of the immune response (IL-6, IL-8, IL-10, TNFα) and; 
energy production (ApoE, FASN). Since the ECM/ tumor microenvironment encompasses many 
components, including stromal cells, ECM components (cytokines, MMPs, integrins, etc.) and 
exosomes, it plays an important role in OC dissemination and metastasis through a variety of 
mechanisms that include the activation of signaling pathways (AKT and FAK) that induce invasion 
and metastasis, the initiation of EMT changes, and the release of proteases and angiogenic factors 
that remodel ECM and stimulate microvessel formation [220]. While the immune response 
recognizes and eliminates tumor cells, in malignant states, immunosuppression and 
immunoediting often prevail leading to unhindered tumor growth. Though increased tumor-
infiltrating leukocyte expression is associated with improved survival, OC is associated with an 
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immunosuppressive environment. Therefore, future therapies might aim to reverse 
immunosuppression and modulate the immune response to combat OC [221]. Lastly, besides 
endogenous energy production, OC cells induce stromal fibroblasts to secrete energy metabolites 
lactate and pyruvate that are then shuttled into the tricarboxylic acid (TCA) cycle in OC cell 
mitochondria. This shuttling promotes increased energy production contributing to accelerated 
tumor growth and angiogenesis [222].  
Identifying additional key regulators of OC 
The best OC biomarker in clinical use today is CA-125 which has a number of limitations 
including expression in less than 50% of stage I disease and expression that is rarely elevated in 
mucinous, endometrioid or clear-cell carcinomas. CA-125 is elevated in advanced-stage OC and 
in some benign and malignant conditions and is dependent on additional factors including age, 
history of hysterectomy and weight. Though many potential OC biomarkers have been identified 
in the literature (see above), none have overcome CA-125’s clinical limitations [26]. However, the 
potential biomarkers reported in literature highlight different biological pathways of ovarian 
tumorigenesis that could increase our understanding of the etiology of OC. Many of the OC 
biomarkers identified so far fall loosely within three functional groups - immune response, 
ECM/microenvironment modifications, energy production and metabolism. Therefore, these 
protein regulators of OC may be relevant for elucidating mechanisms and pathways of disease 
initiation and progression.  
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Figure 1.1. OC biomarkers have functional interactions. Analysis of the interactivity of published 
OC biomarkers by String produced a network of predicted associations for these proteins. The 
network nodes are proteins, whereas the edges represent the predicted or known functional 
associations. An edge may be drawn with up to 7 differently colored lines that represent the 
existence of the seven types of evidence used in predicting the associations. A red line indicates 
the presence of fusion evidence; a green line - neighborhood evidence; a blue line – co-occurrence 
evidence; a purple line - experimental evidence; a yellow line – text mining evidence; a light blue 
line - database evidence; a black line – co-expression evidence.  
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Figure 1.2. Summarial schematic identifying additional protein regulators of OC. Proteins 
(70,616) of the human proteome were subjected to sequential computational analysis to 
identify proteins (21) that are secreted, ordered and aggregation-prone and which interact 
with previously reported OC biomarkers (27). 
 
70,616 non-redundant proteins
8,059 proteins have signal peptide
1,848 proteins have signal peptides 
and are secreted
1,578 proteins have signal pepties, 
are secreted and ordered
758 secreted proteins with signal 
peptides, are ordered and have 
aggregation-prone regions
Literature review of monomer OC 
biomarkers with more than 100 
publications in PubMed and proteins 
explored by PLCO screening trial 
and/or the NACB 
 
Secreted proteins with export signal 
peptide sequences that are ordered, 
hydrophilic, and have aggregation-
prone sequences 
 
21 proteins that 
interact with literature 
biomarkers 
27 literature 
derived 
proteins 
683 
computational 
derived 
proteins 
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Consequently, expanding upon the characteristics of stable and secreted OC biomarkers 
noted above (ordered, aggregation-prone, hydrophilic, export signal peptide sequence and secreted 
proteins) potentially involved in immune response, ECM/microenvironment modifications, and 
energy production and metabolism, I explored the human proteome to identify additional protein 
regulators of OC (Figure 1.2). According to the Uniprot Database, the human proteome contains 
70,616 non-redundant proteins, of which 8,059 proteins contain an export signal peptide and of 
which 1,848 proteins are secreted. Of these 1,848 proteins 1,578 proteins are ordered and 758 of 
the non-redundant proteins have aggregation-prone regions that cover 30% of their total amino 
acid composition. Of these proteins, 75 proteins are putative or uncharacterized proteins of 
unknown function and, therefore, were removed from the proposed list of proteins to identify 683 
proteins as potential protein regulators of OC (Appendix I). Interestingly, of those 683 proteins, 
243 proteins are functionally related to the regulation/modulation of the immune response, 235 
proteins functionally related to ECM/microenvironment modifications, 120 proteins functionally 
related to energy production and metabolism and 86 proteins of unknown function. Subsequent 
String analysis demonstrated possible interactions between 27 of the functionally known literature-
based OC biomarkers and 21/683 putative biomarkers (Figure 1.3, Table 1.3) including three 
isozymes of amylase, a secreted and stable protein involved in carbohydrate metabolism.
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Table 1.3: Proteins that interact with literature reported ovarian cancer biomarkers 
Protein Protein name Function in cancer 
CXCL12
   
Stromal cell-derived factor 1 (SDF-1) (hSDF-1) (C-X-
C motif chemokine 12) (Intercrine reduced in 
hepatomas) (IRH) (hIRH) (Pre-B cell growth-
stimulating factor) (PBSF) [Cleaved into: SDF-1-
beta(3-72); SDF-1-alpha(3-67)] 
Tumor growth, 
angiogenesis, 
immune functions, 
inflammation, 
invasion [26] 
 IL2  Interleukin-2 (IL-2) (T-cell growth factor) (TCGF) 
(Aldesleukin) 
Immune response 
[223] 
GHR  Growth hormone receptor (GH receptor) 
(Somatotropin receptor) [Cleaved into: Growth 
hormone-binding protein (GH-binding protein) 
(GHBP) (Serum-binding protein)] 
Tumor growth and 
metastasis [224] 
 
IFNG  Interferon gamma (IFN-gamma) (Immune interferon) Immune functions, 
Inflammation [225] 
VWF Von Willebrand Factor Angiogenesis [54] 
KDR       Kinase Insert Domain Receptor/ Vascular endothelial 
growth factor receptor 2 
Angiogenesis [54] 
PLAT Tissue-type plasminogen activator (t-PA) (t-
plasminogen activator) (tPA) (EC 3.4.21.68) 
(Alteplase) (Reteplase) [Cleaved into: Tissue-type 
plasminogen activator chain A; Tissue-type 
plasminogen activator chain B] 
Tumor invasion [155] 
PLAU  Urokinase-type plasminogen activator (U-
plasminogen activator) (uPA) (EC 3.4.21.73) [Cleaved 
into: Urokinase-type plasminogen activator long chain 
A; Urokinase-type plasminogen activator short chain 
A; Urokinase-type plasminogen activator chain B] 
Tumor invasion [155] 
HPR Heparanase (EC 3.2.1.166) (Endo-glucoronidase) 
(Heparanase-1) (Hpa1) [Cleaved into: Heparanase 8 
kDa subunit; Heparanase 50 kDa subunit] 
Tumor proliferation 
and metastasis [226] 
TSLP     Thymic stromal lymphopoietin Inflammation [227] 
CRLF2 Cytokine receptor-like factor 2 (Cytokine receptor-like 
2) (IL-XR) (Thymic stromal lymphopoietin protein 
receptor) (TSLP receptor) 
Inflammation [227] 
AMY1A  Alpha-amylase 1 (EC 3.2.1.1) (1,4-alpha-D-glucan 
glucanohydrolase 1) (Salivary alpha-amylase) 
Cleaves alpha 1, 4-
glycosidic bonds in 
polysaccharides; role 
in cancer unknown 
[228] 
AMY2A Pancreatic alpha-amylase (PA) (EC 3.2.1.1) (1,4-
alpha-D-glucan glucanohydrolase) 
Cleaves alpha 1, 4-
glycosidic bonds in 
polysaccharides; role 
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in cancer unknown 
[228] 
AMY2B    Alpha-amylase 2B (EC 3.2.1.1) (1,4-alpha-D-glucan 
glucanohydrolase 2B) (Carcinoid alpha-amylase) 
Cleaves alpha 1, 4-
glycosidic bonds in 
polysaccharides; role 
in cancer unknown 
[228] 
TIMP1 Metalloproteinase inhibitor 1 (Erythroid-potentiating 
activity) (EPA) (Fibroblast collagenase inhibitor) 
(Collagenase inhibitor) (Tissue inhibitor of 
metalloproteinases 1) (TIMP-1) 
Invasion/metastases 
[26] 
TIMP3  Metalloproteinase inhibitor 2 (CSC-21K) (Tissue 
inhibitor of metalloproteinases 2) (TIMP-2) 
Invasion/metastases 
[26] 
LPL Lipoprotein lipase (LPL) (EC 3.1.1.34) Lipid metabolism, 
inflammation [229] 
APOB  Apolipoprotein B (Including Ag(X) Antigen) Tumor growth [26] 
APOA2 Apolipoprotein A-II (Apo-AII) (ApoA-II) 
(Apolipoprotein A2) [Cleaved into: Proapolipoprotein 
A-II (ProapoA-II); Truncated apolipoprotein A-II 
(Apolipoprotein A-II(1-76))] 
Tumor growth [26] 
INS      Insulin [Cleaved into: Insulin B chain; Insulin A 
chain] 
Tumor growth, 
transformation [26] 
LY6G5C Lymphocyte antigen 6 complex locus protein G5c Unknown 
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Figure 1.3. Identification of proteins that interact with literature-derived OC biomarkers. The 27 
literature OC biomarkers interact with 21 proteins from the human proteome with similar structural 
and functional characteristics, including the amylase isozymes AMY-1A, -2A, and -2B. Analysis 
of the interactivity of published OC biomarkers by String produced a network of predicted 
associations for these proteins. The network nodes are proteins, whereas the edges represent the 
predicted or known functional associations. An edge may be drawn with up to 7 differently colored 
lines that represent the existence of the seven types of evidence used in predicting the associations. 
A red line indicates the presence of fusion evidence; a green line - neighborhood evidence; a blue 
line – co-occurrence evidence; a purple line - experimental evidence; a yellow line – text mining 
evidence; a light blue line - database evidence; a black line – co-expression evidence.  
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Rationale 
Given the overall poor survival associated with OC, it is imperative to identify and 
delineate the role of novel protein regulators of OC in order to understand their role OC progression 
and which could also one day serve as potential targets for therapeutic intervention. While 
comprising a diverse group of functional proteins, OC biomarkers share several features including 
a preponderance for a stable protein structure (ordered, hydrophilic, aggregation-prone, 
glycosylated and sumoylated), the ability to be secreted (export signal peptide sequence, 
hydrophilic) and functionality related to ECM modification, immune response and/or energy 
production. Interestingly, several amylase isozymes are noted among the potential OC protein 
biomarkers of interest identified for further investigation (Figure 3, Table 3). Elevated serum levels 
of amylase or hyperamylasemia, has been long associated with OC and has been studied as both a 
diagnostic and prognostic indicator even though its functional contribution to OC progression 
remains unknown. Amylase is also interesting because it can potentially play multiple roles in OC, 
including cleaving alpha 1, 4-glycosidic bonds in polysaccharides to initiate carbohydrate 
metabolism, thereby contributing to energy production. Amylase may also play a role in ECM 
remodeling by cleaving polysaccharide moieties in the tumor microenvironment; amylase has 
already been shown to degrade bacterial biofilm in wounds [228]. It has also been proposed that 
amylase is released as part of an immune response due to inflammatory microenvironment induced 
by OC [230].  
 
Central Hypothesis 
The objective of this study is to determine the function of amylase in OC. My central 
hypothesis is that increased amylase expression and secretion alters ECM structure and 
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composition to enhance OC cell invasion. This study also proposes that Spirulina is a novel 
transcriptional inhibitor of amylase which can decrease OC invasion. Three aims are proposed. 
 
Aim 1: Characterize and predict which amylase isozyme(s) is overexpressed in OC. 
Currently, it is unclear which amylase isozyme is overexpressed in OC. Computational 
analyses will be performed on the amylase isozyme (AMY1A, -1B, -1C, -2A, and -2B) sequences 
to determine the characteristics of each isozyme and predict which isozyme is most likely 
overexpressed in OC. Predicted overexpression of specific amylase isozymes will be validated in 
serum samples from healthy controls and patients with OC.  
 
Aim 2: Determine the extracellular function of amylase in OC. 
In order to begin to understand the role of amylase for OC progression, an in vitro model 
system of OC cell lines that overexpress and secrete amylase will be established, then utilized to 
show that by remodeling ECM, amylase may contribute to OC cell invasion. 
 
Aim 3: Transcriptionally inhibit amylase expression using a novel agent. 
Since hyperamylasemia is associated with poor clinical outcome in cancer [231], amylase may 
represent a novel target for therapeutic intervention. Commercially available amylase inhibitors 
typically inhibit amylase at the protein level. I propose to employ Spirulina, a dietary supplement, 
as a novel transcriptional inhibitor of amylase. Subsequently, the ability of Spirulina to inhibit OC 
cell migration and invasion will be determined.  
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Defining the function of amylase in OC will fill a much needed gap about the etiology of OC. 
Further, these studies will establish a novel transcriptional inhibitor of amylase that may lead to 
more effective treatment options for OC patients with hyperamylasemia. 
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Chapter 2 
Computational Analysis of Amylase Isozymes Contributing to Ovarian Cancer 
 
Introduction 
Glucose metabolism is the fundamental biochemical reaction providing energy to cells. 
Whether by oxidative phosphorylation or glycolysis [232], glucose consumption is typically 
greater in cancer cells than their normal counterparts [233,234]. Alpha-amylase (commonly 
referred to as amylase) was first characterized as a starch digesting enzyme in 1913 [235]. There 
are three main classes of amylase (α, β and γ) that differ in their structure, mechanism of action 
and phylogenetic location; α-amylase is found in animals, plants, fungi, and bacteria, β-amylase is 
found in plant seeds and γ-amylase is found in yeast and fungi [236]. Amylase cleaves alpha 1, 4-
glycosidic bonds in polysaccharides to initiate carbohydrate metabolism. Consequently, since α-
amylase is restricted to mammalian cells and since starch is the major source of dietary glucose, 
changes in the levels of α-amylase could influence cancer cell survival.  
 
History of the amylase genes 
In 1988, cloned amylase genes examined by Southern blot indicated there are three distinct 
copies of the amylase genes in the human genome (AMY1, amy2 and amy3 ) whereas previously, 
it was thought there is only salivary AMY1 and pancreatic AMY2 [237,238]. In 1989, amy2 and 
amy3 were dubbed AMY2A and AMY2B, respectively. Previously, amy3 was mostly associated 
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with carcinoid tissue because it was isolated from lung cancer tissue [239]. The AMY2B amylase 
gene was cloned and characterized; it was found to consist of ten exons that are highly homologous 
to the ten exons that make up AMY1 and AMY2A (amy2). The introns of AMY1, AMY2A, and 
AMY2B were also reported to be highly homologous. However, it was found that AMY2B has 
two unique untranslated regions in the 5’ region, placing the promoter of the AMY2B gene farther 
upstream than the promoters of AMY1 and AMY2A [240]. A later report found AMY1 consists 
of 11 exons [241].  
 
Evolution and expression of amylase genes 
Amylase consists of a family of isozymes derived from a single ancestral gene. The 
evolution of amylase genes started 43 million years ago with the insertion of a γ-actin pseudogene 
before the primordial amylase gene constituting the ancestral amylase gene (Figure. 2.1A). The 
ancestral gene underwent duplication. One copy of the ancestral amylase genes has maintained its 
structural integrity to date and is referred to as AMY-2B (Figure. 2.1A). However, approximately 
39 million years ago, a retroviral insertion interrupted the actin pseudogene of the other copy of 
the ancestral gene and is dubbed the ‘retroviral’ amylase gene. The ‘retroviral’ amylase gene then 
underwent further duplication. One copy of the ‘retroviral’ amylase gene underwent long terminal 
repeat (LTR) recombination to become AMY-2A. Approximately a million years ago, the other 
‘retroviral’ amylase gene triplicated to become AMY-1A, -1B, and -1C. Consequently, 
evolutionary diversification has resulted in five amylase genes (AMY-1A, -1B, -1C, AMY-2A, -
2B) clustered on the short arm of chromosome one at p21 (Figure 2.1B). These genes are 
characterized by three distinct gene flanking regions including a retroviral insertion (AMY1A, 
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AMY1B, and AMY1C), a 3/5’LTR recombination (AMY2A) and an actin pseudogene (AMY2B) 
(Figure 2.1C) [242].  
 
Figure 2.1. Schematic of mammalian amylase gene distinction. (A) The five amylase genes 
evolved from a single primordial gene. Adapted from [244]. (B) Current amylase genes are 
clustered on chromosome 1.p21. Figure adapted from [242]. (C) Evolution of amylase resulted 
in three distinct regions flanking the amylase genes characterized by a retroviral insertion 
(AMY1A, AMY1B, and AMY1C), a 3/5’LTR recombination (AMY2A) and an actin 
pseudogene (AMY2B). Figure adapted from [244]. 
 
A 
B 
C 
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The retroviral insertion is thought to have resulted in amylase tissue specificity. 
Historically, AMY-1A, AMY-1B, and AMY-1C were thought to encode salivary amylase, 
whereas AMY2A and AMY2B encoded pancreatic amylase [243]. However, recently, AMY-2B 
protein has been found endogenously in many normal tissues because it does not have tissue 
specificity established by the retroviral insertion [243,244]. There are also reports of AMY2B 
protein expression in normal tissue such as the liver, gonads, fallopian tubes, ovary, leukocytes 
and intestinal tract. There has been evidence that AMY2B’s expression in different tissues is 
regulated by unique promoters. The AMY2B’s pancreatic start site differs from its hepatic start 
site [243]. AMY1 expression was thought to be exclusively found in salivary glands, however, 
AMY1 expression has been reported in two cases of normal thyroid gland tissue, two cases of 
cervix tissue, and one case of fallopian tube tissue. A case of normal ovary tissue presented with 
AMY1 expression, but a second case of ovarian tissue did not present with AMY1 expression 
[245,246]. Both AMY2B and AMY1 expression have been isolated in normal lung tissue [246]. 
Total amylase levels in the serum of normal healthy human adults are elevated with age;  amylase 
levels are elevated in women in their 30s and 40s [247]. 
 
Amylase gene regulation 
The promoter of AMY-2B, the ancestral amylase gene, has not yet been identified. It is 
hypothesized that the retroviral insertion either activates a hidden promoter within the actin 
pseudogene or acts as an enhancer that drives the endogenous promoter of AMY-2B. Regardless, 
the retroviral insertion plays an important regulatory role in the transcription of amylase [248,249]. 
No work has been done on the regulation of AMY2A and the promoter of AMY2A has not been 
validated experimentally.  
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In contrast, it has been assumed that the promoters for AMY-1A, -1B, and -1C reside in the 
region flanking these genes. Studies targeting the flanking regions of AMY-1C indicate that AMY-
1C can be activated by integrin and/or growth factor stimulation [248]. Integrin activation leads to 
stimulation of downstream signaling cascades and an increase in intracellular calcium levels that 
leads to increased amylase expression. Transforming growth factor (TGF)-α activation triggers 
phosphatidylinositol phospholipase C (PLC), inositol triphosphate (IP3) and increases intracellular 
calcium levels. Downstream protein kinase C (PKC) and ERK1/2 phosphorylation activate the 
amylase 1C promoter [249,250]. Both pathways result in increased amylase 1C expression 
indicating that the region flanking the amylase gene may play a role in the regulation of amylase 
1C expression.  
It has been reported that the amylase genes contain general transcriptional enhancer (GRE) 
regions in their promoters that respond to glucocorticoid binding. There are two GRE regions in 
the promoters of the pancreatic amylase genes and five GRE regions in the promoter of the salivary 
amylase genes [238]. The LTRs inserted in the promoters of the salivary AMY1 and AMY2A 
genes contain transcriptional control elements including a TATA box, a CCAAT box, a 
polyadenylation signal, and GREs [244].  
 
Differentiating amylase isozymes  
The amylase enzymes are predominately secreted by the pancreas and salivary glands [251]. 
Amylase isozymes have been differentiated by digestion of the fluorogenic substrate, FG5P, by 
salivary (AMY-1A, -1B, or -1C), pancreatic (AMY-2A) and AMY-2B amylases into FG3 and p-
nitrophenyl α-maltoside or FG4 and p-nitrophenyl α-glucoside. The FG4/FG3 ratios are 1.88 for 
AMY2B, 1.08 for AMY-2A and 0.52 AMY-1A, -1B, or -1C [252].    
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Amylase isozymes can also be distinguished by differences in isoelectric points (pI) and 
molecular weight. Experimentally, salivary amylase (AMY1A, AMY1B, and AMY1C) has a pI at 
6.36 and 6.65 and pancreatic amylase has a pI at 7.4 [253]. On western blots, ovarian tumor 
amylase and salivary amylase have a similar migratory pattern and appear as a doublet of 
approximately 57 and 60 kDa. The doublet formation is believed to be due to posttranslational 
modifications including glycosylation and deamination. In contrast, the pancreatic amylase 
isoenzyme migrates as a single band at 55 kDa [253].  
 
Known amylase characteristics 
It has been reported that the amylase genes are located on the short arm of chromosome 1 and 
amylase proteins have an average molecular weight of 56 kDa [254]. There is also high homology 
among the amylase genes. The three AMY1 are more than 99.9% homologous. AMY1 is 93.2% 
homologous to AMY2A and 93.6% homologous to AMY2B. AMY2A and AMY2B are 94% 
homologous [255]. The 3D structures of the pancreatic [256] and salivary [257] α-amylase were 
obtained by X-ray crystallography. The resulting tertiary structures of the salivary and pancreatic 
amylase were revealed to be very similar. However, in these studies it was not indicated which 
pancreatic amylase (AMY2A or AMY2B) was used to elucidate the tertiary structure. Further, 
while calcium (Asn100, Arg158, Asp167, and His201) and chloride ion (Arg195, Asn298, 
Arg337) binding sites of the pancreatic amylase protein have been elucidated, all amylase 
isozymes have three similar domains: Domain A (residues 1-99, 469-404), Domain B (residues 
100-168), and Domain C (residues 405-496) with active sites at residues Asp197, Glu233, and 
Asp300.  
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A trans-species comparison of human pancreatic amylase, porcine amylase, Aspergillus oryzae 
“Taka” (fungus) amylase and Aspergillus niger (fungus) amylase revealed very little primary 
sequence homology among these amylases. Yet, strong homology across species in residues 96-
101, 201, 233-236, and 294-301 confers structural homology of amylases derived from different 
animal species [256]. Likewise, amylase isozymes exhibit similar enzyme activity and degrees of 
inhibition [253]. Amylase from Aspergillus oryzae has been reported to have a single N-
glycosylation site at Asn 197 [258,259].  
In rats, amylase activity is affected significantly by the sex cycle; the change in amylase 
expression is not correlated to calcium levels in the ovary, but to sex hormones acting on the ovary. 
Both salivary and pancreatic amylases were isolated in rat ovary, but only salivary amylase was 
isolated in rat serum [260].  
 
Amylase in cancer 
Amylase is overexpressed in and secreted by a number of tumors [261]  including ovarian 
tumors [262]. However, it remains controversial as to which amylase gene encodes amylase 
isoenzymes secreted by tumors. Some suggest that amylase secreted by tumors is encoded by 
AMY-2B [237,245,263–265], while others consider salivary AMY-1A, -1B, or -1C [240,246,266–
271] as the source of tumor amylases. A unique amylase isoenzyme secreted by tumors has also 
been suggested [253,272–274]. Further, it is unknown whether several amylase isozymes or a 
single isoform is secreted by tumors. As a result, disagreement and mischaracterization of tumor 
amylase isozyme expression is common [253,271].  
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Objectives 
Hyperamylasemia is associated with disease progression although its contribution to OC is 
unclear [1]. Although functionally similar, differential expression of amylase isozymes in OC may 
be clinically significant for diagnostic and/or prognostic outcome. Since there is a controversy as 
to which amylase isozyme(s) is overexpressed in OC, in this chapter I sought to characterize and 
predict which amylase isozyme is overexpressed in OC using computational analyses (evolution, 
disorder, hydrophobicity, aggregation, structure, structural features, possible binding partners, 
mutation profile, and promoter transcription factors) of human amylase isozymes AMY-1A, -1B, 
-1C, -2A, and -2B. Lastly, I sought to validate my prediction in clinical serum samples.  
 
Materials and methods  
Sequences used in computational characterization  
Computational amylase analyses were performed using the human AMY-1A (NCBI Reference 
Sequence: NP_001008222.1); AMY-1B (NCBI Reference Sequence: NP_001008219.1); AMY-
1C (NCBI Reference sequence: NP_001008220.1); AMY-2A (NCBI Reference Sequence: 
NP_000690.10) and AMY-2B (NCBI Reference Sequence: NP_066188.1) protein sequences. 
Amylase isozyme homology 
ClustalW2 is a program used to align multiple DNA and protein sequences using pairwise 
sequence alignment tools; ClustalW2 [275–277] was used to determine the percentage of 
homology between amylase protein sequences. 
Protein biochemical properties databases  
ProtParam [278] was used to define the molecular weight, theoretical pI, instability index 
(distinctive dipeptides that confer instability to a protein), and GRAVY (grand average of 
hydropathy—the sum of hydropathy values of the entire protein, divided by the number of residues 
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in the sequence). Uniprot  [187] was used to determine regions of protein instability, signal 
localization, and binding sites. The information gathered from Uniprot jointly with SignalP 4.1 
and SBASE was also used to construct a general structure depicting the common features shared 
by the amylase isozymes.  
SignalP 4.1 [279] was used to predict the presence and the cleavage site of a possible signal 
transport sequence. The protein sequences were run in SBASE [280] to determine which domains 
are in each amylase isozyme. Domains were confirmed with pfam [281,282], a large collection of 
the protein families. 
Protein disorder 
The distribution of intrinsic amylase protein disorder was analyzed using disorder 
predictors PONDR® VLXT [183] and PONDR® VSL2 [184,185] which identify regions of protein 
disorder and hydropathy. PONDR® VLXT is capable of identifying potential molecular 
interactions motifs in disordered proteins and disordered protein regions [184] while PONDR® 
VSL2 more accurately predicts general protein disorder. 
Secondary structure prediction 
CSSP (Consensus Secondary Structure Prediction)[283] was used to predict the consensus 
secondary structure of the amylase isozymes. I-TASSER was used to predict the tertiary structure 
of the amylase isozymes [284–287]. Amylpred 2 [186] was used to identify protein sequences 
prone to form protein aggregates.  
Potential protein binding sites within amylase isozyme proteins were identified by the 
ANCHOR algorithm [288,289] which determines protein binding motifs within regions of 
disordered proteins. String [219] analysis was performed to identify potential amylase isozyme 
binding partners by depicting a network of proteins that physically and/or functionally interact 
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with amylase. RaptorX-binding [290] analysis was performed to determine ligands that potentially 
bind to the amylase isozymes.  
Posttranslational modification   
HMMpTM [291] was used to predict phosphorylation and glycosylation sites in the 
amylase isozymes. Disorder Enhanced Phosphorylation Predictor (DEPP) is a PONDR 
phosphorylation predictor that determines possible phosphorylated amino acid residues through 
patterns of disorder, hydrophobicity and charge. Sumoylation was predicted by SUMOplot 
Analysis Program. 
Transcription regulation by promoter analysis 
The promoters of the amylase isozymes have not been previously validated by 
experimentation. The suspected amylase promoters used were the -600 base pairs flanking the 5' 
transcription start site as retrieved from Ensembl genome browser [292]. The promoter regions of 
all five amylase isozymes were examined by the Promo database [293,294] to find possible 
transcription factor binding sites that could regulate amylase expression. To find other regulatory 
regions in the promoter, the Eukaryotic Promoter Database (EPD) [295] was utilized to find the 
promoter of the amylase isozymes and then find the TATA box, the GC box and the CCAAT box 
sequences within the promoter sequence to better distinguish the core promoter elements.  
Mutational analysis of the amylase isozymes 
The mutation profiles of AMY-1A, AMY-2A, and AMY-2B were found on cBioPortal 
[296,297] for Cancer Genomics, a large scale cancer genomics database that determines the 
individual mutations in genes as well as the prevalence of mutations in cancer.  
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Clinical Specimens 
With prior University of South Florida Institutional Review Board committee approval 
serum samples were collected at the H. Lee Moffitt Cancer Center and at the University of South 
Florida. A total of 30 de-identified serum samples were collected from women with benign 
gynecologic disease (N = 8) as well as from patients with serous OC (N = 8), endometrial cancer 
(N = 5), mucinous OC (N = 5), thecoma (N = 1), teratoma (N=1), ovarian anaplastic metastatic 
carcinoma (N =1) and clear cell OC (N = 1). Pooled serum (N = 4) from healthy individuals was 
obtained from Valley Biomedical Cat. HS1021, Lot. 7A0032 and Lot. 6K2146 (Winchester, VA) 
and Atlanta Biomedical Cat. S40590, Lot. M14161 and Lot. C16037 (Flowery Branch, GA) to be 
used as control. All serum samples were kept on ice following collection, centrifuged at 3000 g 
for 15 minutes at 4°C and supernatants were then aliquoted and stored at –20°C.  
Western blot  
Serum samples were diluted in CHAPS buffer and 120ug of serum protein were separated 
by a 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were 
transferred to Polyvinylidene fluoride (PVDF) membranes, washed in Tween 20-Tris buffered 
Saline (TBST), and blocked in 5% milk in TBST. Blots were incubated in their respective primary 
antibodies overnight, followed by incubation with a horseradish peroxidase (HRP)-conjugated 
secondary antibody (Fisher, Pittsburgh, PA), and developed via FEMTO Cat. 34095 Life 
Technologies (Grand Island, NY). Antibodies used were: AMY1A (1:1000) Cat.H00000276-M04 
Abnova (Taipei City, Taiwan); AMY2A (1:500) LS-C114393 LSBio (Seattle, WA); AMY2B 
(1:2000) Cat. LS-C173958 LSBio (Seattle, WA); Transferrin ab82411 abcam (San Francisco, CA). 
Densitometry was performed using ImageJ software to normalize amylase band strength to the 
transferrin bands in serum samples. 
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Results:  
Amylase isozymes are highly homologous. 
Alignment analyses were performed on amylase isozyme protein sequences using 
ClustalW2 software. AMY-1A, -1B, and -1C have 100% alignment, whereas they were only 96% 
homologous to AMY-2A and 97% homologous to AMY-2B. Amy-2B and AMY-2A are 98% 
homologous (Figure 2.2). In short, all the amylase proteins are highly homologous. Henceforth, 
AMY-1A, -1B, and -1C are collectively referred to as AMY1. 
Amylase isozymes have similar molecular weights and isoelectric points. 
While the amylase isozymes contain up to 12 exons (11 exons in AMY1 and 12 exons in 
AMY2B), all the amylase isozymes contain 10 coding exons resulting in proteins of 511 amino 
acids (Table 2.1). Computational analysis revealed the molecular weight of salivary amylase 
(AMY1) and pancreatic amylases (AMY2A and AMY2B) are 57,767.8 Da, 57,706.8 Da and 
57,709.8 Da respectively (Table 2.1). Computational pI for AMY1A, AMY2A and AMY2B is 
6.47, 6.60 and 6.64, respectively (Table 2.1).  
Amylases are highly ordered proteins with one predicted protein binding site.  
Protparam predicted that all amylases are stable (ordered) proteins, because they were 
beneath the threshold of 40, above of which indicates instability. In mammalian cells, all the 
amylase isozymes have an identical half-life of 30 hours in vitro (Table 2.1). PONDR protein 
disorder predictor indicated that all amylase isozymes are mostly ordered proteins with small 
regions of disorder. While the amylase isozymes have similar regions of disorder, AMY1 and 
AMY2B have unique regions of disorder that are not found in AMY2A. AMY1 has two unique 
regions of disorder encompassing amino acids 51 through 63 and amino acids 375 through 384; 
AMY2B also has two unique regions of disorder encompassing amino acids 51 through 63 and 
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Figure 2.2. Amylase proteins are highly homologous. The protein sequences of the amylase 
isozymes were subjected to ClustalW2 for alignment. AMY-1A, -1B, and -1C have 100% 
alignment, whereas they were only 96% homologous to AMY-2A. AMY-1A, -1B, and -1C are 
97% homologous to AMY-2B. Amy-2B and AMY-2A are 98% homologous. Homologous 
amino acids share the same color. Clear amino acids are non-homologous. 
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Table 2.1. Biochemical properties of amylase determined by computational analyses 
  AMY1—AMY-
1A, AMY-1B, 
AMY-1C 
AMY-2A AMY-2B Significance 
Exons 11 but only 10 
coding 
10  12 but only 
10 coding 
All amylase 
isozymes have 10 
coding exons   
Length of α-
amylase (amino 
acids) 
511 511 511 All amylase 
isozymes are the 
same length 
Theoretical 
molecular 
weight (Da) 
57767.8 57706.8 57709.8 All amylase 
isozymes have an 
average 
computational 
molecular weight of 
57KDa 
Theoretical pI 6.47 6.60 6.64 All amylase 
isozymes have an 
average 
computational 
isoelectric point of 
6.57. 
Instability index 23.58  23.56 25.26 All amylase 
isozymes are 
ordered 
Half-life The estimated half-life is:  
        >30 hours (mammalian reticulocytes, in    
vitro). 
        >20 hours (yeast, in vivo). 
        >10 hours (Escherichia coli, in vivo). 
All amylase 
isozymes are stable 
for long periods of 
time 
Possible protein 
binding 
(ANCHOR) 
aa107-112 aa109-110 aa108-111 All amylase 
isozymes have one 
possible binding site 
GRAVY 
(hydrophobicity) 
-0.436    -0.396   -0.417  All amylase 
isozymes are 
hydrophilic 
PONDR 
hydropathy 
0.4516 0.4559 0.4537 All amylase 
isozymes are 
hydrophilic 
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Figure 2.3. Amylase isozymes are ordered proteins. Amylase isozymes AMY-1A, -1B, -
1C (A), AMY-2A (B) and AMY-2B (C) were subjected to PONDR analyses for protein 
disorder. AMY1 has two unique regions of disorder encompassing amino acids 51 through 
63 and 375 through 384; AMY2B has two unique regions of disorder encompassing amino 
acids 51 through 63 and 117 through 134 (denoted by*). 
A 
* * 
B 
C 
* 
* 
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A 
C 
B 
Figure 2.4. Amylase isozymes are hydrophilic. Amylase isozymes AMY-1A, -1B, -1C (A), 
AMY-2A (B) and AMY-2B (C) were subjected to PONDR analyses for protein 
hydropathy. The amylase isozymes are hydrophilic according to the mean scale 
hydropathy. The amylase isozymes also have low absolute mean net charge values 
indicating that amylase isozymes are ordered.  
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amino acids 117 through 134 (Figure 2.3; denoted by *). 
The ANCHOR program predicted a single potential protein binding site within the ordered 
protein regions, unique to each amylase isozyme. AMY1 could potentially bind another protein at 
amino acids 108-111; AMY2A at 109-110 and AMY2B at 107-112 (Table 2.1).  
Amylase isozymes are hydrophilic. 
All amylase isozymes have low negative GRAVY (grand average of hydrophobicity index) 
scores: AMY1 is -0.436, AMY2A is -0.396 and AMY2B is -0.417 (Table 2.1) indicating they are 
hydrophilic (increasing positive GRAVY values indicate higher hydrophobicity). Likewise, 
PONDR predicted hydrophobicity scores of 0.4516 for AMY1, 0.4559 for AMY2A and 0.4537 
for AMY2B (Figure 2.4, Table 2.1) suggesting that the amylase isozymes are hydrophilic proteins.  
Amylase is predicted to be glycosylated and phosphorylated. 
HMMpTM and PONDR Disorder Enhanced Phosphorylation Predictor (DEPP) database 
were used to identify potential posttranslational modifications, especially glycosylation and 
phosphorylation sites (Table 2.2). According to HMMpTM, the amylase isozymes do not differ 
significantly from each other with each isozyme containing 13-15 possible glycosylation and seven 
possible phosphorylation sites. DEPP predicted that all amylase isozymes also have two 
phosphorylated residues at amino acids 166 and 197. AMY2B appears to have a unique 
phosphorylation residue at amino acid 133 (Table 2.2, Figure 2.5). The SUMOplot Analysis 
Program predicted that all amylase isozymes were sumoylated at amino acids 2, 50, 275 and 279 
(Table 2.2).  
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Table 2.2 – Secondary structural and posttranslational modifications among amylase 
isozymes 
  AMY1—AMY-1A, 
AMY-1B, AMY-1C 
AMY-2A AMY-2B 
Phosphorylation 
(DEPP) 
166, 197 166, 197 133, 166, 197 
Phosphorylation 
(HMMpTM) 
7; residues 246, 259, 
269, 279, 290, 291, 
304 
7; residues 246, 259, 
269, 279, 290, 291, 
304 
7; residues 246, 259, 
269, 279, 290, 291, 
304 
Glycosylation 
(HMMpTM)  
14; O-linked: 58, 
127, 452, 457, 493 
N-linked: 61, 96, 
102, 103, 165, 365, 
411, 427, 476 
13; O-linked: 58, 
127, 452, 457, 493 
N-linked: 61, 96, 
102, 103, 165, 365, 
427, 476 
15; O-linked: 58, 123, 
127, 452, 457, 493 
N-linked: 61, 96, 102, 
103, 165, 365, 411, 
427, 476 
Sumoylation 
(SUMO plot) 
2,50, 275, 279 2,50, 275, 279 2,50, 275, 279 
Signal peptide 
(SignalP) 
Yes; 1-15 Yes; 1-15 Yes; 1-15 
Consensus 
Secondary 
Structure 
(CSSP) 
Alpha helix: 15.65% 
beta strand: 22.30% 
 
Alpha helix: 16.24% 
beta strand: 24.07% 
 
Alpha helix: 16.04% 
beta strand: 22.11% 
 
Aggregation 
prone regions 
(Amylpred) 
16 aggregation prone 
regions 
21 aggregation prone 
regions 
22 aggregation prone 
regions 
 
The amylase isozymes have common domains, and structural features. 
According to SBASE and pfam, all the amylase isozymes have two main structural domains: 
an alpha amylase catalytic domain from amino acids 36 to 351 and a C-terminal all-beta domain 
from amino acids 421 to 510 (Figure 2.5). The C-terminal all-beta domain is unique to the glycosyl 
hydrolase family members and is important for folding and secretion of amylase [298]. SignalP 
analysis predicted a transport signal cleavage site at amino acid 15 in all amylase isozymes (Table 
2.2) which is in keeping with secretion of amylase out of the cell [299].  
Uniprot determined possible cofactor binding sites in amylase isozymes. All amylase 
proteins require calcium and chloride cofactors for enzymatic function [300,301] and have calcium 
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binding sites at amino acids 115, 173, 182, and 216 and chloride binding sites at amino acids 210, 
313, and 352. Amino acids 212 and 248 play an essential role in the active site of all amylase 
isozymes (Figure 2.5). All amylase isozymes have four disulfide bonds connecting amino acids 43 
to 101, amino acids 85 to 130, amino acids 156 to 175, and amino acids 393 to 399.  ProtParam 
also predicted that amylase requires calcium and chloride as cofactors with calcium and chloride 
binding sites at the same residues predicted by Uniprot (Figure 2.5).  
Amylase isozymes have unique binding regions for chloride, calcium and glucose. 
RaptorX binding analysis suggested that while all the amylase isozymes bind chloride, 
calcium, and glucose, individually, they may have additional binding residues for chloride, 
calcium and glucose. All amylase isozymes can bind chloride at residues R210, E248, N313, and 
R352 (Figure 2.5). However, AMY2A and AMY2B could bind chloride at residue T269 and 
AMY2B might additionally bind chloride at residue H216 (Figure 2.5). Likewise, all amylase 
isozymes could bind calcium at residues R173 and D182 (Figure 2.5). However, AMY1 can also 
bind calcium at residues N115 while AMY2A might bind calcium at residues N115 and H216 
(Figure 2.5). All amylase isozymes appear capable of binding glucose at residues W73, W74, Y77, 
Q78, H116, L177, L180, R210, D212, A213, H216, E248, I250, H314, D315, and H320 (Figure 
2.5). However, AMY2A and AMY2B can also bind glucose at residues T178 and G321 (Figure 
2.5). Therefore, AMY2A and AMY2B appear to share the greatest number of unique binding 
residues for chloride, calcium, and glucose which further supports the high homology between 
these isozymes. 
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Transport signal cleavage site  
Calcium binding sites     
Chloride binding sites     
Glucose binging sites     
Active sites      
Phosphorylation sites     
O-linked glycosylation     
N-linked glycosylation     
Disulfide bonds    
AMY1 calcium binding site 
AMY2A calcium binding site 
AMY2B calcium binding site 
AMY1 anchor possible binding site 
AMY2A anchor possible binding site 
AMY2B anchor possible binding sites 
AMY2A/AMY2B glucose binding site 
AMY1/AMY2B N-linked glycosylation site 
AMY2A/AMY2B chloride binding site 
AMY2B phosphorylation site 
AMY2B O-linked glycosylation site 
Figure 2.5. Amylase isozymes share structural 
features. The SBASE, Uniprot, and DEPP database, 
Raptor binding, HMMpTM databases were used to 
define general structural features of the amylase 
isozymes including domains, co-factor binding sites, 
post-translational modifications and residues that 
may play an important role in amylase catalytic 
activity. The amylase isozymes have an amylase 
catalytic domain from amino acid 36 to 351, a C-
terminal all-beta domain from amino acid 421 to 510, 
calcium binding sites at amino acids 173 and 182, 
chloride binding sites at amino acids 210, 248, 313, 
and 352, and glucose binding sites at amino acids 73, 
74, 77, 78, 116, 117, 180, 210, 212, 213, 2116, 248, 
250, 314, 315, and 320. The amylase isozymes also 
have four disulfide bonds at amino acids 43 to 101, 
amino acids 85 to 130, amino acids 156 to 175, and 
amino acids 393 to 399. Uniprot also determined that 
amino acids 212 and 248 play an essential role in the 
active site. All amylase isozymes have 
phosphorylation sites at amino acids 166, 197, 246, 
259, 269, 279, 290, 291, and 304. All amylase 
isozymes have O-linked glycosylation sites at amino 
acids 58, 127, 452, 457, and 493 and N-linked 
glycosylation sites at amino acids 61, 96, 102, 103, 
165, 365, 427, and 476. B) Unique calcium, chloride, 
and glucose binding sites, phosphorylation and 
glycosylation sites and anchor potential binding sites 
are also depicted on the bottom of the figure.  
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The amylase isozymes have similar secondary and tertiary structure profiles. 
The secondary structure of amylase isozymes was examined by Consensus Secondary 
Structure (CSSP) (Table 2.2). The predicted secondary structure of all amylase isozymes is 
composed of over 50% of coil. The other 50% is composed of alpha helices and beta sheets. AMY1 
is predicted to have 15.65% alpha helical structure and 22.30% beta sheet structure. AMY2A is 
predicted to have 16.24% alpha helical structure and 24.07% beta sheet structure. AMY2B is 
predicted to have 16.04% alpha helical structure and 22.11% beta sheets. Therefore, the predicted 
secondary structure makeup of the amylase isozymes is very similar.  
The tertiary structure as isolated by I-TASSER analysis shows that the tertiary structure of 
amylase isozymes AMY1 and AMY2B is identical (Figure 2.6). Though the structure of AMY2A 
was similar to the structure of AMY1 and AMY2B, it has looser, less organized and less defined 
coil structures (Figure 2.6, denoted by orange arrows).  
 
B 
Figure 2.6. AMY2A has a unique 3D structure. The amylase isozymes 
were subjected to RAPTORX to render a 3D structure. The 3D structure of 
AMY1 (A), AMY2A (B), and AMY2B (C) determined that the structures 
of AMY1 and AMY2B are identical and AMY2A has different coil 
structures as denoted by orange arrows. 
 
C A
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Multiple regions of amylase are prone to aggregation. 
The aggregation prone regions of the amylase isozymes were predicted by AmylPred2. 
AMY1 has 16 aggregation prone regions. AMY2A has 21 regions of aggregation and AMY2B has 
22 regions of aggregation (Table 2.2, Figure 2.7). AMY2A and AMY2B displayed unique 
aggregation prone regions (Figure 2.7). Unique aggregation regions within AMY2A were mapped 
to amino acids 2, 64-68, 97-98, 116, 118, 197, 279-281, 325-332,340-345, 355-356, 383-386, 407-
415, 439, 456, and 478-480. Likewise, unique aggregation regions within AMY2B mapped to 
amino acids 2, 26, 40, 97-98, 116, 176-182, 325-332, 340-345, 355-356, 383-386, 408-409, 413-
414, 439, and 464-466. While aggregation prone regions were found throughout the proteins, the 
isozyme unique aggregation prone regions were mostly found at the terminal ends of the protein 
isozymes (Figure. 2.7).   
 
Figure 2.7. Amylase 
isozymes have multiple 
aggregation prone regions. 
The amylase isozymes were 
subjected to analysis by 
AmylPred2 in order to 
determine aggregation prone 
regions. AMY1 has 16 
aggregation prone regions. 
AMY2A has 21 regions of 
aggregation and AMY2B has 
22 regions of aggregation.  
AMY2A and AMY2B have 
unique regions of aggregation 
not found in AMY1 (*). 
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The amylase isozymes functionally interact with metabolic proteins 
According to String analysis, amylase interacts functionally with metabolic proteins 
(Figure 2.8). Using a medium confidence interval of interaction, I could isolate proteins that most 
likely interact with amylase. Proteins that interact with all amylase isozymes are glycogen 
phosphorylase, brain form (PYGB), glucan (1,4-alpha-) branching enzyme 1 (GBE1), glycogen 
phosphorylase, liver form (PYGL), glycogen debranching enzyme (AGL), and sucrase-isomaltase 
(SI). The proteins that interact with all the amylase isozymes have functions associated with 
carbohydrate metabolism (Table 2.3, Figure 2.8). Both AMY2A and AMY2B interact with 
Thyroid Stimulating Hormone, Beta (TSHB) 
 However, amylase isozymes also have unique probable interactions. AMY1 interacts with 
lactase (LCT), kinase A anchor protein 1 (AKAP1), kinase A anchor protein 8 (AKAP8), collagen, 
type X, alpha 1 (COL10A1), and bacterial/permeability-increasing protein (BPI). The unique 
proteins associated with AMY1 are connected to carbohydrate metabolism, antibacterial functions, 
and extracellular matrix glycoprotein remodeling. AMY2A interacts with maltase-glucoamylase 
(MGAM), glycoprotein 2 (GP2), enolase 1 (ENO1), and pancreatic lipase (PNLIP). The unique 
proteins associated with AMY2A are connected to carbohydrate and lipid metabolism, and 
immune and antibacterial functions. AMY2B interacts with phosphoglucomutase 1 (PGM1), CD 
molecule (CD2), ATPase, Na+/K+ transporting, Alpha 4 Polypeptide (ATP1A4), ATPase, 
Na+/K+ transporting, and Alpha 1 Polypeptide (ATP1A1). The unique proteins associated with 
AMY2B are connected to carbohydrate metabolism, energy production and immune functions. 
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A 
B 
C 
Figure 2.8. Amylase isozymes form functional interactions with other metabolic enzymes. 
String database indicate that AMY1 (A), AMY2A (B), and AMY2B (C) have functional 
interactions with other starch digesting enzymes. Shown is the interaction network of the 
amylase isozymes at medium confidence. Green lines connect proteins which are associated 
by recurring conserved genomic neighborhood, red lines indicate gene-fusion events in other 
species, blue connections are inferred by phylogenetic co-occurrence derived from similar 
patterns of absence and presence of genes, black lines indicate co-expression analysis derived 
from similar patterns of mRNA expression, purple lines indicate high-throughput 
experimental data, light blue lines indicate associations in curated database, and light green 
lines indicate textmining or co-occurrence of gene/protein names in abstracts. 
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Table 2.3. Proteins that functionally interact with amylase isozymes  
Proteins that interact with all amylase isozymes  
AGL Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase. Glycogen debrancher 
enzyme which is involved in glycogen degradation.   
PYGB Phosphorylase, glycogen; brain; Glycogen phosphorylase found predominantly in 
the brain as an allosteric enzyme in carbohydrate metabolism.  
GBE1 Glucan (1,4-alpha-), branching enzyme 1; Glycogen branching enzyme required 
for sufficient glycogen accumulation.  
PYGL Phosphorylase, glycogen, liver. This gene encodes a protein that cleaves alpha-1, 
4-glucosidic bonds to release glucose-1-phosphate from liver glycogen stores.  
SI Sucrose-isomaltase (alpha-glucosidase). This gene encodes a sucrose-isomaltase 
complex essential for the final stage of digestion of dietary carbohydrates. 
Proteins that interact with both AMY2A and AMY2B 
TSHB Thyroid Stimulating Hormone, Beta is indispensable for the control of thyroid 
function and metabolism. 
Proteins that interact only with AMY1 
LCT Lactase-glycosylceramidase is an integral protein in the plasma membrane that has 
both lactase activity and phlorizin hydrolase activity. 
AKAP1 A kinase (PRKA) anchor protein 1; binds to type I and II regulatory subunits of 
protein kinase A and anchors them to the mitochondrion. 
AKAP8 A kinase (PRKA) anchor protein 8; anchoring protein that mediates the 
compartmentation of PKA and other signaling molecules. AKAP8 may target 
PKA and the condensin complex to chromatin during mitosis for chromosome 
condensation.  
COL10A1 Collagen, type X, alpha 1; type X collagen is a homotrimer product of 
hypertrophic chondrocytes during endochondral ossification  
BPI Bactericidal/permeability-increasing protein. This gene encodes a 
lipopolysaccharide binding protein associated with human neutrophil granules and 
has antimicrobial activity against gram-negative organisms.  
Proteins that interact with only AMY2A 
MGAM Maltase-glucoamylase (alpha-glucosidase) is a brush border membrane enzyme 
that plays a role in the final steps of digestion of starch. 
GP2 Glycoprotein 2 (zymogen granule membrane) encodes an integral membrane 
protein that is secreted from intracellular zymogen granules and associates with 
the plasma membrane via glycosylphosphatidylinositol (GPI) linkage. The 
encoded protein binds pathogens such as enterobacteria, thereby playing an 
important role in the innate immune response.  
ENO1 Enolase 1, (alpha).  Each isoenzyme is a homodimer composed of 2 alpha, 2 
gamma, or 2 beta subunits, and functions as a glycolytic enzyme. Alternative 
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splicing of this gene results in a shorter isoform that has been shown to bind to the 
c-myc promoter and function as a tumor suppressor. 
PNLIP Pancreatic lipase.  It encodes a carboxyl esterase that hydrolyzes insoluble, 
emulsified triglycerides, and is essential for the efficient digestion of dietary fats. 
Proteins that interact with only AMY2B 
PGM1 Phosphoglucomutase 1 belongs to the phosphohexose mutase family. There are 
several PGM isozymes, which are encoded by different genes and catalyze the 
transfer of phosphate between the 1 and 6 positions of glucose. In most cell types, 
this PGM isozyme is predominant, representing about 90% of total PGM activity.  
ATP1A4 ATPase, Na+/K+ Transporting, Alpha 4 Polypeptide. The protein encoded is the 
catalytic subunit of the subfamily of Na+/K+ -ATPases, an integral membrane 
protein responsible for establishing and maintaining the electrochemical gradients 
of Na and K ions across the plasma membrane essential for osmoregulation, for 
sodium-coupled transport of molecules, and for electrical excitability of nerve and 
muscle.  
ATP1A1 The catalytic component catalyzes the hydrolysis of ATP coupled with the 
exchange of sodium and potassium ions across the plasma membrane. This action 
creates the electrochemical gradient of sodium and potassium ions, providing the 
energy for active transport of various nutrients.  
CD2 CD2 molecule, a surface antigen of the human T-lymphocyte lineage that is 
expressed on all peripheral blood T cells. It is one of the earliest T-cell markers, 
being present on more than 95% of thymocytes and on some natural killer cells. 
* Protein description was retrieved from GeneCards 
 
 
Amylase isozyme expression may be driven by differential promotor activation 
To begin to understand the mechanisms responsible for hyperamylasemia in OC, additional 
computational analyses were performed to identify potential transcription factors that might 
regulate amylase expression. Promo was used to analyze the probable promoter regions of the 
amylase isozymes. Promo predicted probable attractive transcription factor binding sites within 
each probable promoter region. It also predicted which transcription factors would be most likely 
to bind to these potential transcription factor binding sites (Figure 2.9). The binding sites of these 
transcription factors are located at different regions of the isozyme promoter sequences, suggesting 
differing patterns of regulation.  
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Transcription factors C/EBP alpha (regulates cell cycle regulation), C/EBP delta (regulates 
immune and inflammatory responses), and Zic1/2 (regulates mammalian development) were 
predicted to regulate AMY1 and AMY2A promoter activity. STAT5A (signal transduction and 
transcription factor) is a unique transcription factor of AMY1. C/EBP delta was also identified as 
a candidate transcription factor for AMY2B, however, POU1F1 (regulates mammalian 
development) and Cdx-1 (regulates intestine-specific gene expression) were uniquely predicted to 
regulate AMY2B (Figure 2.9).  
The EPD was utilized to find potential core promoter elements such as the TATA, CG and 
CCAAT boxes (Figure 2.9). AMY1 has a TATA box at residues -51 to -33 and a CG box at 
residues 40 to 55. AMY2A has TATA boxes at residues -52 to -21 and -17 to -5. AMY2A also has 
two CCAAT boxes at residues -598 to -585 and -547 to -534. AMY2B has two TATA boxes at 
residues -138 to -101 and -50 to -33 and a CG box at residues 15 to 28. 
AMY2B overexpression is the most likely to be associated with amplification mutations in 
cancer 
cBioPortal for Cancer Genomics database determined the frequency and pattern of mutations in 
the amylase isozymes. The number of reported amylase genes’ mutation reflects their evolutionary 
history. AMY2B, the most evolutionarily conserved amylase gene, has developed the most 
mutations (n = 86), whereas AMY1, the most recently evolved, has developed the least amount of 
mutations (n = 4). All the AMY1 mutations are missense mutations; AMY2B mutations are 90.7% 
missense mutations, 3.5% nonsense mutations, 4.6% frameshift mutations and 1.1% splice site 
mutations. AMY2A has an intermediate number of mutations (n = 51). Mutations in AMY2A are 
82.4% missense mutations and 17.6% nonsense mutations (Figure 2.10). 
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Figure 2.9. AMY2B has unique potential transcription factors. The potential promoters of the 
amylase isozymes were retrieved from Ensembl genome browser and analyzed by Promo database 
to identify candidate transcription factors driving amylase promoter activity.  
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Figure 2.10. Mutational events are highest in AMY2B. cBioPortal for Cancer Genomics 
database determined the pattern of mutations in the amylase isozymes AMY1 (A), AMY2A 
(B), and AMY2B (C). Mutations are denoted by lollipops – green lollipops denote missense 
mutations, red lollipops denote truncating mutations, black lollipops denote inframe deletions 
and insertions. Purple lollipops denote residues affected by multiple mutation types. AMY2B, 
the most conserved amylase gene, has developed 86 mutations, whereas AMY1, the most 
recently evolved, has developed 4 mutations. AMY2A developed 41 mutations.  
 
A
B 
C
63 
  
Figure 2.11: AMY2B is altered in most cancer types (Continued on Next Page) 
B 
A 
64 
  
 
 
 
cBioPortal for Cancer Genomics database determinations also revealed a variety of mutations 
among the amylase isozymes, including non-specific mutations, deletion mutations and 
amplification mutations present in many cancer types including cancers of the lung, colon, uterus 
and skin (Figure 2.11). Mutations in AMY1, AMY2A, and AMY2B were found in 21, 24, and 26 
cancer types, respectively. AMY1 mutations in cancers other than OC mostly arise from genetic 
amplifications and deletions whereas AMY2A mutations in other cancers are comprised of a 
C 
Figure 2.11. AMY2B is altered in most cancer types.  Amplifications comprise the majority 
of amylase mutations in OC. cBioPortal for Cancer Genomics database determined the 
mutational profiles for amylase; AMY1 (A), AMY2A (B), and AMY2B (C).  
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mixture of deletions, amplifications and missense mutations. Likewise, AMY2B mutations in 
other cancers typically occur as missense mutations and amplification mutations (Figure 2.11). 
The pattern of amylase isozyme mutations in OC is somewhat different from that in other 
cancer types. In OC, the mutational profile of amylase isozyme AMY1 consists mostly of 
amplifications and deletions while the mutational profile of the amylase isozyme AMY2A in OC 
is mostly amplifications as well as some deletions and nonsense mutations. The pattern genetic 
mutation of the amylase isozyme AMY2B in OC is also mostly due to amplifications although 
some deletions, truncations and in-frame mutations are also noted. Further, in OC, the mutation 
frequency of the amylase isozyme AMY1 was determined to be 2.2% amplifications and 0.3% 
deletions. The mutation frequency of AMY2A was 2.1% amplification, 0.3% deletion, 0.1% 
missense mutation and 0.1% mixed missense mutation and amplification while the mutation 
frequency of AMY2B was 2.2% amplifications and 0.3% deletions (Figure 2.11). 
Lastly, cBioPortal for Cancer Genomics database was utilized to determine amylase isozyme 
mRNA expression in different cancers (Figure 2.12). AMY1 mRNA expression was low in most 
cancers. Only OC, lung squamous carcinoma, thyroid cancer and lung adenocarcinoma expressed 
relatively high AMY1 mRNA levels. AMY2A mRNA expression was almost negligible in most 
cancers except for its high mRNA expression in pancreatic cancer. AMY2B mRNA expression 
was relatively high in all cancers explored by the database. In OC, AMY2B mRNA expression 
levels were highest followed by AMY1 and AMY2A mRNA expression levels.   
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Figure 2.12: AMY2B is the most expressed amylase isozyme in OC (Continued on Next Page) 
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Clinical validation confirms elevated levels of AMY2B protein in OC 
While my computational analyses predicted elevated AMY2B RNA levels in OC, validation 
of elevated AMY2B protein had yet to be determined in OC. Therefore, to validate differential 
amylase isozyme protein expression with OC, serum samples from healthy controls, women with 
benign gynecologic disease and women with OC and endometrial cancer were subjected to WB 
analyses. Using the 95th percentile of amylase values for healthy controls as the threshold for serum 
C 
Figure 2.12. AMY2B is the most expressed amylase isozyme in OC. cBioPortal for Cancer 
Genomics database determined amylase isozyme mRNA expression in cancers at the 
transcriptional level; AMY1 (A), AMY2A (B), and AMY2B (C). AMY2B demonstrated the 
highest RNA expression in OC when compared with other amylase isozymes (denoted by 
boxes). AMY2B RNA is most expressed in OC followed by AMY1 and AMY2A mRNA. 
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amylase positivity, the amount of serum AMY1, AMY2A and AMY2B was generally negligible 
in healthy pooled controls and individual serum samples from women with benign gynecologic 
disease (Figure 2.13). Likewise, negligible amounts of AMY1A and AMY2A protein were present 
in serum samples from endometrial cancer, clear cell carcinoma and mucinous OC. While elevated 
levels of AMY2B protein were noted in most endometrial cancers (4/5) and clear cell OC (1/1), 
AMY2B protein levels were only elevated in 2/5 mucinous OC. AMY2B levels. In contrast, serum 
samples from patients with serous ovarian carcinoma revealed AMY1 (in 3/8 samples) and 
AMY2B (in 7/8 samples) protein levels up to 2x greater than healthy controls. 
 
 
 
 
 
 
Figure 2.13: Serum levels of AMY2B protein are altered in OC (Continued on Next Page) 
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Discussion:  
The chromosomal localization of the amylase isozymes on chromosome 1p21 [302,303], 
evolutionary development of the amylase isozymes from a single ancestral gene [242–244], and 
similar biochemical properties such as the molecular weight, isoelectric point [242,304] and 
calcium and chloride cofactor binding features common to the amylase isozymes have been 
identified in the literature previously [305,306]. Further, the catalytic domain and the C-terminal 
domain of the amylase isozymes [307], and crystalized tertiary structure of the amylase isozymes 
[257,308] have also been elucidated.  
Figure 2.13. Serum levels of AMY2B protein are altered in OC. Serum samples from normal 
controls (*), women with benign gynecologic disease and cancer were subjected to western 
immunoblotting for amylase AMY1, AMY2A, AMY2B (upper panel). Amylase band intensity 
was quantified and densitometry values are expressed relative to the transferrin control group 
(lower panel).  
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Given the common evolutionary background and shared sequence homology, it is not 
surprising that the amylase isozymes share biochemical and structural features despite differential 
tissue expression. Computational analyses indicated that the amylase isozymes are composed of 
511 amino acids, have an average computational molecular weight of 57 kDa and an average 
computational isoelectric point of 6.57. The amylase isozymes also bind chloride and calcium as 
enzymatic cofactors. This, coupled with predictions that the amylase isozymes are hydrophilic, 
suggests that amylase is secreted from cells, in keeping with its known digestive function. 
Structurally, the amylase isozymes share a common structure dominated by an amino terminal 
transport signal site and a catalytic domain. The amylase isozymes also share common 
phosphorylation, glycosylation, and calcium, chloride and glucose binding sites.  
Computational analysis was not always in agreement with known properties of amylase 
reported in literature. Both computational and known literature reported the homology of the 
amylase isozymes as being above 90%; however, the amylase isozymes are much more 
homologous according to the computational analysis. Literature reported molecular weight and 
isoelectric point did not differentiate between the AMY2A and AMY2B making the computational 
analysis of the amylase isozymes size more specific. There was no agreement between the results 
of the computational analysis and literature reported domains of the amylase isozyme, the position 
of the active sites or the calcium and chloride binding sites. This discrepancy may be due to the 
different algorisms used by the computational programs and may not accurately depict biological 
conditions. It may also be that experimental validation of the new biological knowledge found by 
computational programs has not been done.  
In order to begin to understand the role of and mechanisms contributing to hyperamylasemia 
seen in OC, I performed computational analyses to identify unique features of the amylase 
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isozymes in order to predict which isozyme would most likely be overexpressed in OC-associated 
hyperamylasemia. Computational analyses highlighted new features of the amylase isozymes not 
previously reported (Table 2.4). They include the following: 
First, potential unique post-translational modifications, including novel glycosylation and 
phosphorylation sites, were identified among the amylase isozymes. Glycosylation is a regulated 
and reversible modification including the covalent bonding of a sugar moiety of variable length 
and arrangement to a protein residue [309]. Glycosylation plays a role in folding and structural 
stability of protein, protein localization and interactions as well as immune responses and 
modifying cell signaling. Glycosylation of proteins confers a more stable configuration that is less 
prone to degradation [310–312]. Glycan dysfunction can lead to cancer, diabetes and liver cirrhosis 
[209,313,314], therefore, additional glycan sites at residues 411 for AMY1 and residues 423 and 
411 for AMY2B may lead to enhanced protein stability.   
Phosphorylation is a flexible, simple, reversible regulatory mechanism utilized by 30% of 
human proteins via protein kinases. Phosphorylation can alter protein activity, stability, function, 
and interactions. Abnormal phosphorylation is often a cause or consequence of human disease 
[208,315]. Phosphorylation affects intracellular signaling cascades that regulate metabolism, 
enzyme reactions and protein degradation [209] so a unique phosphorylation site at amino acid 
residue 133 in AMY2B (according to DEPP) can be responsible for increased protein stability and 
possibly more protein-protein interactions. These potential posttranslational modifications may be 
key for amylase function. Together, these unique and/or aberrant posttranslational modifications 
could alter amylase transcription, secretion or enzymatic activity contributing to overexpression 
of amylase in cancer. 
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Table 2.4. Distinguishing computational characteristics among amylase isozymes 
 AMY1 AMY2A AMY2B 
Tissue specificity Salivary gland Pancreas None 
Unique regions of 
disorder 
Amino acid 51-63, 
117-134 and 375-384 
- Amino acid 51-63 and 
117-134 
Unique calcium 
binding residues 
N115 N115, H216 H216 
Unique chloride 
binding residues 
- 269 T269 
Unique glucose 
binding residues 
- T178, G321 V178, G321 
Unique 3D structure - + - 
Unique regions of 
aggregation 
- 2, 64-68, 97-98, 116, 
118, 197, 279-281, 
325-332,340-345, 
355-356, 383-386, 
407-415, 439, 456, 
478-480  
2, 26, 40, 97-98, 116, 
176-182, 325-332, 
340-345, 355-356, 
383-386, 408-409, 
413-414, 439, 464-466 
Unique 
phosphorylation 
sites 
- - Amino acid 133 
Unique 
glycosylation sites 
N-linked: residue 411 - N-linked: residue 411 
O-linked: residue 123 
Unique interacting 
proteins 
LCT, BPI, COL10A1, 
AKAP1, AKAP8 
MGAM, TSHB, 
GP2, PNLIP, ENO1 
TSHB, ATP1A4, 
ATP1A1, CD2, PGM1 
Unique transcription 
factors 
C/EBP alpha, Zic1/2, 
STAT5A 
C/EBP alpha and 
Zic1/2 
POU1F1 and Cdx-1 
No. of mutations 4 41 86 
* Common features of the amylase isozymes are discussed in the results section. Table indicates 
the unique characteristics of the different amylase isozymes.  
Sumoylation is the reversible attachment of a Small Ubiquitin-related MOdifiers (SUMO) to 
proteins. SUMO protein is added to a specific peptide sequence of a hydrophobic residue bound 
to a lysine bound to any amino acid followed by an acidic residue [316]. Sumoylated proteins 
appear to take a part in transcription [211,212], apoptosis [213], and signal transduction [214]. 
While the mechanisms that regulate sumoylation are not well understood, conjugation of SUMO 
to proteins can alter protein configuration potentially leading to new protein-protein interactions, 
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inhibition of existing protein-protein interactions and/or changes to existing protein functions and 
activity [215], thereby enhancing functional diversity. In this way, sumoylation can increase 
protein stability by promoting the formation of multimeric protein complexes as well as by 
inhibition of ubiquitination [216]. Since all amylase isozymes are predicted to be sumoylated, it is 
expected that sumoylation imparts stability and may result in a longer half-life due to lack of 
ubiquitination and, subsequently, degradation.  
Second, protein function is determined by protein structure which, in turn, is based on protein 
sequence. Consequently, evolutionarily related proteins have similar structural motifs and the 
structural similarities between the amylase isozymes are indicative of their evolutionary history 
[317]. In agreement, I found that all the amylase isozymes are generally highly ordered proteins 
with long half-lives. Therefore, the amylase isozymes have a stable secondary and/or tertiary 
structure. Since ordered proteins have low binding potential to other proteins and usually do not 
form complexes, it is unlikely that amylase forms larger protein complexes [205]. However, I also 
found that AMY1 and AMY2B have unique internal regions of protein disorder. AMY1 has unique 
disorder regions at amino acids 51 to 63 and 375 to 384 while AMY2B has a unique disorder 
profile at amino acids 51 to 63 and 117 to 134. These internal regions of protein disorder in AMY1 
and AMY2B represent zones of flexible protein configurations that: (1) are more prone to 
posttranslational modifications (such as the unique phosphorylation site at amino acid 133 in 
AMY2B) that increase protein functionality; (2) may function as linkers between the two 
structured domains of the amylase isozymes or; (3) may confer increased binding potential to the 
structured domains of other proteins [317].  
Third, amylase function may be related to protein aggregation inherent in amylase protein 
structure. Alpha-amylase was found to be more prone to aggregation as compared to β-amylase 
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due to the presence of cysteine residues on the surface of amylase which help form intermolecular 
sulfide bonds that covalently-link amylase dimers [318]. Computational analyses revealed that the 
amylase isozymes share multiple, common aggregation prone regions, but AMY2A and AMY2B 
have additional unique regions of aggregation. Unique aggregation prone regions were mostly 
found in AMY2B, indicating it is most likely to aggregate. Aggregation prone regions are more 
likely to be in ordered regions and stabilize proteins. Aggregation prone regions are also very likely 
to be found in close structural proximity to catalytic residues further indicating that aggregation 
prone regions contribute to protein function. Aggregation prone regions can be conserved in 
proteins to maintain protein stability and function [206]. AMY2A and AMY2B have unique 
regions of aggregation which is in keeping with their evolutionary history. Unlike AMY1, since 
AMY2B is the oldest of the amylase isozymes, it has the most conserved ordered protein regions 
which is in keeping with the view that intrinsically ordered proteins are associated with high self-
aggregability. This was further supported by analyses of tertiary amylase structure. Specifically, 
alpha helixes are the most common secondary structure to transverse the membrane due to their 
ability to maintain more polar structures inside the helix [319] while beta sheets play a large part 
in amyloid formation [320]. The pancreatic amylase isozyme AMY2A has more alpha helix 
structure indicating it may more readily transverse the membrane than AMY1 and AMY2B 
amylase isozymes.  
The salivary glands and pancreas account for most of the amylase activity in the body. 
Increased amylase expression and activity (hyperamylasemia) has been associated with insult to 
the pancreas or salivary glands, chronic alcoholism, amylase secreting cancers and anorexia 
nervosa or bulimia. Hyperamylasemia is due to an overproduction of amylase that is secreted into 
the serum as well as decreased amylase clearance. Decreased amylase clearance may be due to 
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macroamylasemia, an asymptomatic condition wherein amylase aggregates into high-molecular 
weight complexes containing immunoglobulins [321]. Reportedly, hyperamylasemia and 
macroamylasemia can occur as secondary conditions to cancer [322]. The amylase proteins 
displayed different potential aggregation-prone regions. Since AMY2A and AMY2B may be more 
prone to self-aggregate because they have more aggregation prone regions, they may contribute to 
macroamylasemia [323].  
Fourth, while the ordered nature of the amylase isozymes typically precludes their physical 
interaction with other proteins, computational analyses predicted several potential functional 
amylase-protein interactions, mostly associated with carbohydrate metabolism. However, unique 
functional interactions among amylase isozyme family members were also noted and might 
represent novel functions limited to specific amylase isozymes. That is, AMY1 has unique 
interactions with lactase (LCT), kinase A anchor protein 1 (AKAP1), kinase A anchor protein 8 
(AKAP8), collagen, type X, alpha 1 (COL10A1), and bacterial/permeability-increasing protein 
(BPI). These unique interactions indicate that AMY1 might participate in a variety of established 
and novel functions including carbohydrate metabolism, extracellular matrix remodeling, and cell 
immunity. AMY2A has interactions with maltase-glucoamylase (MGAM), glycoprotein 2 (GP2), 
enolase 1 (ENO1), pancreatic lipase (PNLIP), and TSHB. These unique interactions indicate that 
AMY2A could participate in a variety of functions including carbohydrate and lipid metabolism 
and cell immunity. With possible involvement in lipid metabolism, AMY2A may play a role in 
alternate energy production. AMY2B has interactions with phosphoglucomutase 1 (PGM1), CD 
molecule (CD2), ATPase, Na+/K+ transporting, Alpha 4 Polypeptide (ATP1A4), Alpha 1 
Polypeptide (ATP1A1), and TSHB. These unique interactions suggest that AMY2B could also 
participate in carbohydrate metabolism as well as ATP production and cell immunity. 
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Interestingly, all amylase isozymes functionally interact with different immunity related proteins, 
indicating that amylase may modulate the immune response. These novel interactions point to 
potential alternative functions of the amylase isozymes. It is important to note that all the proteins 
that interact with amylase do not form physical interactions, but have functional interactions. There 
is no indication that amylase forms complexes with other metabolic enzymes. However, it has 
been proposed that amylase is sequestered in normal tissue and during inflammatory events, 
amylase is released into the blood [324]. Consequently, the high levels of tissue amylase may be 
related to an anti-bacterial role [325]. 
Fifth, unique amylase isozyme expression profiles may arise through differential gene 
expression regulated, in part, by different transcription factors. The current study revealed that 
AMY1 transcription may be regulated by the C/EBP alpha, C/EBP delta, zic1/2, and STAT5a 
while AMY2A is regulated by C/EBP alpha, C/EBP delta and zic1/2 and AMY2B is regulated by 
C/EBP delta, POU1F1 and Cdx-1. The function of the differentiation-inducing C/EBP 
transcription factor family has been found to be abrogated in hematopoietic, lung and skin cancers 
[326]. C/EBP beta is overexpressed in OC epithelial cells in vivo and C/EBP alpha and delta have 
constant expression levels regardless of tumor stage/progression [327]. Zic1 plays a role in cancer 
progression in medulloblastomas, endometrial cancers, colorectal and mesenchymal neoplasms 
such that Zic1 is downregulated during transformation [328]. In breast cancer, loss of STAT5A is 
associated with poor clinical outcome and advanced tumor progression [329]. Not much is known 
about the role many of these transcription factors play in OC in particular though it is clear that 
they play a large role in cancer progression in other cancer types.  
In addition to all the above, all three amylase isozymes had TATA boxes in their promoter 
regions while only AMY1 and AMY2B have CG boxes in their promoter regions and only 
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AMY2A has CCAAT boxes in its promoter region. Core promoter elements determine 
transcriptional regulations by governing which transcription factors are recruited. The TATA box 
is a DNA sequence that specifies where transcription initiates by binding transcription factors. 
TATA boxes are typically found in highly regulated genes [330]. The GC box is usually found 
upstream of the TATA box and acts like a transcriptional enhancer that binds transcription factors 
[331]. The CCAAT box also occurs upstream of the transcription start site and is known to be part 
of the core promoter. Interestingly, the C/EBP proteins are highly conserved CCAAT enhancer-
binding proteins with multiple functions in proliferation, metabolism, immunity and inflammation 
[332–335]. This indicates that the amylase isozymes have different core promoter and enhancer 
regions that recruit transcriptional factors by unique methods.   
Lastly, computational analyses indicated that the number of potential mutations among 
amylase isozymes was greatest in AMY2B (with 86 possible mutations) compared with AMY2A 
(with 41 possible mutations) and AMY1 (with 4 possible mutations). It is also interesting that the 
AMY1 mutations are located at the end of the alpha-amylase catalytic domain while mutations in 
AMY2A are localized mutations mostly in the N-terminal and alpha-amylase catalytic domain. 
This suggests that the alpha-amylase catalytic domain may be prone to mutations. In contrast, 
AMY2B has mutations uniformly distributed throughout its protein. Nonetheless, mutations of 
amylase isozymes often lead to amplification and could explain overexpression leading to 
hyperamylasemia in OC.  
Despite many similarities among the amylase isozymes, computational analyses revealed 
significant differences among these isozymes based on regions of protein disorder, calcium 
binding sites, glycosylation sites, phosphorylation sites, regulatory transcription factors, tertiary 
structure, aggregation prone regions and susceptibility for mutational events. Consequently, 
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structural, functional and regulatory differences among the amylase isozymes may contribute to 
differential tissue expression in disease. The computational differences among amylase isozymes 
leads me to believe that AMY2A and AMY2B may be more prone to self-aggregation. AMY1 and 
AMY2B have unique regions of disorder indicating these isozymes may mediate more 
interactions, and be more susceptible to mis-folding and aggregation. AMY1 and AMY2B have 
identical tertiary structures indicating AMY1 and AMY2A may have similar interactions and 
patterns of secretion. AMY2B is endogenously expressed in many tissues due to its lack of a 
retroviral insertion that induces tissue specificity. During malignant transformation, AMY2B 
expression may be exacerbated by genetic deregulation.  
Taken together, my computational analyses predict that AMY2B and, to a lesser extent, 
AMY1 may be the amylase isozymes overexpressed in OC-associated hyperamylasemia. While 
my computational analyses suggest that AMY2B RNA is overexpressed in OC and elevated levels 
of AMY2B amylase have been anecdotally reported in OC serum and tissues, information about 
the specific amylase isozyme overexpressed at the protein level in OC disease is lacking. 
Therefore, to validate my computational predictions, serum samples from normal controls and 
from women with benign gynecologic disease and reproductive cancers were assessed by amylase 
isozyme protein expression by western immunoblotting. I was able to confirm that, compared to 
normal controls and benign disease, AMY2B was preferentially overexpressed at the protein in 
serous ovarian cancers, the most frequently occurring ovarian histologic subtype. Consequently, 
computational strategies can serve as a first step to help identify novel protein regulators for OC, 
such as AMY2B, which can then be expanded in further studies on the molecular mechanism(s) 
contributing to OC progression.   
 
C/EBP alpha 
C/EBP delta 
STAT5A 
vitamin D 
C/EBP alpha 
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Chapter 3 
Amylase promotes OC cell invasion in vitro 
 
Introduction: 
Hyperamylasemia has been reported in OC [262,336,337], specifically in women with serous 
ovarian tumors [338] and ovarian cystadenocarcinoma [230]. Zakrezewska et al. found that 
amylase is overexpressed in 39% of OC patients [339]. Hyperamylasemia is associated with poor 
prognostic outcome including rapid disease progression and increased mortality; it has been 
suggested that amylase is a marker of disease progression as amylase activity only decreases in 
response to treatment and rapidly increases when diseases relapse [340–343]. However, its 
contribution to OC disease etiology remains unknown [1]. Nonetheless, since hyperamylasemia in 
OC patients is reduced after ovarian tumor removal or treatment, elevated serum levels of amylase 
in patients with hyperamylasemia are thought to result by secretion of amylase by OC cells 
[269,336].  
My computational analyses predicted AMY1A and AMY2B as the most likely amylase 
isozymes overexpressed in OC, and western blot analysis of OC patient serum samples confirmed 
high levels of AMY1 and AMY2B in OC (Chapter 2).  To begin to determine the contribution of 
amylase for OC progression, in this chapter, an in vitro model of amylase secretion by OC cells 
will be developed. The functional contribution amylase for OC will be evaluated by measurement 
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of cellular proliferation and invasion as well as the ability for amylase to degrade ECM 
components. Lastly, by demonstrating amylase within the cellular glycocalyx and the ECM 
environment, I propose a role/mechanism by which amylase may not only drive energy production, 
but invasion by OC cells.  
 
Materials and Methods:  
Tissue culture  
The following human cell lines were used:  normal human dermal fibroblasts HDF; SV 40-
Large T-Antigen transfected human ovarian surface epithelial (IOSE) cell lines MCC3,  IOSE-80, 
IOSE-121, and IOSE-144 derived from normal patients with no family history (NFH) of breast 
and/or OC [344,345]; OC cell lines CaOV3, OVCAR5, OV-90, SKOV3, TOV21G and IGROV; 
colorectal adenocarcinoma cancer cell lines WiDr and SW626; breast cancer cell lines MDA-MB-
231 and MCF7; head and neck cancer cell line HN5α [346]; cervical cancer cell lines Hela, C13, 
OV2008; pancreatic cancer cell line Panc1; lung cancer cell lines NCI-H2009 and H69; and 
glioblastoma U373MG cells. Cells were cultured in Medium 199/MCDB 105 (Sigma, St. Louis, 
MO) with 5% fetal bovine serum (FBS) and gentamicin and incubated at 37°C with 5% CO2. 
Media was concentrated using Centriprep Centrifugal Filter Devices (Ultracel YM-3 Cat.4302 
Merck Millipore Ltd, Tullagreen, Ireland). 
Transmission Electron Microscopy (TEM) 
Cells were grown on routine tissue culture plasticware in a monolayer on a 13mm coverslip in 
6 well plates overnight. Adherent cells were fixed with 75 mM lysine in 0.075% (w/v) alcian blue, 
2% paraformaldehyde (PFA), 2.5% glutaraldehyde (GA) in 0.1 M cacodylate (CAC) buffer 
solution, buffered at pH 7.2, for 0.5 hour at 37°C. The coverslips were then washed for 1.5 hours 
at room temperature followed by storage at 4°C overnight. Coverslips were then rinsed three times 
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for five minutes with 0.1 M CAC, pH 7.2 and postfixed with 1% osmium tetroxide-potassium 
ferrocyanide (OsO4/0.8% K4Fe(CN)6) in 0.1M CAC, pH 7.2 for 1 hr. Coverslips were then rinsed 
for five minutes with 0.1M CAC, pH 7.2, and washed with dH2O twice for five minutes. Coverslips 
were dehydrated with a graded ethanol (ETOH) series: 35%, 50%, 70%, and 95% ETOH followed 
by three exchanges of anhydrous 100% ETOH prior to critical point drying via three ten minute 
washes in 100% acetone. For resin infiltration, cells were incubated in graded acetone/Epon 812 
resin solutions:  2:1 acetone to resin solution for ten min, 1:1 acetone to resin solution for 48 hours, 
1:2 acetone to resin solution for two hours and pure resin twice for two hours each. The coverslips 
were then cut into 2mm x 6.5mm segments and baked on pure resin at 40°C for 2-4 hours and at 
70°C overnight to polymerize the resin. The coverslips were then sectioned, examined and 
photographed on a Zeiss EM 30 electron microscope. Cell cultures were screened for yeast 
contamination and contaminated cultures were replaced.  
Quantitative PCR  
Cells were treated with TRIzol reagent from Invitrogen (Carlsbad, CA) and ribonucleic acid 
(RNA) was isolated according to the manufacturer’s instructions. To generate single-stranded 
complementary DNA (cDNA), the Applied Biosystems GeneAmp RNA polymerase chain 
reaction (PCR) Core Kit (Foster City, CA) was used with 3 ug/mL total RNA using a Biometra 
UNO-thermo-block and Perkin-Elmer-GeneAmp PCR system 9600. qPCR was carried out with 
SYBR Green Universal Master Mix (Applied Biosystems), cDNA, and primers. Primers used were 
AMY1A (GeneCopoeia: Hs-QRP-21480; Rockville, MD), AMY2A (GeneCopoeia: Hs-QRP-
21450), AMY2B (GeneCopoeia: Hs-QRP-21451; Rockville, MD), and GAPDH (GeneCopoeia: 
Hs-QRP-20169; Rockville, MD) as control. Sequences for the amylase primers remain the 
proprietary property of GeneCopoeia. Amplification was performed with 40 cycles of denaturation 
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(95°C, 10 sec), annealing (60°C, 20 sec), and extension (72°C, 15 sec) using a Bio-RAD Chromo4 
Real Time PCR Detector using Opticon Monitor 3 program. Levels of amylase were normalized 
to their respective GAPDH message values and the fold difference was determined by dividing the 
threshold cycle (Ct) value by the reference sample.  
Western blot 
Cells were washed in PBS, trypsinized, pelleted, rewashed with PBS and counted. Cells 
were lysed in CHAPS buffer for 30 minutes on ice before being centrifuged at 115,000 x g, at 4°C 
for 1h. Twenty ug of protein were separated by a 10% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). Proteins were transferred to Polyvinylidene fluoride (PVDF) 
membranes, washed in Tween 20-Tris buffered Saline (TBST), and blocked in 5% milk in TBST. 
Blots were incubated in their respective primary antibodies overnight, followed by incubation with 
a horseradish peroxidase (HRP)-conjugated secondary antibody (Fisher, Pittsburgh, PA), and 
developed via FEMTO Cat. 34095 Life Technologies (Grand Island, NY). Antibodies used were: 
AMY1A (1:1000) Cat.H00000276-M04 Abnova (Taipei City, Taiwan); AMY2A (1:500) 15845-
1-AP Proteintech (Chicago, IL); AMY2B (1:2000) Cat. LS-C173958 LSBio (Seattle, WA); Beta 
Actin Loading Control Antibody (BA3R) (1:10,000) Cat. # MA5-15739 Thermo Scientific 
(Rockford, IL).  Densitometry was performed using ImageJ software to normalize amylase band 
strength to the actin band. 
Amylase ELISA 
To measure amylase protein levels in OC samples and/or their conditioned medium, 100ul 
of samples corresponding to 104 cells were assayed in triplicate using the quantitative double 
sandwich enzyme-linked immunosorbent assay (Amy-p ELISA Kit; Cat. MBS264855; 
MyBioSource, San Diego, CA). Absorbance was read on a Microplate Reader BioTek ELx800 
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(Winooski, Vermont) using Gen5 Data Analysis Software (Biotek, Winooski, Vermont). Resultant 
values were derived from a standard curve and expressed as the mean amylase concentration of 
triplicate samples.  
Amylase activity assay 
The Amylase Assay Kit (Cat: ab102523 Abcam, Cambridge, MA) was used to measure 
amylase activity according to the manufacturer’s instructions from concentrated conditioned 
media (CCM). The CCM corresponding to 104 cells was incubated with ethylidene-pNP-G7, a 
substrate that is cleaved by amylase into smaller fragments targeted by α-glucosidase to release a 
chromophore whose concentration was measured at 405 nm using μQuant plate reader from Bio-
tek instruments, Inc. (Winooski, VT).  
Amylase transfection 
For silencing experiments, IOSE and OC cells were split into four groups, including a 
control group supplemented with only the transfection reagent, a negative control group 
transfected with a non-targeting control scramble siRNA and the transfection reagent, a third group 
supplemented separately with the three different amylase siRNAs and the transfection reagents 
and, lastly, a fourth group transfected with GFP to monitor transfection efficiency. Cells were 
transfected with ON-TARGETplus Human AMY1A siRNA-SMARTpool (Cat. L-012691-01-
0010), ON-TARGETplus Human AMY2B siRNA-SMARTpool (Cat. L-015880-01-0010), and 
ON-TARGETplus Human AMY2A siRNA-SMARTpool (Cat. L-016978-01-0010) or ON-
TARGETplus Non-targeting scramble siRNAs (Cat. D-001810-01-0010) GE Healthcare 
Dharmacon (Lafayette, CO).  The SMARTpool is a mix of four siRNAs provided as a single 
reagent. Cells were plated in 6 well plates, serum starved overnight then treated with 145 pmol 
siRNA per well incubated with Lipofectamine 3000 Transfection Reagent (Invitrogen, Madison, 
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WI, United States) according to the manufacturer’s instructions. Transfection efficiency was 
determined by transfecting cells with pmaxGFP™ Control Vector (Cat. VCA-1003) Lonza (Basel, 
Switzerland). Transfected cells were maintained for 48 h before further experiments, unless 
otherwise described. 
Invasion assay  
Cells were incubated on type I collagen coated transwells (CytoSelect 96-Well Cell Invasion 
Assay, catalog number: CBA-112-COL (San Diego, CA)) for 24 hours. Following incubation, 
cells that had invaded through the collagen gel and onto the transwell membrane insert were 
stained with 0.1% crystal violet solution and photographed using an Olympus DP20 digital camera 
(Burnaby, BC, Canada) under a Leica DMIRE2 microscope. The number of cells that invaded the 
transwell was then counted and subjected to statistical analysis. 
Glycosaminoglycan (GAG)/proteoglycan quantification assay 
GAG content was determined using a Blyscan colorimetric assay (Biocolor Assays, County 
Antrim, BT38 8YF, United Kingdom). After transfection with amylase siRNA, and scramble 
RNA, 7x106 IOSE-121 and OVCAR5 cells were digested in a papain extraction reagent. The GAG 
content in each sample was detected with spectrometry at 656 nm after precipitation and dye 
binding of GAG according to the manufacturer’s instructions. A standard curve was created using 
controls according to the manufacturer’s instructions. 
Immunogold staining 
For immunogold staining, cells were grown on coverslips and prepared for TEM analysis 
as described earlier. Sectioned grids of cells were incubated in 4% w/v aqueous sodium 
metaperiodate for two minutes, washed multiple times in water, blocked in PBSG (PBS containing 
0.001% (v/v) Tween 20 and Triton X-100 and 1% (w/v) gelatin from cold water fish) for 10 
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minutes before incubation overnight in 6ug/ml anti-salivary alpha amylase antibody (Cat. ab54765 
Abcam (Cambridge, MA)). The grids were then washed twice in PBS then eight times in water 
before a two-hour incubation in goat-anti-mouse IgG (H&L) conjugated to 15nm colloidal gold 
particles 1:40 (Cat. 25133 Electron Microscopy Sciences (Hatfield, PA)). The grids were rinsed in 
H2O for 30-40 sec then counterstained in uranyl acetate (saturated) in 50% methanol for 2 minutes. 
To confirm the specificity of the primary antibody, non-immune goat IgG were used as negative 
control in place of primary antibody.  The cells were then viewed by TEM.  
Statistical analyses 
For real time PCR, error bars illustrate RQmin and RQmax, which were calculated as:  RQave 
divided by (standard deviation^ student’s t value at the 95% confidence interval, for 5 degrees 
freedom) and RQave times (standard deviation^ student’s t value at the 95% confidence interval, 
for 5 degrees of freedom), respectively. This range represents the 95% confidence level.  For 
amylase activity assay, amylase ELISA, GAG assay and invasion assay, student’s t test was 
performed to assess statistical difference between means of triplicates ± standard error. P-values ≤ 
0.05 were considered statistically significant. 
 
Results:  
Confirmation of yeast-free cell cultures. 
Since cell culture contaminants, including commensal yeast, can produce amylase, it was 
necessary to ensure that cell lines used for this study were free of microbial contaminants. 
Examination of cell cultures by light microscopy did not detect presence of yeast in any cultures. 
However, for more stringent examination, IOSE and OC cell lines were examined by TEM for 
possible yeast contamination. IOSE-121, HIO118, SKOV3, OV-90 and OVCAR5 were found to 
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be free of yeast, while yeast was found in CaOV3 and IGROV (Figure 3.1). I replaced the yeast-
infected cell lines with yeast-free cell lines as validated by TEM visualization.  
A. CaOV3: 
 
 
B. IGROV:  
 
 
 
 
 
 
 
Figure 3.1. Establishing cell cultures are free of yeast. Cells cultures were examined by TEM 
to detect microbial contamination, including yeast. Representative photographs illustrate 
endogenous yeast (arrows) in CaOV3 (A) and IGROV (B) ovarian cancer cell lines. 
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OC cells overexpress amylase in vitro. 
Computational analyses predicted that AMY1 and AMY2B would be overexpressed in OC 
(Chapter 2). A panel of cell lines was used to confirm which amylase isozymes are overexpressed 
in established OC cell lines as well as from other cancer types at the message level using qPCR 
(Figures 3.2 and 3.3) and at the protein level using western immunoblotting (Figure 3.4). At the 
message level, there were variable levels of amylase expression in OC and normal cell lines (Figure 
3.2). Moderate levels of AMY1 and AMY2B RNA were expressed in MCC3, while IOSE-121 
essentially only expressed AMY1 RNA. As defined by the average signal ratio of 
amylase/GAPDH in IOSE cells, only 2/5 (40%) of OC cell lines, OVCAR5 and IGROV, 
overexpressed amylase AMY1 and AMY2B to a greater extent than IOSE cells. Though 
expressing small levels of amylase message, SKOV3, OV-90, and TOV21G were shown to 
express AMY1 and AMY2B RNA. Likewise, there was no clear pattern of which amylase isozyme 
is overexpressed in other cancer types at the RNA level (Figure 3.3). Whereas human dermal 
fibroblast (HDF) most notably expresses AMY1 RNA, lung cancer cells H2009 displayed an 
overexpression of amylase AMY1 and AMY2A while amylase RNA was not detected in H69 
cells. Likewise, colorectal cancer WiDr cells displayed an overexpression of amylase AMY1 and 
AMY2B while SW626 cells expressed negligible amounts of AMY1. Similarly, cervical cancer 
cells (Hela, C13) expressed small amounts of AMY1 and AMY2B. Cells lines representing breast 
cancer, head and neck cancer, glioblastoma and pancreatic cancer expressed negligible amounts 
of amylase although when detected, these cell lines preferentially expressed AMY1 RNA and, 
occasionally, AMY2B (Figure 3.3).  
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At the protein level, all OC cell lines examined, TOV21G (8x for AMY1 and 4x for AMY2B), 
OV-90 (13x for AMY1 and 8x for AMY2B), OVCAR5 (10x for AMY1 and 20x for AMY2B), 
SKOV3 (5x for AMY1 and 16x for AMY2B) and IGROV (3x for AMY1 and 9x for AMY2B), 
Figure 3.2. Amylase AMY1 and AMY2B RNA are typically expressed in OC cell lines. 
Cellular RNA was collected from IOSE and OC cells and analyzed by qPCR to determine 
AMY1, AMY2A, and AMY2B message expression. Data are expressed as the average ratio of 
amylase isozyme expression to control GAPDH mRNA from triplicate samples.  
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expressed 3x-20x more amylase AMY1 and AMY2B protein relative to IOSE-121 and IOSE-144 
cells (Figure 3.4, Table 3.1). With the exception of U373MG, MDA231 and H2009 cells, cells 
representing other cancer types, also expressed more AMY1 and/or AMY2B protein relative to 
HDF. That is, breast cancer MCF7 (7x), colorectal cancer WIDR (2x) and SW626 (12x), pancreatic 
cancer PANC1 (9x) and cervical cancer Hela (3x) overexpress AMY1; colon cancer cell line 
SW626 (114x), and pancreatic cancer cell line PANC1 (137x) cells overexpress AMY2A. Breast 
cancer cell line MCF7 (214x), colorectal cancer cell lines WIDR (74x) and SW626 (475x), 
glioblastoma cell line U373MG (20x), pancreatic cancer cell line PANC1 (412x), and cervical 
cancer cell line HELA (200x) overexpressed AMY2B (Figure 3.4, Table 3.1). Overall, protein 
levels of the amylase isozymes were greater in cancer cell lines than normal cells and the amylase 
isozymes most typically expressed are AMY2B and AMY1. Analysis of amylase at the protein 
level showed that AMY1 and AMY2B are consistently elevated in OC cells, whereas, other cancer 
types don’t show consistent amylase overexpression. 
 
 
 
 
 
 
 
 
Figure 3.4: AMY1 and AMY2B protein are overexpressed in OC cell lines (Continued on Next 
Page) 
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Figure 3.4. AMY1 and AMY2B protein are overexpressed in OC cell lines. HDF, IOSE and a 
panel of cancer cells were subjected to western blot to determine the expression of amylase 
isozymes at the protein level (upper panel). Densitometry analysis of was used to determine 
the intensity ratio of amylase isozyme band signal to respective loading control actin bands 
and are shown in corresponding lower panels.  
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Table 3.1: AMY1 and AMY2B are typically overexpressed in cancer cells 
Cancer type Cell line Amylase isozyme overexpressed 
Ovarian TOV21G AMY2B 
Ovarian OV-90 AMY1, AMY2A and AMY2B 
Ovarian OVCAR5 AMY2B 
Ovarian IGROV AMY2B 
Breast MCF7 AMY1 and AMY2B 
Colorectal SW626 AMY1 and AMY2B 
Glioblastoma U373MG AMY2A 
Lung H2009 AMY1 and AMY2A 
Pancreas Panc1 AMY1 and AMY2B 
Cervical Hela AMY1, AMY2A and AMY2B 
 
Amylase secreted by OC cells is metabolically active. 
To determine the proportion of amylase that remains in cell lysates and the proportion that 
is secreted into the media, cytoplasmic lysates from IOSE-121, IOSE-144, OVCAR5 and SKOV3 
cells and their respective CCM of equivalent 104 cells were subjected to an amylase ELISA. 
Normal cells IOSE-121 (total 3 ng/ml) and IOSE-144 (total 2.26 ng/ml) produced negligible 
amounts of amylase protein in cell lysate and CCM, whereas OVCAR5 (total 47.9 ng/ml) and 
SKOV3 (total 8.9 ng/ml) produced 3x to 16x more amylase than normal cells with the majority of 
amylase produced by OC cells secreted into their conditioned medium (Figure 3.5)  
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To determine if secreted amylase was metabolically active, CCM from a panel of cancer 
cell lines was subjected to the amylase activity assay. All cancer cell lines secreted active amylase 
ranging from 0.7 mU/ml to 10 mU/ml. Cervical cancer cell lines secreted active amylase ranging 
from 0.7 mU/ml to 10.5 mU/ml, averaging 4.9 mU/ml. Lung cancer cell lines secreted active 
amylase ranging from 2.6 mU/ml to 3.7 mU/ml, averaging 3.2 mU/ml (Figure 3.6). Levels of 
amylase activity by IOSE cells ranged from 1.5 to 3.7, averaging 2.4 mU/ml. OC cells secreted 
metabolically active amylase to a greater extent than IOSE cells, ranging from 5.1 mU/ml to 34.2 
mU/ml, averaging 11.2 mU/ml so that OC cells secreted up to 4x more active amylase compared 
to normal OSE cells (Figure 3.6). Interestingly, only the glioblastoma (U373MG) and a single 
cervical cancer cell line (C13) secreted greater amounts of metabolically active amylase (6.5 & 
10.5 mU/ML) than IOSE cells. All other remaining cancer cell lines examined secreted amounts 
of metabolically active amylase within a similar range seen in IOSE cells.  
Figure 3.5. OC cells produce more amylase than normal cells. Cell lysates and their CCM were 
subjected to amylase elisa to determine the amounts of amylase in cell lysates and secreted into 
the cell media. Data are expressed as the average of triplicates ± standard deviation (*P < 0.05). 
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Inhibiting amylase decreases OC invasion.  
To begin to understand how amylase promotes OC progression, I investigated whether 
abrogation of amylase affected the invasive capacity of OC cells using collagen coated Boyden 
chambers. Amylase knockdown was performed using pooled amylase siRNAs targeting all 
amylase isozymes. Amylase knockdown was validated by qPCR for amylase mRNA levels 
(Figure 3.7A). Compared to untreated cells, siAMY abrogated AMY1 and AMY2B RNA levels 
in OVCAR5 cells up to 3.7x and 7.8x, respectively. While scramble RNA inhibited AMY2B to 
a lesser extent than siAMY, it did not alter AMY1 expression. As determined by parallel GFP 
signals, transfection efficiency in OVCAR5 and IOSE 121 was determined to be 80% and 76%, 
respectively. Amylase knockdown reduced OC cell invasion especially in SiAMY-treated OC 
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Figure 3.6. OC cells secrete more metabolically active amylase than IOSE cells. CCM, 
equivalent to 104 cells, was subjected to the amylase activity assay. Results are expressed as 
the average amylase activity in mU/ml, normalized for cell number from triplicate samples 
± SE. 
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cell line OVCAR5 by 32% (Figure 3.7B). Scramble RNA did not alter invasive capacities of 
OC cells. Since IOSE121 cells have little amylase expression, reduction of their amylase 
expression did not significantly affect IOSE121 invasion (Figure 3.7). After transfection, cell 
numbers did not change, therefore, amylase does not affect cell proliferation. Cells were 
counted after transfection with scramble RNA and amylase SiRNA for 48 hours and an 
insignificant percent change ranging from 0.5% to 5.3% was noted.  
The glycocalyx of OC cells is thicker than the glycocalyx of IOSE cells:  
Given that amylase appears to mediate OC cell invasion and that amylase is an extracellular 
metabolically active enzyme, I proceeded to examine whether amylase could modulate the 
ECM/tumor microenvironment.  To begin, IOSE121 cells and OC cells were examined by TEM 
to determine the thickness of their respective glycocalyces. As shown in Figure 3.8, the average 
glycocalyx thickness measured from 10 fields of IOSE-121, IGROV, and CAOV3, OVCAR5 and 
SKOV3 was 83.7 nm, 207.4 nm, 264.8 nm, 257.2 nm, and 263 nm, respectively. The glycocalyces 
of OC cells, then, were 2.4x to 3.2x thicker than the glycocalyx of IOSE121 cells (Figure 3.8).  
In order to localize amylase to the OC cell surface and/or its immediate ECM, immunogold 
labeling for amylase was performed. Immunogold labeling illustrated the presence of anti-amylase 
gold particles in OVCAR5 cells (Figure 3.9). Immunogold particles appeared localized at the 
external cell membrane and within the immediate tumor microenvironment. Control sections failed 
to demonstrated presence of immunogold particles. 
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Figure 3.7. Abrogation of amylase reduces invasion in OC cells. A) IOSE121 and OVCAR5 
cells were treated with siRNA targeting amylase and scramble RNA as control. Verification 
of siRNA efficiency was validated by qPCR. B) Treated cells were then seeded into invasion 
assay chambers and number of invasive cells were evaluated after 24-hour incubation. Results 
are expressed as the average relative fluorescence (a measure of the number of invasive cells) 
from triplicate samples ± SE (*P < 0.05). 
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Figure 3.9 Amylase can be localized to the OC cells glycocalyx/cell surface. OVCAR5 cells 
were examined by TEM following immunogold labeling with anti-AMY antibodies (upper 
panel) or serum controls (lower panel).  
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Inhibiting amylase increases GAG production.  
In order to better understand how extracellular amylase could promote OC cell invasion, 
IOSE-121 and OVCAR5 cells were treated with scramble RNA and siRNA targeting amylase and 
subjected to the  Blyscan Sulfated Glycosaminoglycan Assay to measure sulfated glycan 
(proteoglycans and glycosaminoglycans) content at the same time as my Boyden chamber 
experiments. Successful validation of transfection is shown in Figure 3.7A. Abrogating amylase 
in IOSE-121 cells slightly increased cellular GAG content over untreated IOSE-121 cells from 
0.11 ug GAG to 0.33 ug GAG. In contrast, abrogating amylase increased cellular GAG levels in 
OVCAR5 over untreated or scramble RNA treated cells from 1.382 ug to 3.787 ug (Figure 3.10).  
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Figure 3.10 Amylase promotes GAG digestion. IOSE 121 and OVCAR5 cells were treated 
with scramble RNA and amylase siRNA and subjected to the sulfated glycosaminoglycan 
assay. Results are expressed as the total ug of GAGs from triplicate samples ± SE (*P < 0.05). 
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Discussion: 
Amylase (originally known as ptyalin) was discovered in 1831 [347] and has been 
extensively studied since its isolation in 1862 from pancreatic trypsin [348]. Since Weiss et al. 
(1950s) reported a case of an amylase-producing tumor, multiple cases of cancer-associated 
hyperamylasemia have been reported although hyperamylasemia appears limited to few types of 
cancers [273] Nonetheless, hyperamylasemia has been strongly associated with lung cancer, 
ovarian cancer, multiple myeloma and pheochromocytoma cancers [349]. Hyperamylasemia is 
typically asymptomatic and its cause, isozyme profile and contribution to cancer progression are 
still unknown. Salivary amylase (AMY1) and pancreatic amylase (AMY2B) have both been 
proposed to be overexpressed in cancer. AMY2A has also been proposed to be a tumor suppressor 
gene; mutation, deletion, or silencing of AMY2A may lead to malignant transformation in gastric 
cancer [350]. Since OC remains the most lethal gynecologic cancer, studies on the contribution of 
hyperamylasemia to OC are warranted, but require the establishment of an appropriate model 
system.  
Potentially owing to differences in reproductive physiology, humans are the only animals in 
which OC occurs with regular frequency. Laying hens are the only animals that spontaneously 
develop OC, therefore, a laying hen model of OC was characterized to determine its validity as an 
in vivo model of OC [351]. Laying hens spontaneously developed serous, endometrioid, mucinous 
and clear cell ovarian carcinomas with staging, histology and metastatic characteristics similar to 
human OC conditions. However, laying hens only have one ovary, making staging ovarian cancer 
more challenging in hens. Also, lymph nodes in chickens are not well organized so OC metastasis 
in laying hens is not reflective of OC in humans [351]. Rabbit models for papillogenesis may be 
informative for the very early stages of ovarian tumor growth, but these benign conditions 
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indicative of hyper-proliferative events do not progress to full malignant transformation [352]. 
Current mouse models of OC are also of limited use because they either employ intraperitoneal 
(IP) or subcutaneous xenografts or are of genetic backgrounds that do not produce ovarian tumors 
that histologically reflect serous adenocarcinoma of the human ovary. Of note, the most common 
mouse models of OC employ xenograft model types which are effective in mimicking different 
aspects of OC growth and metastasis. However, xenograft models do not reflect the initial 
transformation events that lead to OC tumorigenesis. Genetically engineered mouse models 
(GEMM) are important for investigating early changes that lead to OC; however, GEMMs are 
complicated to generate due to lack of knowledge on OC etiology [353]. Therefore, I chose to use 
an in vitro model system using established human cells lines to study the contribution of amylase 
to OC progression. While a number of OC cell lines have been established and many are 
commercially available, an important advantage for using an in vitro model for studies on the role 
of amylase for OC progression is that normal control cell lines derived from pure human ovarian 
surface epithelium and transfected with SV-40 large T antigen for enhanced lifespan are also 
available. As a result, studies using IOSE cell lines have shown the capacity of OSE cells to 
produce, lyse and reconstruct extracellular matrix components [344,345,354] and a demonstration 
that OSE has the capacity to undergo epithelial-mesenchymal conversions [355].  
As predicted in chapter 2, using cell lines devoid of yeast contamination, I found increased 
protein levels of amylase AMY1 and AMY2B in OC cell lines. In addition, since the majority of 
amylase produced by OC cells was both secreted and metabolically active, so these cell lines 
represent a valid model system to pursue studies on the biological and molecular contribution of 
amylase to OC disease. 
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The glycocalyx is the outermost layer of the cell composed of a negatively charged web of 
enzymes, proteins, and glycoconjugates—one or more glycan units covalently bound to non-
carbohydrate units. Glycoconjugates include glycosaminoglycans (GAGs), glycoproteins, 
glycolipids, and proteoglycans [356]. The glycocalyx is associated with many functions including 
mediating cell-to-cell and cell-to-matrix interactions [357]. It also mediates ligand-receptor 
interactions and other biological processes including specific recognition events. During malignant 
transformation, atypical glycocalyx component expression and structure influences tumor 
progression [356] by enhancing tumor growth, adhesion, motility, and invasion [358]. The 
glycocalyx is also proposed to facilitate cancer progression [356] and cancer metastasis [359]. 
There is a correlation between glycoconjugates present at the cell membrane and the metastatic 
potential of a cell [360]. A denser glycocalyx may promote more receptor interaction and lead to 
more adhesion and migration of tumor cells [358]. It is also believed that the bulky glycocalyx of 
malignant cells may serve a drug-resistant function by acting as a barrier against therapeutic agents 
[358]. My survey of OC cell lines indicated that cancer cell lines have a bulkier glycocalyx 
compared to normal IOSE cells.  
Quintarelli et al. found that amylase degraded the glycan moieties that crosslink collagen 
fibrils, therefore disassociating collagen fibrils and allowing for collagen degradation [361,362]. 
Inhibition of amylase decreased the ability of OC cells to invade collagen coated Boyden 
chambers, thereby identifying a functional behavior of amylase to promote OC progression. 
Amylase secreted by OC cells may, therefore, degrade the glycosylation links that play a role in 
linking collagen fibrils to facilitate OC cell invasion. The role of amylase in the glycocalyx is 
further supported by the presence of amylase in the glycocalyx and ECM as indicated with 
immunogold studies. Amylase in the glycocalyx and ECM suggests that amylase may modify the 
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ECM to promote invasion. Amylase, which cleaves alpha 1, 4-glycosidic bonds in polysaccharides 
to initiate carbohydrate metabolism and contribute to energy production, can also play a role in 
ECM remodeling by cleaving polysaccharide moieties in the tumor microenvironment. Amylase 
has already been shown to degrade connective tissue in bacterial biofilm in wounds [228].  
In summary, to test the hypothesis that secreted amylase may modify the cancer cell glycocalyx 
by digesting α1, 4-glycosidic bonds [235] found in glycosaminoglycans, which in turn leads to 
altered downstream signaling that promotes proliferation, survival or migration/invasion, an in 
vitro model to explore the contribution of hyperamylasemia to OC was established by analyzing 
amylase message and protein levels from a panel of established cell lines. The activity of amylase 
in cell lysates and conditioned concentrated media was also investigated. Lastly, to begin to 
explore the contribution of hyperamylasemia to OC, the in-vitro model established was used to 
determine how amylase contributes to OC cell invasion.  
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Chapter 4 
Regulation of Amylase by Spirulina 
 
Introduction  
Using an in vitro model system, I have been able to demonstrate that elevated levels of 
amylase in OC cells lines, representing hyperamylasemia, may drive disease progression, at least 
in part, by promoting cellular invasion related to alterations in the tumor microenvironment 
(Chapter 3). Amylase, then, may serve as a novel target for therapeutic intervention in OC patients 
with hyperamylasemia. However, commercially available amylase inhibitors typically inhibit 
amylase activity at the protein level and produce a variety of adverse gastrointestinal side effects 
such as flatulence, abdominal distension, and diarrhea [363]. Therefore, there is a need for the 
development of new amylase inhibitors. Spirulina, a dietary supplement, has recently gained 
popularity with many health claims including that it enhances immunity, controls high blood 
pressure and serum cholesterol levels and has anti-tumorigenic, anti-inflammatory and anti-
oxidant properties [364,365]. Spirulina is also associated with neuro-protective properties, as has 
been shown by reduced ischemic brain damage in rats, improved post-stroke locomotor activity 
and reduced levels of pro-inflammatory cytokines in the brain [366–368].  
There are several species of the microalgae spirulina: Spirulina platensis, Spirulina 
fusiforme, and Spirulina maxima. Spirulina has been used as a food source for centuries; with the 
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earliest recorded human consumption of spirulina by the Chadiansa of Africa and Aztecs of 
Mexico [369]. Spirulina is a good nutritional source because of its high protein content; 60-70% 
and 5-10% of spirulina’s dry weight is protein and lipid, respectively. Further, the protein in 
spirulina is complete, meaning it contains all the essential amino acids. Spirulina also contains 
many essential fatty acids (gamma-linolenic, linoleic and oleic acids) and, lastly, spirulina contains 
high levels of vitamin B12, beta-carotene, phycocyanin, superoxide dismutase, iron, calcium and 
phosphorous [369,370].  
In this chapter, I propose employing spirulina or phycocyanin, one of the active ingredients 
in spirulina with high anti-inflammatory potential [371], as novel transcriptional inhibitors of 
amylase. By determining whether spirulina can inhibit OC cell invasion without cytotoxicity to 
normal cells, a novel clinical use for spirulina will be established.  
 
 
Materials and Methods  
Tissue Culture  
The following human cell lines were used:  normal human dermal fibroblasts HDF; SV 40-
Large T-Antigen transfected human ovarian surface epithelial (IOSE) cell lines MCC3,  IOSE-80, 
IOSE-121, and IOSE-144 [344,345]; OC cell lines CaOV3, OVCAR5, OV-90, SKOV3, TOV21G 
and IGROV; colorectal cancer cell lines WiDr and SW626; breast cancer cell lines MDA-MB-
231, MDA-MB-231, MCF7; head and neck cancer cell line HN5α [346]; cervical cancer cell line 
Hela; pancreatic cancer cell line Panc1; lung cancer cell lines NCI-H2009 and H69; and 
glioblastoma U373MG cells. Cells were cultured in Medium 199/MCDB 105 (Sigma, St. Louis, 
MO) with 5% fetal bovine serum (FBS) and gentamicin and incubated at 37°C with 5% CO2. 
Conditioned media was concentrated (CCM) using Centriprep Centrifugal Filter Devices (Ultracel 
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YM-3 Cat.4302 Merck Millipore Ltd, Tullagreen, Ireland). Cell lines were treated with ± 0-150 
ug/ml spirulina (kindly provided by Dr. P Bickford, USF) or 1-100 ug/ml phycocyanin (Catalog 
number: P2172-25MG; Sigma Aldrich; St. Louis, MO) for 0-72 h.  
Microarray 
HN5α cells were treated for 24h ± 100ug/ml spirulina, RNA collected, reverse transcribed, 
amplified and labeled with biotin at the H. Lee Moffitt Cancer Center Microarray core facility. 
Biotin-labeled DNA was applied to Human Genome U133A Affymetrix chips and analyzed using 
Affymetrix Microarray MAS 5.0 software to identify increased and decreased gene expression at 
p < 0.005.  
Quantitative PCR  
Cells were treated with TRIzol reagent from Invitrogen (Carlsbad, CA) and ribonucleic acid 
(RNA) was isolated according to the manufacturer’s instructions. To generate single-stranded 
complementary DNA (cDNA), the Applied Biosystems GeneAmp RNA polymerase chain 
reaction (PCR) Core Kit (Foster City, CA) was used with 3 ug/mL total RNA using a Biometra 
UNO-thermo-block and Perkin-Elmer-GeneAmp PCR system 9600. qPCR was carried out with 
SYBR Green Universal Master Mix (Applied Biosystems), cDNA, and primers. Primers used were 
AMY1A (GeneCopoeia: Hs-QRP-21480), AMY2A (GeneCopoeia: Hs-QRP-21450), AMY2B 
(GeneCopoeia: Hs-QRP-21451), and GAPDH (GeneCopoeia: Hs-QRP-20169) as control. 
Sequences for the amylase primers remain the proprietary property of GeneCopoeia. Amplification 
was performed with 40 cycles of denaturation (95°C, 10 sec), annealing (60°C, 20 sec), and 
extension (72°C, 15 sec) using a Bio-RAD Chromo4 Real Time PCR Detector using Opticon 
Monitor 3 program. Levels of amylase was normalized to the GAPDH message values and the 
fold difference was determined by dividing the threshold cycle (Ct) value by the reference sample.  
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Western blot 
Cells were washed in PBS, trypsinized, pelleted, rewashed with PBS and counted. Cells were 
lysed in CHAPS buffer for 30 minutes on ice before being centrifuged at 115,000 x g, at 4°C for 
1h. Twenty ug of protein were separated by a 10% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). Proteins were transferred to Polyvinylidene fluoride (PVDF) 
membranes, washed in Tween 20-Tris buffered Saline (TBST), and blocked in 5% milk in TBST 
or PBST. Blots were incubated in their respective primary antibodies overnight, followed by 
incubation with a horseradish peroxidase (HRP)-conjugated secondary antibody (Fisher, 
Pittsburgh, PA), and developed via FEMTO Cat. 34095 Life Technologies (Grand Island, NY).   
Antibodies used were: AMY1A (1:1000) Cat.H00000276-M04 Abnova (Taipei City, Taiwan); 
AMY2A (1:500) 15845-1-AP Proteintech (Chicago, IL); AMY2B (1:2000) Cat. LS-C173958 
LSBio (Seattle, WA); Beta Actin Loading Control Antibody (BA3R) (1:10,000) Cat. # MA5-
15739 Thermo Scientific (Rockford, IL).  Densitometry was performed using ImageJ software to 
normalize amylase band strength to their respective actin band. 
Amylase ELISA 
To measure amylase protein levels, 100ul of cytoplasmic lysate and CCM of equivalent cell 
number (104/well) were assayed in triplicate using the quantitative double sandwich enzyme-
linked immunosorbant assay (Amy-p ELISA Kit; catalog number: MBS264855; MyBioSource, 
San Diego, CA) according to the manufacturer's instructions. Absorbance was read on a Microplate 
Reader BioTek ELx800 (Winooski, Vermont) using Gen5 Data Analysis Software (Biotek, 
Winooski, Vermont). Resultant values were derived from a standard curve and expressed as the 
mean amylase concentration of triplicate samples. 
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Invasion assay  
Spirulina treated cells were incubated on type I collagen coated transwells (CytoSelect 96-
Well Cell Invasion Assay, catalog number: CBA-112-COL (San Diego, CA)) for 24 hours. 
Following incubation, transwell filters were stained with a 0.1% crystal violet solution and 
photographed using an Olympus DP20 digital camera (Burnaby, BC, Canada) under a Leica 
DMIRE2 microscope. The number of cells that had migrated through the collagen cell and across 
the transwell membrane was then counted. 
MTS assay 
Cell growth and cytotoxicity were determined by the MTS assay (Promega, Madison, WI) 
according to the manufacturer's directions. Cells (1 × 103) were seeded in 96-well plates and grown 
in Medium 199/MCDB 105 (Sigma, St. Louis, MO) containing 0.1% FBS. Cells were treated with 
varying concentrations of spirulina (0ug/ml, 50ug/ml, 100ug/ml, 150ug/ml). Absorbance was read 
nm using a multi-well plate reader (BioTek, Winooski, VT, USA) every 24 hours for 72 hours. 
The samples were assayed in two separate experiments, each in triplicate and the results were 
expressed as the mean ± standard error. 
Statistical Analyses 
For real time PCR, error bars illustrate RQmin and RQmax, which were calculated as:  RQave 
divided by (standard deviation^ student’s t value at the 95% confidence interval, for 5 degrees 
freedom) and RQave times (standard deviation^ student’s t value at the 95% confidence interval, 
for 5 degrees of freedom), respectively.  This range represents the 95% confidence level.  For 
amylase activity assays, ELISA, MTS, and invasion student’s t test was performed to assess 
statistical difference between means of triplicates ± standard error.  
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Results  
Amylase is a downstream target of spirulina. 
In order to screen for downstream targets of spirulina, an Affymetrix microarray was 
performed on spirulina treated HN5α cells. The results indicated that spirulina downregulated all 
amylase isozyme expression at least 2.5 fold. Spirulina also suppressed expression of multiple 
transcription factors predicted to regulate amylase gene expression (Chapter 2) including C/EBP 
alpha, C/EBP delta, Zic1 and POU1F1 (Table 4.1).  
Table 4.1: Spirulina transcriptionally targets amylase  
Gene Fold change 
AMY1A, AMY1B, AMY1C, AMY2A, AMY2B, ACTG1P4, AMYP1 -2.62 
AMY1A, AMY1B, AMY1C, AMY2A, AMY2B -2.5 
AMY1A, AMY1B, AMY1C, AMY2A, AMY2B, ACTG1P4, AMYP1 -2.5 
CCAAT/enhancer binding protein (C/EBP), alpha -1.18 
CCAAT/enhancer binding protein (C/EBP), delta -1.15 
Zic1 -1.05 
POU1F1 -1.19 
 
Spirulina downregulates amylase mRNA expression in OC cell lines. 
To confirm that spirulina inhibits amylase expression, a panel of cancer cell lines was 
treated ± 100ug/ml spirulina and amylase expression was measured using qPCR. While spirulina 
downregulated amylase expression in normal human dermal fibroblasts between 43% (AMY2B) 
to 95% (AMY2A) among the amylase isozymes, the pattern of spirulina-mediated inhibition of 
amylase expression varied among cancer cell types (Figure 4.1).  
Spirulina significantly downregulated the expression of all amylase isozymes by 46% to 
99% in colon cancer cells (WIDR and SW626) and by 57% to 77% in breast cancer cells MDA231, 
but it actually increased amylase isozyme expression by 1302% for AMY1, 79418% for AMY2A, 
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and 588% for AMY2B in MCF7 breast cancer cells. Similarly, spirulina increased amylase 
isozyme expression by 511% to 1875% in glioblastoma cells U373MG.  Spirulina also 
downregulated amylase isozyme expression by approximately 80% in cervical cancer cells Hela. 
Spirulina downregulated AMY1 (43%) and AMY2A (82%) expression in pancreatic cancer cells 
PANC1, but increased AMY2B (200%) expression. In addition, spirulina downregulated at least 
two amylase isozymes in lung cancer cells (H2009) by 54%.  
In contrast, spirulina consistently downregulated amylase expression in amylase positive OC 
cells with spirulina-mediated inhibition of AMY1 and AMY2B, ranging from 6% to 99% (Figure 
4.2). However, spirulina did not significantly decrease small endogenous levels of amylase 
expression in IOSE-121 (Figure 4.2).  
Spirulina downregulates amylase protein expression in OC cell lines. 
Since RNA levels do not always accurately reflect target protein levels, to determine if 
spirulina-mediated inhibition of amylase could be detected at the protein level, cells were treated 
with 100ug/ml spirulina for 24 hours and protein amylase isozyme expression was determined 
using western blot. While there was no significant change in amylase protein levels in IOSE-121 
cells after spirulina treatment (Figure 4.3), spirulina reduced AMY1 protein levels in OVCAR5 
and OV-90 cells by 23% and 26%, respectively; spirulina reduced AMY2A protein levels in 
OVCAR5 and OV-90 cells by 51% and77%, respectively and spirulina reduced AMY2B protein 
levels in OVCAR5 and OV-90 cells by 25% and 43%, respectively. 
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Figure 4.2. Spirulina transcriptionally downregulates amylase in OC cell lines. Cells treated 
± 100 ug/ml spirulina treatment were subjected to qPCR to determine amylase isozyme 
expression. Data are expressed as the ratio of amylase isozyme signal to GAPDH. 
0
0.0001
0.0002
0.0003
0.0004
0.0005
0.0006
0.0007
0.0008
0.0009
0.001
A
M
Y1
A
M
Y2
A
A
M
Y2
B
A
M
Y1
A
M
Y2
A
A
M
Y2
B
A
M
Y1
A
M
Y2
A
A
M
Y2
B
A
M
Y1
A
M
Y2
A
A
M
Y2
B
A
M
Y1
A
M
Y2
A
A
M
Y2
B
A
M
Y1
A
M
Y2
A
A
M
Y2
B
A
M
Y1
A
M
Y2
A
A
M
Y2
B
A
M
Y1
A
M
Y2
A
A
M
Y2
B
A
M
Y1
A
M
Y2
A
A
M
Y2
B
A
M
Y1
A
M
Y2
A
A
M
Y2
B
IOSE-121 IOSE-121 +
100ug/ml
spirulina
OV-90 OV-90 +
100ug/ml
spirulina
TOV21G TOV21G +
100ug/ml
spirulina
IGROV IGROV +
100ug/ml
spirulina
OVCAR5 OVCAR5 +
SPIR
R
at
io
 o
f 
A
M
Y/
G
A
P
D
H
 m
R
N
A
Figure 4.3. Spirulina reduces amylase protein levels in OC cell lines. Cells treated ± 100 
ug/ml spirulina were subjected to western blot analysis to determine amylase isozyme protein 
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Spirulina reduces amylase secretion by OC cell lines. 
To determine if spirulina inhibited amylase secretion, cell lysates and CCM collected from 
IOSE-121, IOSE-144, OVCAR5 and SKOV3 cells treated with 100ug/ml spirulina for 24 h and 
then subjected to an amylase ELISA (Figure 4.4). In agreement with figure 4.3, I found 12% 
reduction in cellular amylase in IOSE-121 and -144, respectively. In addition, levels of secreted 
amylase in IOSE-121 and -144 were reduced by 28% and 18% following spirulina treatment, 
respectively. Also in agreement with figure 4.3, I found 72% and 16% reduction in cellular amylase 
in OVCAR5 and SKOV3 cells, respectively. More notably, levels of secreted amylase in OVCAR5 
and SKOV3 cells were reduced by 90% and 6% following spirulina treatment, respectively.  
  
 
 
 
 
Figure 4.4. Spirulina reduces amylase secretion in OC cell lines. Cell lysates and CCM from 
cells treated ± spirulina were subjected to amylase ELISA to determine relative amounts of 
cellular and secreted amylase. Data are presented as the mean of triplicates ± SE (*P<0.05). 
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Spirulina decreases the invasive capacity of OC cells. 
Using Boyden chamber assays, I found that spirulina did not significantly reduce invasive 
capacity in IOSE-121 cells (Figure 4.5). However, spirulina significantly reduced invasive 
capacity of OVCAR5 by 51% compared to untreated cells.  
  
 
Spirulina decreased migration of OVCAR5 cells. 
To confirm the inhibitory effect of spirulina for OC cell motility, OVCAR5 cells were 
visualized in a scratch assay for 0-24 hours ± 100 ug/ml spirulina. Untreated cells migrated to fill 
the scratch gap within 24 h (Figure 4.6) However, spirulina-treated cells did not migrate as quickly 
and had only filled in 64% of their scratch gap at 24h.  
Figure 4.5. Spirulina decreased invasive capacity in OC cells. IOSE-121 and OVCAR5 cells 
were treated ± 100 ug/ml spirulina and assayed in Boyden chambers. Data are presented as 
the mean of triplicates ± S.E.  (*P<0.05).  
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 OVCAR5 + 100 ug/ml spirulina 
Figure 4.6. Spirulina reduced migration in OVCAR5 cells. OVCAR5 
cells were visualized in a scratch assay for 0-24h ± 100 ug/ml spirulina. 
Experiment was performed in triplicate. Representative scratch assay is 
illustrated in the upper panel while lower panel represents percent wound 
closure. 
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Spirulina does not alter OC proliferation. 
To determine whether spirulina is potentially cytotoxic for normal or OC cells, IOSE and 
OC cell survival and growth were measured by MTS assay for 0-72 hours when treated with a 
range of concentrations of spirulina (Figure 4.7). Spirulina did not significantly alter or affect 
proliferation of either OSE or OC cells.  
  
Figure 4.7. Spirulina did not alter IOSE or OC cell survival and proliferation. IOSE-121, IOSE-
144, OVCAR5 and OV-90 cells were treated with varying concentrations—0ug/ml, 50ug/ml, 
100ug/ml, 150ug/ml— of spirulina and proliferation was measured every 24 hours for 72 hours. 
Data are presented as the mean of two biological experiments, each performed in triplicates ± 
SE. 
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Phycocyanin abrogates amylase RNA expression.  
IOSE-121 and OVCAR5 cells were treated with spirulina or phycocyanin in order to 
determine if transcriptional downregulation of amylase by spirulina is due to one of its major active 
ingredients, phycocyanin. In agreement with my earlier data (Figure 4.2), spirulina failed to 
suppress amylase isozyme RNA expression in IOSE-121 (Figure 4.8), but phycocyanin increased 
AMY1 and AMY2B RNA expression levels in a dose related manner. In contrast, but also in 
agreement with my earlier data (Figure 4.2), spirulina completely inhibited AMY1 and AMY2B 
RNA levels in OVCAR cells. Likewise, phycocyanin completely abrogated AMY1 and AMY2B 
RNA levels in OC cells.  
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Figure 4.8. Phycocyanin abrogates amylase expression in OC cells. IOSE-121 and OVCAR5 
cells were treated with 100 ug/ml spirulina, 1ug/ml phycocyanin or 100 ug/ml phycocyanin and 
subjected to qPCR for amylase isozyme RNA expression. Data are expressed as the ratio of 
amylase isozyme signal to GAPDH.  
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Spirulina-induced inhibition of OC invasion is driven, in part, by phycocyanin. 
To determine whether spirulina-mediated inhibition of OC invasive capacity was driven by 
phycocyanin, using Boyden chamber assays, I found that neither spirulina nor phycocyanin 
significantly reduced invasive capacity in IOSE-121 cells (Figure 4.9). In agreement with my 
earlier data (Figure 4.5), spirulina reduced the invasive capacity of OVCAR5 cells by 
approximately 51%. However, phycocyanin was only able to reduce the invasive capacity of 
OVCAR5 cells by approximately 32%, suggesting that spirulina-induced inhibition of OC 
invasion is driven only in part by phycocyanin.  
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Figure 4.9. Spirulina driven inhibition of OC invasion is partly mediated by phycocyanin. 
IOSE-121 and OVCAR5 cells were treated with 100 ug/ml spirulina or 1ug/ml phycocyanin 
and assayed in collagen-coated Boyden chambers. Data are presented as the mean of 
triplicates (*P<0.05).  
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Discussion 
Dietary supplements are widely recognized for their medicinal benefits. Many are or 
contain free radical scavengers that promote improved health through anti-inflammatory activity 
and clinically manifest as reduced incidence of disease, reduced damage associated with disease 
and/or accelerated healing from disease. For example, curcumin, an active component of the spice 
turmeric is widely used traditional Chinese herbal medicine. It has anti-cancer properties related 
to suppression of the NF-κB signaling pathway which inhibits cellular proliferation and metastasis 
[372]. Further, treatment of endometrial carcinoma cells, HEC-1B, with curcumin results in 
decreased migration and invasion by reducing the expression and activity of MMP-2/9 via 
suppression of the ERK signaling pathway [372,373]. 
Likewise, the clinical benefits of spirulina have also been investigated with regards to its 
anti-oxidant, anti-inflammatory and anti-cancer properties. Several preclinical and clinical studies 
have investigated the hypolipidemic effects of spirulina, that is, its ability to reduce cholesterol by 
decreasing low-density lipoproteins (LDL), very low-density lipoproteins (HLDL), and 
triglycerides (TG) and increase protective high-density lipoproteins (HDL). The cumulative data 
indicates that spirulina has hypolipidemic activity in healthy young [374] and elderly volunteers, 
patients with type 2 diabetes [375], patients with nephrotic syndrome [376] and patients with 
ischaemic heart disease [377]. However, the exact molecular mechanism by which spirulina 
promotes its hypolipidemic effects has not yet been elucidated [364]. 
The antioxidant and anti-inflammatory effects of spirulina were examined in in-vitro, pre-
clinical and some clinical studies. Spirulina can decrease the inflammatory reaction induced by 
toxic, oxidative and physical damaging agents [378,379]. Spirulina’s antioxidant and anti-
inflammatory effects have been attributed to phycocyanin and β-carotene. Phycocyanin is an 
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antioxidant that can scavenge free radicals and lower lipid peroxidation [371]. Phycocyanin has 
also been reported to inhibit TNF alpha and nitrile production [380]. On the other hand, the anti-
oxidant properties of β-carotene are related to its ability to decrease production of nitric oxide 
(NO) and PGE(2), inducible NO synthase (iNOS), cyclooxygenase-2, TNF-alpha, and IL-1beta 
[381].  
Lastly, the anti-cancer properties of spirulina have also been studied. Spirulina and 
compounds isolated from spirulina, including phycocyanobilin and chlorophyllin, tetrapyrrolic, 
significantly decrease proliferation of human pancreatic cancer cells in xenotransplanted nude 
mice [382]. Spirulina has been reported to down-regulate inflammation and carcinogenesis 
induced by UVB irradiation in the skin [383]. Additionally, spirulina exhibited anti-proliferative 
activity with low cytotoxicity in five cancer cell lines – HepG2 (liver cancer cell line), MCF-7 
(breast cancer cell line), SGC-7901 (gastric cancer cell line), A549 (non-small cell lung cancer), 
and HT-29 (colon colorectal cancer cell line) [384]. Finally, colon colorectal cells (Caco-2) treated 
with spirulina display decreased proliferation, migration and increased apoptosis that may be 
related to increased intracellular reactive oxygen species (ROS) and nitric oxide (NO) levels [385].  
In contrast, there have only been two reports investigating the role of spirulina in OC and 
both studies were limited to the effect of phycocyanin in a single OC cell line. By targeting 
mitochondrial proteins, phycocyanin was reported to inhibit cellular proliferation and induce 
apoptosis by increased ROS production and activation of caspase-3, -8, and -9 in SKOV3 cells. 
[386]. Ying et al. (2016) suggested that the anti-proliferative action of phycocyanin in SKOV3 
cells could be mediated through 18 cellular pathways [387].  
In the present study, I showed that amylase is a downstream target of spirulina. Spirulina 
consistently downregulated amylase isozyme expression at the message and protein levels. As a 
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result, spirulina, and to a lesser degree, phycocyanin appear to abrogate OC invasion by inhibiting 
amylase-mediated OC cell migration and invasion. Importantly, spirulina did not appear to 
adversely affect normal OSE cells. Given that the high mortality associated with OC is due, to a 
large extent, by its propensity to metastasize early, the subset of patients whose cancers 
overexpress amylase may benefit from adjuvant spirulina therapy to minimize burden of disease. 
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Chapter 5 
Concluding Remarks 
 
Although its etiology is poorly understood, OC accounts for 4% of all cancer cases and 
4.2% of all cancer deaths worldwide. OC is the most lethal gynecological cancer because early 
symptoms of the disease are generally lacking. As a result, more than 70% of OC patients are 
diagnosed in later stages when the disease has already metastasized. Women diagnosed in late 
disease stage have a 5-year survival rate of less than 20% compared with approximately 90% 
survival for women diagnosed with early stage disease. The current gold standard for OC 
detection, serum CA-125, is only elevated in 50% of stage I OC patients so that CA-125 is more 
useful as a prognostic rather than a diagnostic marker [388]. Therefore, there remains an urgent 
need to better understand the cellular and molecular regulators that drive OC progression in order 
to reduce metastatic spread as well as identify novel diagnostic and therapeutic targets.  
A number of potential OC biomarkers have been reported to date. However, their efficacy 
for disease detection or functional contribution to OC progression is limited. Therefore, I initiated 
my studies with a computational analysis of the 27 most commonly reported literature-derived 
ovarian cancer (LDOC) protein biomarkers. I found that LDOC protein biomarkers share many 
biochemical features including a preponderance for a stable protein structure (ordered, hydrophilic, 
aggregation-prone, glycosylated and sumoylated), the ability to be secreted (export signal peptide 
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sequence, hydrophilic) and functionality related to ECM modification, immune response and/or 
energy production. Subsequently, I analyzed the human proteome to identify additional proteins 
that also share these biochemical features. Of the 70,616 proteins in the human proteome, 683 
proteins were found to have similar biochemical features to the 27 LDOC proteins. With further 
computational analyses I identified a subset of 21 potential additional protein regulators of ovarian 
cancer (APROC) sharing similar functional and biochemical protein profiles and interactivity with 
LDOCs in the humane proteome.   
Three of the APROCs identified were amylase (AMY) AMY1A, AMY2A, and AMY2B, 
which compromise the members of the human amylase gene family. Amylase cleaves alpha 1, 4-
glycosidic bonds in polysaccharides to initiate carbohydrate metabolism, thereby contributing to 
energy production. Amylase is reportedly overexpressed in and secreted by ovarian tumors [262]. 
Hyperamylasemia has been studied as both a diagnostic and prognostic indicator even though its 
functional contribution to OC progression remains unknown [1]. Since amylase can degrade 
bacterial biofilms in wounds [228], it is possible that, by cleaving polysaccharide moieties in the 
tumor microenvironment, amylase also plays a role in ECM remodeling. Consequently, I sought 
to determine whether amylase could promote OC cell migration and invasion.  
 I initiated my studies on the role of amylase to drive OC invasion with additional 
computational studies focused on characterizing the different amylase isozymes in order to predict 
which amylase isozyme(s) is most likely overexpressed in and contributory to OC invasion. I found 
that there were significant differences among the isozymes. Specifically, AMY1 and AMY2B have 
unique regions of disorder, unique regions of aggregation and unique phosphorylation sites 
indicating that AMY1 and AMY2B would be more likely to interact with other proteins, to 
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aggregate and to be easily secreted. Using serum samples from patients with OC, I was able to 
validate AMY1 and AMY2B overexpression by western immunoblotting.  
I then developed an in vitro model system to study the molecular contribution of amylase 
to OC using IOSE and OC cell lines. I showed that OC cells generally overexpress and secrete 
metabolically active amylase isozymes AMY1 and AMY2B. Abrogating amylase activity using 
siRNA silencing technology decreased the capacity of OC cells to invade collagen coated Boyden 
chambers and increased sGAG production. Since a survey of OC cell lines indicated that cancer 
cells have a bulkier glycocalyx compared to IOSE cells and immunogold labeling studies indicated 
the presence of amylase within the immediate OC microenvironment, my data suggest that, by 
cleaving alpha 1, 4-glycosidic bonds in glycoconjugates (glycosaminoglycans (GAGs), 
glycoproteins, glycolipids, and proteoglycans) present within ECM, amylase may remodel the 
ECM to promote an invasive cancer phenotype.  
Further studies are needed to validate the hypothesis that amylase may promote OC 
invasion by altering the glycocalyx/ECM architecture in OC. Assuming that amylase maintains its 
traditional enzymatic activity in the OC ECM, GAGs within the glycocalyx containing α-1, 4-
glycosidic bonds should be susceptible to hydrolysis by amylase enzymatic activity. By cleaving 
α-1, 4-glycosidic bonds in negatively charged repellant GAGs [356], amylase may lead to 
proteoglycan condensation. Consequently, this proteoglycan condensation could result in integrin 
clustering and dimerization, leading to an altered glycocalyx characteristic of malignant cells that 
is associated with an invasive phenotype (Figure 5.1). Weaver et al. described metastatic tumors 
which overexpress bulky glycan structures and glycoproteins that alter integrin organization by 
funneling active integrins together. Glycocalyx –mediated integrin clustering promote phenotypes 
associated with cancer [389,390].   
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Amylase could, then, be a target for therapeutic intervention in OC patients with 
hyperamylasemia. However, commercially available amylase inhibitors typically inhibit amylase 
activity at the protein level and produce a variety of adverse gastrointestinal side effects [363]. I 
established Spirulina, a dietary supplement, as a novel transcriptional inhibitor of amylase. 
Spirulina inhibited amylase expression in OC cell lines at both the message and protein levels. 
Spirulina reduced OC cell invasion and migration in vitro, putatively by decreasing amylase 
expression. Phycocyanin, one of the active ingredients of spirulina, was investigated in order to 
determine if it was responsible for the downregulation of amylase expression and reduced invasion 
induced by spirulina. I found that phycocyanin reduced amylase expression in and invasive 
Figure 5.1. Schematic of the possible influence of amylase in altering the glycocalyx of OC 
cell and consequently lead to a more malignant phenotype. Amylase may cleave α-1, 4-
glycosidic bonds in OC cell glycocalyx which leads to proteoglycan condensation and integrin 
clustering. The resulting altered glycocalyx promotes a malignant phenotype. 
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behavior of OC cells, but the degree to which phycocyanin reduced amylase-mediated activities 
was less than that of spirulina. Therefore, multiple components of spirulina are likely responsible 
for regulating amylase expression.  
Clearly, further studies are warranted to determine the clinical impact of amylase in OC, 
and, potentially other cancer types. Since lung cancer is also often clinically associated with 
hyperamylasemia, it would be interesting to determine whether amylase similarly mediates cellular 
invasion in lung cancer cells. Given the lack of sensitive and specific biomarkers for OC, it might 
also be clinically impactful to examine the potential for serum amylase to serve as a biomarker of 
disease based on amylase isozyme subtype. Furthermore, spirulina may be an attractive and 
effective therapy/therapeutic adjuvant to reduce the migratory and invasive capabilities of OC cells 
leading to decreased disease burden. Going forward, it would be important to identify and isolate 
the specific components of Spirulina that transcriptionally inhibit amylase as well as examine other 
dietary supplements for their ability to inhibit amylase alone or in concert with Spirulina. Lastly, 
I have shown the power of computational analyses to provide insight about the different molecular 
mechanisms employed by disease regulators with shared protein profiles. I would hope that future 
endeavors explore the biochemical features, metabolic pathways and protein-protein networks 
among the remaining APROC candidates to provide additional insights about the appearance of 
diverse histologic subtypes, the propensity for metastatic spread and the emergence of drug 
resistance in OC. This, in turn, could reduce the mortality of a disease that kills thousands of 
women annually. 
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Appendix I 
 
Potential novel regulators or biomarkers of OC – 683 proteins in total of non-redundant, 
secreted, ordered and aggregation-prone human proteins. 
 
Appendix I 
Uniprot 
entry 
Uniprot 
entry 
name 
Gene name Protein name 
Proteins functionally related to ECM/microenvironment modifications 
A8K2U0 A2ML1 A2ML1 CPAMD9   
Q9Y653 AGRG1 ADGRG1 GPR56 TM7LN4 
TM7XN1 UNQ540/PRO1083 
 
P01019 ANGT AGT SERPINA8 Angiotensinogen (Serpin A8) 
[Cleaved into: Angiotensin-1 
(Angiotensin 1-10) (Angiotensin I) 
(Ang I); Angiotensin-2 
(Angiotensin 1-8) (Angiotensin II) 
(Ang II); Angiotensin-3 
(Angiotensin 2-8) (Angiotensin 
III) (Ang III) (Des-Asp[1]-
angiotensin II); Angiotensin-4 
(Angiotensin 3-8) (Angiotensin 
IV) (Ang IV); Angiotensin 1-9; 
Angiotensin 1-7; Angiotensin 1-5; 
Angiotensin 1-4] 
Q13740 CD166 ALCAM MEMD CD166 antigen (Activated 
leukocyte cell adhesion molecule) 
(CD antigen CD166) 
S4R3Y4 S4R3Y4 AMBP Protein AMBP 
Q15389 ANGP1 ANGPT1 KIAA0003 Angiopoietin-1 (ANG-1) 
O15123 ANGP2 ANGPT2 Angiopoietin-2 (ANG-2) 
O95841 ANGL1 ANGPTL1 ANG3 ANGPT3 
ARP1 PSEC0154 
UNQ162/PRO188 
Angiopoietin-related protein 1 
(Angiopoietin-3) (ANG-3) 
(Angiopoietin-like protein 1) 
Q9UKU9 ANGL2 ANGPTL2 ARP2 
UNQ170/PRO196 
Angiopoietin-related protein 2 
(Angiopoietin-like protein 2) 
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P58335 ANTR2 ANTXR2 CMG2 Anthrax toxin receptor 2 
(Capillary morphogenesis gene 2 
protein) (CMG-2) 
O95393 BMP10 BMP10 Bone morphogenetic protein 10 
(BMP-10) 
P22003 BMP5 BMP5 Bone morphogenetic protein 5 
(BMP-5) 
P22004 BMP6 BMP6 VGR Bone morphogenetic protein 6 
(BMP-6) (VG-1-related protein) 
(VG-1-R) (VGR-1) 
P18075 BMP7 BMP7 OP1 Bone morphogenetic protein 7 
(BMP-7) (Osteogenic protein 1) 
(OP-1) (Eptotermin alfa) 
P59826 BPIB3 BPIFB3 C20orf185 LPLUNC3 BPI fold-containing family B 
member 3 (Ligand-binding protein 
RYA3) (Long palate, lung and 
nasal epithelium carcinoma-
associated protein 3) 
Q075Z2 BSPH1 BSPH1 Binder of sperm protein homolog 
1 (Bovine seminal plasma protein 
homolog 1) (Bovine seminal 
plasma protein-like 1) 
P35070 BTC BTC Probetacellulin [Cleaved into: 
Betacellulin (BTC)] 
Q9BXJ1 C1QT1 C1QTNF1 CTRP1 
UNQ310/PRO353 
Complement C1q tumor necrosis 
factor-related protein 1 (G protein-
coupled receptor-interacting 
protein) (GIP) 
Q9BXJ0 C1QT5 C1QTNF5 CTRP5 
UNQ303/PRO344 
Complement C1q tumor necrosis 
factor-related protein 5 
P60827 C1QT8 C1QTNF8 
UNQ5829/PRO19648 
Complement C1q tumor necrosis 
factor-related protein 8 (C1q/TNF-
related protein 8) (CTRP8) 
Q8IUK8 CBLN2 CBLN2 UNQ1892/PRO4338 Cerebellin-2 
P48960 CD97 CD97   
Q9H5V8 CDCP1 CDCP1 TRASK 
UNQ2486/PRO5773 
 
P13688 CEAM1 CEACAM1 BGP BGP1 Carcinoembryonic antigen-related 
cell adhesion molecule 1 (Biliary 
glycoprotein 1) (BGP-1) (CD 
antigen CD66a) 
Q2WEN9 CEA16 CEACAM16 CEAL2 Carcinoembryonic antigen-related 
cell adhesion molecule 16 
(Carcinoembryonic antigen-like 2) 
178 
  
Q9UNI1 CELA1 CELA1 ELA1 Chymotrypsin-like elastase family 
member 1 (EC 3.4.21.36) 
(Elastase-1) (Pancreatic elastase 1) 
P08217 CEL2A CELA2A ELA2A Chymotrypsin-like elastase family 
member 2A (EC 3.4.21.71) 
(Elastase-2A) 
Q9BXR6 FHR5 CFHR5 CFHL5 FHR5 Complement factor H-related 
protein 5 (FHR-5) 
Q15782 CH3L2 CHI3L2 Chitinase-3-like protein 2 
(Chondrocyte protein 39) (YKL-
39) 
Q9BU40 CRDL1 CHRDL1 NRLN1 Chordin-like protein 1 (Neuralin-
1) (Neurogenesin-1) (Ventroptin) 
Q9UQC9 CLCA2 CLCA2 CACC3   
O43405 COCH COCH COCH5B2 
UNQ257/PRO294 
Cochlin (COCH-5B2) 
P12109 CO6A1 COL6A1   
P12111 CO6A3 COL6A3   
A8TX70 CO6A5 COL6A5 COL29A1 VWA4  
A6NMZ7 CO6A6 COL6A6   
Q8IVL8 CBPO CPO Carboxypeptidase O (CPO) (EC 
3.4.17.-) 
O75629 CREG1 CREG1 CREG 
UNQ727/PRO1409 
Protein CREG1 (Cellular repressor 
of E1A-stimulated genes 1) 
Q9H0B8 CRLD2 CRISPLD2 CRISP11 LCRISP2 
UNQ2914/PRO1156/PRO9783 
Cysteine-rich secretory protein 
LCCL domain-containing 2 
(Cysteine-rich secretory protein 
11) (CRISP-11) (LCCL domain-
containing cysteine-rich secretory 
protein 2) 
O60676 CST8 CST8 CRES Cystatin-8 (Cystatin-related 
epididymal spermatogenic protein) 
Q9H4G1 CST9L CST9L CTES7B 
UNQ1835/PRO3543 
Cystatin-9 (Cystatin-like 
molecule) 
Q8N907 DAND5 DAND5 CER2 CKTSF1B3 
GREM3 SP1 
DAN domain family member 5 
(Cerberus-like protein 2) (Cerl-2) 
(Cysteine knot superfamily 1, 
BMP antagonist 3) (Gremlin-3) 
Q07507 DERM DPT Dermatopontin (Tyrosine-rich 
acidic matrix protein) (TRAMP) 
O60469 DSCAM DSCAM   
Q14507 EP3A EDDM3A FAM12A HE3A Epididymal secretory protein E3-
alpha (Human epididymis-specific 
protein 3-alpha) (HE3-alpha) 
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P56851 EP3B EDDM3B FAM12B HE3B 
UNQ6412/PRO21187 
Epididymal secretory protein E3-
beta (Human epididymis-specific 
protein 3-beta) (HE3-beta) 
O43854 EDIL3 EDIL3 DEL1 EGF-like repeat and discoidin I-
like domain-containing protein 3 
(Developmentally-regulated 
endothelial cell locus 1 protein) 
(Integrin-binding protein DEL1) 
Q12805 FBLN3 EFEMP1 FBLN3 FBNL EGF-containing fibulin-like 
extracellular matrix protein 1 
(Extracellular protein S1-5) 
(Fibrillin-like protein) (Fibulin-3) 
(FIBL-3) 
O95967 FBLN4 EFEMP2 FBLN4 
UNQ200/PRO226 
EGF-containing fibulin-like 
extracellular matrix protein 2 
(Fibulin-4) (FIBL-4) (Protein 
UPH1) 
P20827 EFNA1 EFNA1 EPLG1 LERK1 
TNFAIP4 
Ephrin-A1 (EPH-related receptor 
tyrosine kinase ligand 1) (LERK-
1) (Immediate early response 
protein B61) (Tumor necrosis 
factor alpha-induced protein 4) 
(TNF alpha-induced protein 4) 
[Cleaved into: Ephrin-A1, secreted 
form] 
P52798 EFNA4 EFNA4 EPLG4 LERK4 Ephrin-A4 (EPH-related receptor 
tyrosine kinase ligand 4) (LERK-
4) 
Q96BH3 ESPB1 ELSPBP1 E12   
Q9UJA9 ENPP5 ENPP5 UNQ550/PRO1107 Ectonucleotide 
pyrophosphatase/phosphodiesteras
e family member 5 (E-NPP 5) 
(NPP-5) (EC 3.1.-.-) 
Q6UW88 EPGN EPGN UNQ3072/PRO9904 Epigen (Epithelial mitogen) (EPG) 
M5A8F1 SUPYN ERVH48-1 C21orf105 HERV-
Fb1 NDUFV3-AS1 
Suppressyn (Endogenous 
retrovirus group 48 member 1) 
(NDUFV3 antisense RNA 1) 
(endogenous retrovirus group Fb 
member 1) 
Q5T1H1 EYS EYS C6orf178 C6orf179 C6orf180 EGFL10 EGFL11 SPAM 
UNQ9424/PRO34591 
P03951 FA11 F11 Coagulation factor XI (FXI) (EC 
3.4.21.27) (Plasma thromboplastin 
antecedent) (PTA) [Cleaved into: 
Coagulation factor XIa heavy 
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chain; Coagulation factor XIa light 
chain] 
P13726 TF F3 Tissue factor (TF) (Coagulation 
factor III) (Thromboplastin) (CD 
antigen CD142) 
P08709 FA7 F7 Coagulation factor VII 
P00740 FA9 F9 Coagulation factor IX (EC 
3.4.21.22) (Christmas factor) 
(Plasma thromboplastin 
component) (PTC) [Cleaved into: 
Coagulation factor IXa light chain; 
Coagulation factor IXa heavy 
chain] 
Q96MK3 FA20A FAM20A UNQ9388/PRO34279 Pseudokinase FAM20A 
Q8IXL6 FA20C FAM20C DMP4 Extracellular serine/threonine 
protein kinase FAM20C (EC 
2.7.11.1) (Dentin matrix protein 4) 
(DMP-4) (Golgi casein kinase) 
(Golgi-enriched fraction casein 
kinase) (GEF-CK) 
Q9Y6R7 FCGBP FCGBP   
P08620 FGF4 FGF4 HST HSTF1 KS3 Fibroblast growth factor 4 (FGF-
4) (Heparin secretory-
transforming protein 1) (HST) 
(HST-1) (HSTF-1) (Heparin-
binding growth factor 4) (HBGF-
4) (Transforming protein KS3) 
P10767 FGF6 FGF6 HST2 HSTF2 Fibroblast growth factor 6 (FGF-
6) (Heparin secretory-
transforming protein 2) (HST-2) 
(HSTF-2) (Heparin-binding 
growth factor 6) (HBGF-6) 
P21781 FGF7 FGF7 KGF Fibroblast growth factor 7 (FGF-
7) (Heparin-binding growth factor 
7) (HBGF-7) (Keratinocyte 
growth factor) 
P02679 FIBG FGG PRO2061 Fibrinogen gamma chain 
Q9NZU1 FLRT1 FLRT1 UNQ752/PRO1483 Leucine-rich repeat 
transmembrane protein FLRT1 
(Fibronectin-like domain-
containing leucine-rich 
transmembrane protein 1) 
O43155 FLRT2 FLRT2 KIAA0405 
UNQ232/PRO265 
Leucine-rich repeat 
transmembrane protein FLRT2 
(Fibronectin-like domain-
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containing leucine-rich 
transmembrane protein 2) 
Q9NZU0 FLRT3 FLRT3 KIAA1469 
UNQ856/PRO1865 
Leucine-rich repeat 
transmembrane protein FLRT3 
(Fibronectin-like domain-
containing leucine-rich 
transmembrane protein 3) 
P0C091 FREM3 FREM3   
P01225 FSHB FSHB Follitropin subunit beta (Follicle-
stimulating hormone beta subunit) 
(FSH-B) (FSH-beta) (Follitropin 
beta chain) 
Q9BTY2 FUCO2 FUCA2 PSEC0151 
UNQ227/PRO260 
Plasma alpha-L-fucosidase (EC 
3.2.1.51) (Alpha-L-fucoside 
fucohydrolase 2) (Alpha-L-
fucosidase 2) 
Q9UBS5 GABR1 GABBR1 GPRC3A   
Q9NR23 GDF3 GDF3 UNQ222/PRO248 Growth/differentiation factor 3 
(GDF-3) 
O60383 GDF9 GDF9 Growth/differentiation factor 9 
(GDF-9) 
Q3B7J2 GFOD2 GFOD2 UNQ9430/PRO34691 Glucose-fructose oxidoreductase 
domain-containing protein 2 (EC 
1.-.-.-) 
P10912 GHR GHR Growth hormone receptor (GH 
receptor) (Somatotropin receptor) 
[Cleaved into: Growth hormone-
binding protein (GH-binding 
protein) (GHBP) (Serum-binding 
protein)] 
Q86XP6 GKN2 GKN2 BLOT GDDR TFIZ1 
UNQ465/PRO813 
Gastrokine-2 (Blottin) (Down-
regulated in gastric cancer) 
(Trefoil factor interactions(z) 1) 
P0CG01 GKN3 GKN3P Gastrokine-3 
Q6UWM
5 
GPRL1 GLIPR1L1 UNQ2972/PRO7434 GLIPR1-like protein 1 
P01148 GON1 GNRH1 GNRH GRH LHRH Progonadoliberin-1 
(Progonadoliberin I) [Cleaved 
into: Gonadoliberin-1 
(Gonadoliberin I) (Gonadorelin) 
(Gonadotropin-releasing hormone 
I) (GnRH-I) (Luliberin I) 
(Luteinizing hormone-releasing 
hormone I) (LH-RH I); GnRH-
associated peptide 1 (GnRH-
associated peptide I)] 
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P51654 GPC3 GPC3 OCI5 Glypican-3 (GTR2-2) (Intestinal 
protein OCI-5) (MXR7) [Cleaved 
into: Secreted glypican-3] 
O75487 GPC4 GPC4 UNQ474/PRO937 Glypican-4 (K-glypican) [Cleaved 
into: Secreted glypican-4] 
P78333 GPC5 GPC5 Glypican-5 [Cleaved into: 
Secreted glypican-5] 
Q9Y625 GPC6 GPC6 UNQ369/PRO705 Glypican-6 [Cleaved into: 
Secreted glypican-6] 
Q96T91 GPHA2 GPHA2 GPA2 ZSIG51 Glycoprotein hormone alpha-2 
(Putative secreted protein Zsig51) 
(Thyrostimulin subunit alpha) 
Q86YW7 GPHB5 GPHB5 GPB5 ZLUT1 Glycoprotein hormone beta-5 
(Thyrostimulin subunit beta) 
Q02747 GUC2A GUCA2A GUCA2 Guanylin (Guanylate cyclase 
activator 2A) (Guanylate cyclase-
activating protein 1) (Guanylate 
cyclase-activating protein I) 
(GCAP-I) [Cleaved into: HMW-
guanylin; Guanylin] 
Q96RW7 HMCN1 HMCN1 FIBL6   
Q9Y251 HPSE HPSE HEP HPA HPA1 HPR1 
HPSE1 HSE1 
Heparanase (EC 3.2.1.166) (Endo-
glucoronidase) (Heparanase-1) 
(Hpa1) [Cleaved into: Heparanase 
8 kDa subunit; Heparanase 50 kDa 
subunit] 
Q8WWQ
2 
HPSE2 HPSE2 HPA2 Inactive heparanase-2 (Hpa2) 
P02790 HEMO HPX Hemopexin (Beta-1B-
glycoprotein) 
Q92743 HTRA1 HTRA1 HTRA PRSS11 Serine protease HTRA1 (EC 
3.4.21.-) (High-temperature 
requirement A serine peptidase 1) 
(L56) (Serine protease 11) 
P83110 HTRA3 HTRA3 PRSP Serine protease HTRA3 (EC 
3.4.21.-) (High-temperature 
requirement factor A3) 
(Pregnancy-related serine 
protease) 
P83105 HTRA4 HTRA4 Serine protease HTRA4 (EC 
3.4.21.-) (High-temperature 
requirement factor A4) 
Q12794 HYAL1 HYAL1 LUCA1 Hyaluronidase-1 (Hyal-1) (EC 
3.2.1.35) 
(Hyaluronoglucosaminidase-1) 
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(Lung carcinoma protein 1) 
(LuCa-1) 
O43820 HYAL3 HYAL3 LUCA3 Hyaluronidase-3 (Hyal-3) (EC 
3.2.1.35) 
(Hyaluronoglucosaminidase-3) 
(Lung carcinoma protein 3) 
(LuCa-3) 
P35858 ALS IGFALS ALS Insulin growth factor-like family 
member 1 
Q8N6C5 IGSF1 IGSF1 IGDC1 KIAA0364 
PGSF2 
 
P35968 VGFR2 KDR FLK1 VEGFR2   
Q14667 K0100 KIAA0100 BCOX1   
O43240 KLK10 KLK10 NES1 PRSSL1 Kallikrein-10 (EC 3.4.21.-) 
(Normal epithelial cell-specific 1) 
(Protease serine-like 1) 
Q9UKR0 KLK12 KLK12 KLKL5 
UNQ669/PRO1303 
Kallikrein-12 (EC 3.4.21.-) 
(Kallikrein-like protein 5) (KLK-
L5) 
P07288 KLK3 KLK3 APS Prostate-specific antigen (PSA) 
(EC 3.4.21.77) (Gamma-
seminoprotein) (Seminin) 
(Kallikrein-3) (P-30 antigen) 
(Semenogelase) 
Q9Y5K2 KLK4 KLK4 EMSP1 PRSS17 PSTS Kallikrein-4 (EC 3.4.21.-) 
(Enamel matrix serine proteinase 
1) (Kallikrein-like protein 1) 
(KLK-L1) (Prostase) (Serine 
protease 17) 
P49862 KLK7 KLK7 PRSS6 SCCE Kallikrein-7 (hK7) (EC 
3.4.21.117) (Serine protease 6) 
(Stratum corneum chymotryptic 
enzyme) (hSCCE) 
Q9UKQ9 KLK9 KLK9 Kallikrein-9 (EC 3.4.21.-) 
(Kallikrein-like protein 3) (KLK-
L3) 
P03952 KLKB1 KLKB1 KLK3 Plasma kallikrein (EC 3.4.21.34) 
(Fletcher factor) (Kininogenin) 
(Plasma prekallikrein) (PKK) 
[Cleaved into: Plasma kallikrein 
heavy chain; Plasma kallikrein 
light chain] 
P25391 LAMA1 LAMA1 LAMA   
P24043 LAMA2 LAMA2 LAMM   
Q16787 LAMA3 LAMA3 LAMNA   
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O15230 LAMA5 LAMA5 KIAA0533 KIAA1907  
Q13751 LAMB3 LAMB3 LAMNB1   
Q6JVE6 LCN10 LCN10 Epididymal-specific lipocalin-10 
Q6JVE9 LCN8 LCN8 LCN5 Epididymal-specific lipocalin-8 
Q6P5S2 LEG1H LEG1 C6orf58 Protein LEG1 homolog 
O95970 LGI1 LGI1 EPT UNQ775/PRO1569 Leucine-rich glioma-inactivated 
protein 1 (Epitempin-1) 
P01229 LSHB LHB Lutropin subunit beta (Lutropin 
beta chain) (Luteinizing hormone 
subunit beta) (LH-B) (LSH-B) 
(LSH-beta) 
P02750 A2GL LRG1 LRG Leucine-rich alpha-2-glycoprotein 
(LRG) 
Q8N6Y2 LRC17 LRRC17 P37NB 
UNQ3076/PRO9909 
Leucine-rich repeat-containing 
protein 17 (p37NB) 
P21941 MATN1 MATN1 CMP CRTM Cartilage matrix protein (Matrilin-
1) 
O15232 MATN3 MATN3 Matrilin-3 
O95460 MATN4 MATN4 Matrilin-4 
P08581 MET MET   
P08493 MGP MGP MGLAP GIG36 Matrix Gla protein (MGP) (Cell 
growth-inhibiting gene 36 protein) 
P03956 MMP1 MMP1 CLG Interstitial collagenase (EC 
3.4.24.7) (Fibroblast collagenase) 
(Matrix metalloproteinase-1) 
(MMP-1) [Cleaved into: 22 kDa 
interstitial collagenase; 27 kDa 
interstitial collagenase] 
P09238 MMP10 MMP10 STMY2 Stromelysin-2 (SL-2) (EC 
3.4.24.22) (Matrix 
metalloproteinase-10) (MMP-10) 
(Transin-2) 
P39900 MMP12 MMP12 HME Macrophage metalloelastase 
(MME) (EC 3.4.24.65) 
(Macrophage elastase) (ME) 
(hME) (Matrix metalloproteinase-
12) (MMP-12) 
P51512 MMP16 MMP16 MMPX2 Matrix metalloproteinase-16 
(MMP-16) (EC 3.4.24.-) (MMP-
X2) (Membrane-type matrix 
metalloproteinase 3) (MT-MMP 3) 
(MTMMP3) (Membrane-type-3 
matrix metalloproteinase) (MT3-
MMP) (MT3MMP) 
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Q99542 MMP19 MMP19 MMP18 RASI Matrix metalloproteinase-19 
(MMP-19) (EC 3.4.24.-) (Matrix 
metalloproteinase RASI) (Matrix 
metalloproteinase-18) (MMP-18) 
O60882 MMP20 MMP20 Matrix metalloproteinase-20 
(MMP-20) (EC 3.4.24.-) (Enamel 
metalloproteinase) (Enamelysin) 
Q8N119 MMP21 MMP21 Matrix metalloproteinase-21 
(MMP-21) (EC 3.4.24.-) 
Q9H239 MMP28 MMP28 MMP25 
UNQ1893/PRO4339 
Matrix metalloproteinase-28 
(MMP-28) (EC 3.4.24.-) 
(Epilysin) 
P08254 MMP3 MMP3 STMY1 Stromelysin-1 (SL-1) (EC 
3.4.24.17) (Matrix 
metalloproteinase-3) (MMP-3) 
(Transin-1) 
P22894 MMP8 MMP8 CLG1 Neutrophil collagenase (EC 
3.4.24.34) (Matrix 
metalloproteinase-8) (MMP-8) 
(PMNL collagenase) (PMNL-CL) 
P08118 MSMB MSMB PRSP Beta-microseminoprotein 
(Immunoglobulin-binding factor) 
(IGBF) (PN44) (Prostate secreted 
seminal plasma protein) (Prostate 
secretory protein of 94 amino 
acids) (PSP-94) (PSP94) (Seminal 
plasma beta-inhibin) 
Q1L6U9 MSMP MSMP PSMP Prostate-associated 
microseminoprotein (PC3-secreted 
microprotein) 
Q99972 MYOC MYOC GLC1A TIGR Myocilin (Myocilin 55 kDa 
subunit) (Trabecular meshwork-
induced glucocorticoid response 
protein) [Cleaved into: Myocilin, 
N-terminal fragment (Myocilin 20 
kDa N-terminal fragment); 
Myocilin, C-terminal fragment 
(Myocilin 35 kDa N-terminal 
fragment)] 
Q8TB73 NDNF NDNF C4orf31 
UNQ2748/PRO6487 
Protein NDNF (Neuron-derived 
neurotrophic factor) 
Q00604 NDP NDP EVR2 Norrin (Norrie disease protein) 
(X-linked exudative 
vitreoretinopathy 2 protein) 
Q15223 NECT1 NECTIN1 HVEC PRR1 PVRL1 Nectin-1 (Herpes virus entry 
mediator C) (Herpesvirus entry 
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mediator C) (HveC) (Herpesvirus 
Ig-like receptor) (HIgR) (Nectin 
cell adhesion molecule 1) 
(Poliovirus receptor-related 
protein 1) (CD antigen CD111) 
Q96NY8 NECT4 NECTIN4 LNIR PRR4 PVRL4 Nectin-4 (Ig superfamily receptor 
LNIR) (Nectin cell adhesion 
molecule 4) (Poliovirus receptor-
related protein 4) [Cleaved into: 
Processed poliovirus receptor-
related protein 4] 
Q8TDF5 NETO1 NETO1 BTCL1 Neuropilin and tolloid-like protein 
1 (Brain-specific transmembrane 
protein containing 2 CUB and 1 
LDL-receptor class A domains 
protein 1) 
Q6P988 NOTUM NOTUM OK/SW-CL.30 Palmitoleoyl-protein 
carboxylesterase NOTUM (EC 
3.1.1.98) (hNOTUM) 
P0C0P6 NPS NPS Neuropeptide S 
P47972 NPTX2 NPTX2 Neuronal pentraxin-2 (NP2) 
(Neuronal pentraxin II) (NP-II) 
Q92823 NRCAM NRCAM KIAA0343   
O95156 NXPH2 NXPH2 NPH2 Neurexophilin-2 
Q99784 NOE1 OLFM1 NOE1 NOEL1 Noelin (Neuronal olfactomedin-
related ER localized protein) 
(Olfactomedin-1) 
Q6UX06 OLFM4 OLFM4 GW112 
UNQ362/PRO698 
Olfactomedin-4 (OLM4) 
(Antiapoptotic protein GW112) 
(G-CSF-stimulated clone 1 
protein) (hGC-1) (hOLfD) 
Q6IE37 OVOS1 OVOS1   
Q6IE36 OVOS2 OVOS2   
P09466 PAEP PAEP Glycodelin (GD) (Placental 
protein 14) (PP14) (Pregnancy-
associated endometrial alpha-2 
globulin) (PAEG) (PEG) 
(Progestagen-associated 
endometrial protein) 
(Progesterone-associated 
endometrial protein) 
P0C8F1 PATE4 PATE4 Prostate and testis expressed 
protein 4 (PATE-like protein B) 
(PATE-B) 
Q96QU1 PCD15 PCDH15 USH1F   
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Q15113 PCOC1 PCOLCE PCPE1 Procollagen C-endopeptidase 
enhancer 1 (Procollagen COOH-
terminal proteinase enhancer 1) 
(PCPE-1) (Procollagen C-
proteinase enhancer 1) (Type 1 
procollagen C-proteinase enhancer 
protein) (Type I procollagen 
COOH-terminal proteinase 
enhancer) 
Q9UKZ9 PCOC2 PCOLCE2 PCPE2 
UNQ250/PRO287 
Procollagen C-endopeptidase 
enhancer 2 (Procollagen COOH-
terminal proteinase enhancer 2) 
(PCPE-2) (Procollagen C-
proteinase enhancer 2) 
Q15198 PGFRL PDGFRL PRLTS Platelet-derived growth factor 
receptor-like protein (PDGFR-like 
protein) (PDGF receptor beta-like 
tumor suppressor) 
P12273 PIP PIP GCDFP15 GPIP4 Prolactin-inducible protein (Gross 
cystic disease fluid protein 15) 
(GCDFP-15) (Prolactin-induced 
protein) (Secretory actin-binding 
protein) (SABP) (gp17) 
Q504Y2 PKDCC PKDCC SGK493 VLK Extracellular tyrosine-protein 
kinase PKDCC (EC 2.7.10.2) 
(Protein kinase domain-containing 
protein, cytoplasmic) (Protein 
kinase-like protein SgK493) 
(Sugen kinase 493) (Vertebrate 
lonesome kinase) 
P00750 TPA PLAT Tissue-type plasminogen activator 
(t-PA) (t-plasminogen activator) 
(tPA) (EC 3.4.21.68) (Alteplase) 
(Reteplase) [Cleaved into: Tissue-
type plasminogen activator chain 
A; Tissue-type plasminogen 
activator chain B] 
P00749 UROK PLAU Urokinase-type plasminogen 
activator (U-plasminogen 
activator) (uPA) (EC 3.4.21.73) 
[Cleaved into: Urokinase-type 
plasminogen activator long chain 
A; Urokinase-type plasminogen 
activator short chain A; 
Urokinase-type plasminogen 
activator chain B] 
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Q15195 PLGA PLGLA PLGLA1 PLGP2 
PRGA 
Plasminogen-like protein A 
(Plasminogen-like protein A1) 
(Plasminogen-related protein A) 
P40967 PMEL PMEL D12S53E PMEL17 SILV Melanocyte protein PMEL 
(ME20-M) (ME20M) (Melanocyte 
protein Pmel 17) (Melanocytes 
lineage-specific antigen GP100) 
(Melanoma-associated ME20 
antigen) (P1) (P100) 
(Premelanosome protein) (Silver 
locus protein homolog) [Cleaved 
into: M-alpha (95 kDa 
melanocyte-specific secreted 
glycoprotein) (P26) (Secreted 
melanoma-associated ME20 
antigen) (ME20-S) (ME20S); M-
beta] 
Q7Z5L7 PODN PODN SLRR5A 
UNQ293/PRO332 
Podocan 
Q15063 POSTN POSTN OSF2   
P07478 TRY2 PRSS2 TRY2 TRYP2 Trypsin-2 (EC 3.4.21.4) (Anionic 
trypsinogen) (Serine protease 2) 
(Trypsin II) 
Q8NHM4 TRY6 PRSS3P2 T6 TRY6 Putative trypsin-6 (EC 3.4.21.4) 
(Serine protease 3 pseudogene 2) 
(Trypsinogen C) 
Q6UWY2 PRS57 PRSS57 PRSSL1 
UNQ782/PRO1599 
Serine protease 57 (EC 3.4.21.-) 
(Serine protease 1-like protein 1) 
Q16557 PSG3 PSG3 Pregnancy-specific beta-1-
glycoprotein 3 (PS-beta-G-3) 
(PSBG-3) (Pregnancy-specific 
glycoprotein 3) 
(Carcinoembryonic antigen SG5) 
Q00889 PSG6 PSG6 CGM3 PSG10 PSG12 
PSGGB 
Pregnancy-specific beta-1-
glycoprotein 6 (PS-beta-G-6) 
(PSBG-6) (Pregnancy-specific 
glycoprotein 6) (Pregnancy-
specific beta-1-glycoprotein 10) 
(PS-beta-G-10) (PSBG-10) 
(Pregnancy-specific glycoprotein 
10) (Pregnancy-specific beta-1-
glycoprotein 12) (PS-beta-G-12) 
(PSBG-12) (Pregnancy-specific 
glycoprotein 12) 
Q13046 PSG7 PSG7 Putative pregnancy-specific beta-
1-glycoprotein 7 (PS-beta-G-7) 
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(PSBG-7) (Pregnancy-specific 
glycoprotein 7) 
Q9UQ74 PSG8 PSG8 Pregnancy-specific beta-1-
glycoprotein 8 (PS-beta-G-8) 
(PSBG-8) (Pregnancy-specific 
glycoprotein 8) 
Q96A98 TIP39 PTH2 TIP39 TIPF39 Tuberoinfundibular peptide of 39 
residues (TIP39) (Parathyroid 
hormone 2) 
P21246 PTN PTN HBNF1 NEGF1 Pleiotrophin (PTN) (Heparin-
binding brain mitogen) (HBBM) 
(Heparin-binding growth factor 8) 
(HBGF-8) (Heparin-binding 
growth-associated molecule) (HB-
GAM) (Heparin-binding neurite 
outgrowth-promoting factor 1) 
(HBNF-1) (Osteoblast-specific 
factor 1) (OSF-1) 
P10082 PYY PYY Peptide YY (PYY) (PYY-I) 
(Peptide tyrosine tyrosine) 
[Cleaved into: Peptide YY(3-36) 
(PYY-II)] 
P20742 PZP PZP CPAMD6   
P78509 RELN RELN   
Q6XE38 SG1D4 SCGB1D4 UNQ517/PRO812 Secretoglobin family 1D member 
4 (IFN-gamma-inducible 
secretoglobin) (IIS) 
Q96PL1 SG3A2 SCGB3A2 PNSP1 UGRP1 
UNQ566/PRO1128 
Secretoglobin family 3A member 
2 (Pneumo secretory protein 1) 
(PnSP-1) (Uteroglobin-related 
protein 1) 
Q07699 SCN1B SCN1B Sodium channel subunit beta-1 
P01009 A1AT SERPINA1 AAT PI PRO0684 
PRO2209 
Alpha-1-antitrypsin (Alpha-1 
protease inhibitor) (Alpha-1-
antiproteinase) (Serpin A1) 
[Cleaved into: Short peptide from 
AAT (SPAAT)] 
P29622 KAIN SERPINA4 KST PI4 Kallistatin (Kallikrein inhibitor) 
(Peptidase inhibitor 4) (PI-4) 
(Serpin A4) 
P05154 IPSP SERPINA5 PCI PLANH3 
PROCI 
Plasma serine protease inhibitor 
(Acrosomal serine protease 
inhibitor) (Plasminogen activator 
inhibitor 3) (PAI-3) (PAI3) 
(Protein C inhibitor) (PCI) (Serpin 
A5) 
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P01008 ANT3 SERPINC1 AT3 PRO0309 Antithrombin-III (ATIII) (Serpin 
C1) 
P05121 PAI1 SERPINE1 PAI1 PLANH1 Plasminogen activator inhibitor 1 
(PAI) (PAI-1) (Endothelial 
plasminogen activator inhibitor) 
(Serpin E1) 
P07093 GDN SERPINE2 PI7 PN1 Glia-derived nexin (GDN) 
(Peptidase inhibitor 7) (PI-7) 
(Protease nexin 1) (PN-1) 
(Protease nexin I) (Serpin E2) 
A8MV23 SERP3 SERPINE3 Serpin E3 
P36955 PEDF SERPINF1 PEDF PIG35 Pigment epithelium-derived factor 
(PEDF) (Cell proliferation-
inducing gene 35 protein) (EPC-1) 
(Serpin F1) 
P08697 A2AP SERPINF2 AAP PLI Alpha-2-antiplasmin (Alpha-2-
AP) (Alpha-2-plasmin inhibitor) 
(Alpha-2-PI) (Serpin F2) 
P05155 IC1 SERPING1 C1IN C1NH Plasma protease C1 inhibitor (C1 
Inh) (C1Inh) (C1 esterase 
inhibitor) (C1-inhibiting factor) 
(Serpin G1) 
Q99574 NEUS SERPINI1 PI12 Neuroserpin (Peptidase inhibitor 
12) (PI-12) (Serpin I1) 
O75830 SPI2 SERPINI2 MEPI PI14 Serpin I2 (Myoepithelium-derived 
serine protease inhibitor) 
(Pancpin) (Pancreas-specific 
protein TSA2004) (Peptidase 
inhibitor 14) (PI-14) 
Q15465 SHH SHH Sonic hedgehog protein (SHH) 
(HHG-1) [Cleaved into: Sonic 
hedgehog protein N-product; 
Sonic hedgehog protein C-
product] 
O75093 SLIT1 SLIT1 KIAA0813 MEGF4 SLIL1 
X6R3P0 X6R3P0 SLIT2   
O94813 SLIT2 SLIT2 SLIL3   
P55000 SLUR1 SLURP1 ARS Secreted Ly-6/uPAR-related 
protein 1 (SLURP-1) (ARS 
component B) (ARS(component 
B)-81/S) (Anti-neoplastic urinary 
protein) (ANUP) 
Q1W4C9 ISK13 SPINK13 HBVDNAPTP1 
SPINK5L3 
Serine protease inhibitor Kazal-
type 13 (Hepatitis B virus DNA 
polymerase transactivated serine 
protease inhibitor) (Hespintor) 
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(Serine protease inhibitor Kazal-
type 5-like 3) 
Q6IE38 ISK14 SPINK14 SPINK5L2 Serine protease inhibitor Kazal-
type 14 
P20155 ISK2 SPINK2 Serine protease inhibitor Kazal-
type 2 (Acrosin-trypsin inhibitor) 
(Epididymis tissue protein Li 172) 
(HUSI-II) 
O60575 ISK4 SPINK4 Serine protease inhibitor Kazal-
type 4 (Peptide PEC-60 homolog) 
Q6UWN8 ISK6 SPINK6 UNQ844/PRO1782 Serine protease inhibitor Kazal-
type 6 (Kallikrein inhibitor) 
P58062 ISK7 SPINK7 ECG2 
UNQ745/PRO1474 
Serine protease inhibitor Kazal-
type 7 (Esophagus cancer-related 
gene 2 protein) (ECRG-2) 
O60687 SRPX2 SRPX2 SRPUL Sushi repeat-containing protein 
SRPX2 (Sushi-repeat protein 
upregulated in leukemia) 
P02808 STAT STATH Statherin 
P52823 STC1 STC1 STC Stanniocalcin-1 (STC-1) 
Q4LDE5 SVEP1 SVEP1 C9orf13 CCP22 SELOB 
Q2MV58 TECT1 TCTN1 TECT1 
UNQ9369/PRO34160 
Tectonic-1 
O75443 TECTA TECTA   
Q96PL2 TECTB TECTB Beta-tectorin 
P04155 TFF1 TFF1 BCEI PS2 Trefoil factor 1 (Breast cancer 
estrogen-inducible protein) (PNR-
2) (Polypeptide P1.A) (hP1.A) 
(Protein pS2) 
P01135 TGFA TGFA Protransforming growth factor 
alpha [Cleaved into: Transforming 
growth factor alpha (TGF-alpha) 
(EGF-like TGF) (ETGF) (TGF 
type 1)] 
P10600 TGFB3 TGFB3 Transforming growth factor beta-3 
(TGF-beta-3) [Cleaved into: 
Latency-associated peptide (LAP)] 
Q9UPZ6 THS7A THSD7A KIAA0960   
P01033 TIMP1 TIMP1 CLGI TIMP Metalloproteinase inhibitor 1 
(Erythroid-potentiating activity) 
(EPA) (Fibroblast collagenase 
inhibitor) (Collagenase inhibitor) 
(Tissue inhibitor of 
metalloproteinases 1) (TIMP-1) 
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P35625 TIMP3 TIMP3 Metalloproteinase inhibitor 2 
(CSC-21K) (Tissue inhibitor of 
metalloproteinases 2) (TIMP-2) 
Q99727 TIMP4 TIMP4 Metalloproteinase inhibitor 3 
(Protein MIG-5) (Tissue inhibitor 
of metalloproteinases 3) (TIMP-3) 
P24821 TENA TNC HXB   
Q9UQP3 TENN TNN   
Q8WU66 TSEAR TSPEAR C21orf29 Thrombospondin-type laminin G 
domain and EAR repeat-
containing protein (TSP-EAR) 
P04275 VWF VWF F8VWF   
F5GYM2 F5GYM
2 
WNT5B Protein Wnt-5b 
D6RF94 D6RF94 WNT8A Protein Wnt-8a (Protein Wnt-8d) 
O60844 ZG16 ZG16 Zymogen granule membrane 
protein 16 (Zymogen granule 
protein 16) (hZG16) (Secretory 
lectin ZG16) 
P21754 ZP3 ZP3 ZP3A ZP3B ZPC Zona pellucida sperm-binding 
protein 3 (Sperm receptor) 
(ZP3A/ZP3B) (Zona pellucida 
glycoprotein 3) (Zp-3) (Zona 
pellucida protein C) [Cleaved into: 
Processed zona pellucida sperm-
binding protein 3] 
Q12836 ZP4 ZP4 ZPB Zona pellucida sperm-binding 
protein 4 (Zona pellucida 
glycoprotein 4) (Zp-4) (Zona 
pellucida protein B) [Cleaved into: 
Processed zona pellucida sperm-
binding protein 4] 
Q9BS86 ZPBP1 ZPBP ZPBP1 Zona pellucida-binding protein 1 
(Sp38) 
Q6X784 ZPBP2 ZPBP2 ZPBPL Zona pellucida-binding protein 2 
(ZPBP-like protein) 
P15151 PVR PVR PVS Poliovirus receptor (Nectin-like 
protein 5) (NECL-5) (CD antigen 
CD155) 
Q9Y5C1 ANGL3 ANGPTL3 ANGPT5 
UNQ153/PRO179 
Angiopoietin-related protein 3 
(Angiopoietin-5) (ANG-5) 
(Angiopoietin-like protein 3) 
[Cleaved into: ANGPTL3(17-
221); ANGPTL3(17-224)] 
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Q6GPI1 CTRB2 CTRB2 Chymotrypsinogen B2 (EC 
3.4.21.1) [Cleaved into: 
Chymotrypsin B2 chain A; 
Chymotrypsin B2 chain B; 
Chymotrypsin B2 chain C] 
Q99983 OMD OMD SLRR2C 
UNQ190/PRO216 
Osteomodulin (Keratan sulfate 
proteoglycan osteomodulin) 
(KSPG osteomodulin) 
(Osteoadherin) (OSAD) 
Proteins functionally related to the regulation/modulation of the immune response 
Q6UW15 REG3G REG3G PAP1B 
UNQ429/PRO162 
Regenerating islet-derived protein 
3-gamma (REG-3-gamma) 
(Pancreatitis-associated protein 
1B) (PAP-1B) (Pancreatitis-
associated protein IB) (PAP IB) 
(Regenerating islet-derived protein 
III-gamma) (REG III) (Reg III-
gamma) [Cleaved into: 
Regenerating islet-derived protein 
3-gamma 16.5 kDa form; 
Regenerating islet-derived protein 
3-gamma 15 kDa form] 
P07360 CO8G C8G Complement component C8 
gamma chain 
O43699 SIGL6 SIGLEC6 CD33L CD33L1 
OBBP1 
Sialic acid-binding Ig-like lectin 6 
(Siglec-6) (CD33 antigen-like 1) 
(CDw327) (Obesity-binding 
protein 1) (OB-BP1) (CD antigen 
CD327) 
Q9BY15 AGRE3 ADGRE3 EMR3 
UNQ683/PRO1562 
Adhesion G protein-coupled 
receptor E3 (EGF-like module 
receptor 3) (EGF-like module-
containing mucin-like hormone 
receptor-like 3) 
P02771 FETA AFP HPAFP Alpha-fetoprotein (Alpha-1-
fetoprotein) (Alpha-fetoglobulin) 
P28039 AOAH AOAH Acyloxyacyl hydrolase (EC 
3.1.1.77) [Cleaved into: 
Acyloxyacyl hydrolase small 
subunit; Acyloxyacyl hydrolase 
large subunit] 
O75882 ATRN ATRN KIAA0548 MGCA 
P61769 B2MG B2M CDABP0092 HDCMA22P 
Q13072 BAGE1 BAGE BAGE1 B melanoma antigen 1 (B 
melanoma antigen) (Antigen 
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MZ2-BA) (Cancer/testis antigen 
2.1) (CT2.1) 
O95972 BMP15 BMP15 GDF9B Bone morphogenetic protein 15 
(BMP-15) (Growth/differentiation 
factor 9B) (GDF-9B) 
P17213 BPI BPI Bactericidal permeability-
increasing protein (BPI) (CAP 57) 
Q9NP55 BPIA1 BPIFA1 LUNX NASG PLUNC 
SPLUNC1 SPURT 
UNQ787/PRO1606 
BPI fold-containing family A 
member 1 (Lung-specific protein 
X) (Nasopharyngeal carcinoma-
related protein) (Palate lung and 
nasal epithelium clone protein) 
(Secretory protein in upper 
respiratory tracts) (Short 
PLUNC1) (SPLUNC1) (Tracheal 
epithelium-enriched protein) (Von 
Ebner protein Hl) 
Q96DR5 BPIA2 BPIFA2 C20orf70 SPLUNC2 
UNQ510/PRO1025 
BPI fold-containing family A 
member 2 (Parotid secretory 
protein) (PSP) (Short palate, lung 
and nasal epithelium carcinoma-
associated protein 2) 
Q8TDL5 BPIB1 BPIFB1 C20orf114 LPLUNC1 
UNQ706/PRO1357 
BPI fold-containing family B 
member 1 (Long palate, lung and 
nasal epithelium carcinoma-
associated protein 1) (Von Ebner 
minor salivary gland protein) 
(VEMSGP) 
Q8NFQ6 BPIFC BPIFC BPIL2 BPI fold-containing family C 
protein (Bactericidal/permeability-
increasing protein-like 2) (BPI-
like 2) 
Q13410 BT1A1 BTN1A1 BTN Butyrophilin subfamily 1 member 
A1 (BT) 
Q6UWK7 CJ099 C10orf99 UNQ1833/PRO3446 Secreted protein C10orf99 
(Antimicrobial peptide-57) (AP-
57) (Colon-derived SUSD2 
binding factor) (CSBF) 
P02745 C1QA C1QA Complement C1q subcomponent 
subunit A 
P02746 C1QB C1QB Complement C1q subcomponent 
subunit B 
P02747 C1QC C1QC C1QG Complement C1q subcomponent 
subunit C 
Q9BXJ4 C1QT3 C1QTNF3 CTRP3 
UNQ753/PRO1484 
Complement C1q tumor necrosis 
factor-related protein 3 
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(Collagenous repeat-containing 
sequence 26 kDa protein) 
(CORS26) (Secretory protein 
CORS26) 
Q9BXI9 C1QT6 C1QTNF6 CTRP6 
UNQ581/PRO1151 
Complement C1q tumor necrosis 
factor-related protein 6 
Q9BXJ2 C1QT7 C1QTNF7 CTRP7 Complement C1q tumor necrosis 
factor-related protein 7 
Q9NZP8 C1RL C1RL C1RL1 C1RLP CLSPA Complement C1r subcomponent-
like protein (C1r-LP) (C1r-like 
protein) (EC 3.4.21.-) (C1r-like 
serine protease analog protein) 
(CLSPa) 
P01024 CO3 C3 CPAMD1   
P0C0L4 CO4A C4A CO4 CPAMD2   
P0C0L5 CO4B C4B CO4 CPAMD3; C4B_2 
P04003 C4BPA C4BPA C4BP C4b-binding protein alpha chain 
(C4bp) (Proline-rich protein) 
(PRP) 
P07358 CO8B C8B Complement component C8 beta 
chain (Complement component 8 
subunit beta) 
P02748 CO9 C9 Complement component C9 
[Cleaved into: Complement 
component C9a; Complement 
component C9b] 
P49913 CAMP CAMP CAP18 FALL39 HSD26 Cathelicidin antimicrobial peptide 
(18 kDa cationic antimicrobial 
protein) (CAP-18) (hCAP-18) 
[Cleaved into: Antibacterial 
peptide FALL-39 (FALL-39 
peptide antibiotic); Antibacterial 
peptide LL-37] 
P22362 CCL1 CCL1 SCYA1 C-C motif chemokine 1 (Small-
inducible cytokine A1) (T 
lymphocyte-secreted protein I-
309) 
P51671 CCL11 CCL11 SCYA11 Eotaxin (C-C motif chemokine 11) 
(Eosinophil chemotactic protein) 
(Small-inducible cytokine A11) 
Q99616 CCL13 CCL13 MCP4 NCC1 SCYA13 C-C motif chemokine 13 (CK-
beta-10) (Monocyte 
chemoattractant protein 4) 
(Monocyte chemotactic protein 4) 
(MCP-4) (NCC-1) (Small-
inducible cytokine A13) [Cleaved 
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into: C-C motif chemokine 13, 
long chain; C-C motif chemokine 
13, medium chain; C-C motif 
chemokine 13, short chain] 
Q16627 CCL14 CCL14 NCC2 SCYA14 C-C motif chemokine 14 
(Chemokine CC-1/CC-3) (HCC-
1/HCC-3) (HCC-1(1-74)) (NCC-
2) (Small-inducible cytokine A14) 
[Cleaved into: HCC-1(3-74); 
HCC-1(4-74); HCC-1(9-74)] 
Q16663 CCL15 CCL15 MIP5 NCC3 SCYA15 C-C motif chemokine 15 
(Chemokine CC-2) (HCC-2) 
(Leukotactin-1) (LKN-1) (MIP-1 
delta) (Macrophage inflammatory 
protein 5) (MIP-5) (Mrp-2b) 
(NCC-3) (Small-inducible 
cytokine A15) [Cleaved into: 
CCL15(22-92); CCL15(25-92); 
CCL15(29-92)] 
O15467 CCL16 CCL16 ILINCK NCC4 
SCYA16 
C-C motif chemokine 16 
(Chemokine CC-4) (HCC-4) 
(Chemokine LEC) (IL-10-
inducible chemokine) (LCC-1) 
(Liver-expressed chemokine) 
(Lymphocyte and monocyte 
chemoattractant) (LMC) 
(Monotactin-1) (MTN-1) (NCC-4) 
(Small-inducible cytokine A16) 
Q92583 CCL17 CCL17 SCYA17 TARC C-C motif chemokine 17 (CC 
chemokine TARC) (Small-
inducible cytokine A17) (Thymus 
and activation-regulated 
chemokine) 
P55774 CCL18 CCL18 AMAC1 DCCK1 MIP4 
PARC SCYA18 
C-C motif chemokine 18 
(Alternative macrophage 
activation-associated CC 
chemokine 1) (AMAC-1) (CC 
chemokine PARC) (Dendritic cell 
chemokine 1) (DC-CK1) 
(Macrophage inflammatory 
protein 4) (MIP-4) (Pulmonary 
and activation-regulated 
chemokine) (Small-inducible 
cytokine A18) [Cleaved into: 
CCL18(1-68); CCL18(3-69); 
CCL18(4-69)] 
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Q99731 CCL19 CCL19 ELC MIP3B SCYA19 C-C motif chemokine 19 (Beta-
chemokine exodus-3) (CK beta-
11) (Epstein-Barr virus-induced 
molecule 1 ligand chemokine) 
(EBI1 ligand chemokine) (ELC) 
(Macrophage inflammatory 
protein 3 beta) (MIP-3-beta) 
(Small-inducible cytokine A19) 
P13500 CCL2 CCL2 MCP1 SCYA2 C-C motif chemokine 2 (HC11) 
(Monocyte chemoattractant 
protein 1) (Monocyte chemotactic 
and activating factor) (MCAF) 
(Monocyte chemotactic protein 1) 
(MCP-1) (Monocyte secretory 
protein JE) (Small-inducible 
cytokine A2) 
P78556 CCL20 CCL20 LARC MIP3A SCYA20 C-C motif chemokine 20 (Beta-
chemokine exodus-1) (CC 
chemokine LARC) (Liver and 
activation-regulated chemokine) 
(Macrophage inflammatory 
protein 3 alpha) (MIP-3-alpha) 
(Small-inducible cytokine A20) 
[Cleaved into: CCL20(1-67); 
CCL20(1-64); CCL20(2-70)] 
O00626 CCL22 CCL22 MDC SCYA22 A-
152E5.1 
C-C motif chemokine 22 (CC 
chemokine STCP-1) (MDC(1-69)) 
(Macrophage-derived chemokine) 
(Small-inducible cytokine A22) 
(Stimulated T-cell chemotactic 
protein 1) [Cleaved into: MDC(3-
69); MDC(5-69); MDC(7-69)] 
O00175 CCL24 CCL24 MPIF2 SCYA24 C-C motif chemokine 24 (CK-
beta-6) (Eosinophil chemotactic 
protein 2) (Eotaxin-2) (Myeloid 
progenitor inhibitory factor 2) 
(MPIF-2) (Small-inducible 
cytokine A24) 
O15444 CCL25 CCL25 SCYA25 TECK C-C motif chemokine 25 
(Chemokine TECK) (Small-
inducible cytokine A25) (Thymus-
expressed chemokine) 
Q9Y258 CCL26 CCL26 SCYA26 
UNQ216/PRO242 
C-C motif chemokine 26 (CC 
chemokine IMAC) (Eotaxin-3) 
(Macrophage inflammatory 
protein 4-alpha) (MIP-4-alpha) 
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(Small-inducible cytokine A26) 
(Thymic stroma chemokine-1) 
(TSC-1) 
Q9Y4X3 CCL27 CCL27 ILC SCYA27 C-C motif chemokine 27 (CC 
chemokine ILC) (Cutaneous T-
cell-attracting chemokine) 
(CTACK) (ESkine) (IL-11 R-
alpha-locus chemokine) 
(Skinkine) (Small-inducible 
cytokine A27) 
P10147 CCL3 CCL3 G0S19-1 MIP1A SCYA3 C-C motif chemokine 3 (G0/G1 
switch regulatory protein 19-1) 
(Macrophage inflammatory 
protein 1-alpha) (MIP-1-alpha) 
(PAT 464.1) (SIS-beta) (Small-
inducible cytokine A3) (Tonsillar 
lymphocyte LD78 alpha protein) 
[Cleaved into: MIP-1-alpha(4-69) 
(LD78-alpha(4-69))] 
P16619 CL3L1 CCL3L1 D17S1718 G0S19-2 
SCYA3L1; CCL3L3 
C-C motif chemokine 3-like 1 
(G0/G1 switch regulatory protein 
19-2) (LD78-beta(1-70)) (PAT 
464.2) (Small-inducible cytokine 
A3-like 1) (Tonsillar lymphocyte 
LD78 beta protein) [Cleaved into: 
LD78-beta(3-70); LD78-beta(5-
70)] 
P13236 CCL4 CCL4 LAG1 MIP1B SCYA4 C-C motif chemokine 4 (G-26 T-
lymphocyte-secreted protein) 
(HC21) (Lymphocyte activation 
gene 1 protein) (LAG-1) (MIP-1-
beta(1-69)) (Macrophage 
inflammatory protein 1-beta) 
(MIP-1-beta) (PAT 744) (Protein 
H400) (SIS-gamma) (Small-
inducible cytokine A4) (T-cell 
activation protein 2) (ACT-2) 
[Cleaved into: MIP-1-beta(3-69)] 
Q8NHW4 CC4L CCL4L1 CCL4L LAG1 
SCYA4L1; CCL4L2 CCL4L 
SCYA4L2 
C-C motif chemokine 4-like 
(Lymphocyte activation gene 1 
protein) (LAG-1) (Macrophage 
inflammatory protein 1-beta) 
(MIP-1-beta) (Monocyte 
adherence-induced protein 5-
alpha) (Small-inducible cytokine 
A4-like) 
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P13501 CCL5 CCL5 D17S136E SCYA5 C-C motif chemokine 5 (EoCP) 
(Eosinophil chemotactic cytokine) 
(SIS-delta) (Small-inducible 
cytokine A5) (T cell-specific 
protein P228) (TCP228) (T-cell-
specific protein RANTES) 
[Cleaved into: RANTES(3-68); 
RANTES(4-68)] 
P80098 CCL7 CCL7 MCP3 SCYA6 SCYA7 C-C motif chemokine 7 
(Monocyte chemoattractant 
protein 3) (Monocyte chemotactic 
protein 3) (MCP-3) (NC28) 
(Small-inducible cytokine A7) 
P80075 CCL8 CCL8 MCP2 SCYA10 SCYA8 C-C motif chemokine 8 (HC14) 
(Monocyte chemoattractant 
protein 2) (Monocyte chemotactic 
protein 2) (MCP-2) (Small-
inducible cytokine A8) [Cleaved 
into: MCP-2(6-76)] 
Q8TD46 MO2R1 CD200R1 CD200R CRTR2 
MOX2R OX2R 
UNQ2522/PRO6015 
Cell surface glycoprotein CD200 
receptor 1 (CD200 cell surface 
glycoprotein receptor) (Cell 
surface glycoprotein OX2 receptor 
1) 
P13987 CD59 CD59 MIC11 MIN1 MIN2 
MIN3 MSK21 
CD59 glycoprotein (1F5 antigen) 
(20 kDa homologous restriction 
factor) (HRF-20) (HRF20) (MAC-
inhibitory protein) (MAC-IP) 
(MEM43 antigen) (Membrane 
attack complex inhibition factor) 
(MACIF) (Membrane inhibitor of 
reactive lysis) (MIRL) (Protectin) 
(CD antigen CD59) 
P01732 CD8A CD8A MAL T-cell surface glycoprotein CD8 
alpha chain (T-lymphocyte 
differentiation antigen T8/Leu-2) 
(CD antigen CD8a) 
P10966 CD8B CD8B CD8B1 T-cell surface glycoprotein CD8 
beta chain (CD antigen CD8b) 
P00746 CFAD CFD DF PFD Complement factor D (EC 
3.4.21.46) (Adipsin) (C3 
convertase activator) (Properdin 
factor D) 
P05156 CFAI CFI IF Complement factor I (EC 
3.4.21.45) (C3B/C4B inactivator) 
[Cleaved into: Complement factor 
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I heavy chain; Complement factor 
I light chain] 
P36222 CH3L1 CHI3L1 Chitinase-3-like protein 1 (39 kDa 
synovial protein) (Cartilage 
glycoprotein 39) (CGP-39) (GP-
39) (hCGP-39) (YKL-40) 
Q2VPA4 CR1L CR1L Complement component receptor 
1-like protein (Complement C4b-
binding protein CR-1-like protein) 
Q9HC73 CRLF2 CRLF2 CRL2 ILXR TSLPR Cytokine receptor-like factor 2 
(Cytokine receptor-like 2) (IL-XR) 
(Thymic stromal lymphopoietin 
protein receptor) (TSLP receptor) 
P02741 CRP CRP PTX1 C-reactive protein [Cleaved into: 
C-reactive protein(1-205)] 
P15509 CSF2R CSF2RA CSF2R CSF2RY Granulocyte-macrophage colony-
stimulating factor receptor subunit 
alpha (GM-CSF-R-alpha) 
(GMCSFR-alpha) (GMR-alpha) 
(CDw116) (CD antigen CD116) 
P01037 CYTN CST1 Cystatin-SN (Cystain-SA-I) 
(Cystatin-1) (Salivary cystatin-
SA-1) 
P01036 CYTS CST4 Cystatin-S (Cystatin-4) (Cystatin-
SA-III) (Salivary acidic protein 1) 
O76096 CYTF CST7 Cystatin-F (Cystatin-7) (Cystatin-
like metastasis-associated protein) 
(CMAP) (Leukocystatin) 
Q5W186 CST9 CST9 CLM CTES7A Cystatin-9 (Cystatin-like 
molecule) 
P02778 CXL10 CXCL10 INP10 SCYB10 C-X-C motif chemokine 10 (10 
kDa interferon gamma-induced 
protein) (Gamma-IP10) (IP-10) 
(Small-inducible cytokine B10) 
[Cleaved into: CXCL10(1-73)] 
O14625 CXL11 CXCL11 ITAC SCYB11 
SCYB9B 
C-X-C motif chemokine 11 (Beta-
R1) (H174) (Interferon gamma-
inducible protein 9) (IP-9) 
(Interferon-inducible T-cell alpha 
chemoattractant) (I-TAC) (Small-
inducible cytokine B11) 
P48061 SDF1 CXCL12 SDF1 SDF1A SDF1B Stromal cell-derived factor 1 
(SDF-1) (hSDF-1) (C-X-C motif 
chemokine 12) (Intercrine reduced 
in hepatomas) (IRH) (hIRH) (Pre-
B cell growth-stimulating factor) 
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(PBSF) [Cleaved into: SDF-1-
beta(3-72); SDF-1-alpha(3-67)] 
O43927 CXL13 CXCL13 BCA1 BLC SCYB13 C-X-C motif chemokine 13 
(Angie) (B cell-attracting 
chemokine 1) (BCA-1) (B 
lymphocyte chemoattractant) 
(CXC chemokine BLC) (Small-
inducible cytokine B13) 
P42830 CXCL5 CXCL5 ENA78 SCYB5 C-X-C motif chemokine 5 (ENA-
78(1-78)) (Epithelial-derived 
neutrophil-activating protein 78) 
(Neutrophil-activating peptide 
ENA-78) (Small-inducible 
cytokine B5) [Cleaved into: ENA-
78(8-78); ENA-78(9-78)] 
P80162 CXCL6 CXCL6 GCP2 SCYB6 C-X-C motif chemokine 6 
(Chemokine alpha 3) (CKA-3) 
(Granulocyte chemotactic protein 
2) (GCP-2) (Small-inducible 
cytokine B6) [Cleaved into: 
Small-inducible cytokine B6, N-
processed variant 1; Small-
inducible cytokine B6, N-
processed variant 2; Small-
inducible cytokine B6, N-
processed variant 3] 
P10145 IL8 CXCL8 IL8   
Q9NRR1 CYTL1 CYTL1 C4orf4 
UNQ1942/PRO4425 
Neuferricin (Cytochrome b5 
domain-containing protein 2) 
P59665 DEF1 DEFA1 DEF1 DEFA2 MRS; 
DEFA1B 
Neutrophil defensin 1 (Defensin, 
alpha 1) (HNP-1) (HP-1) (HP1) 
[Cleaved into: HP 1-56; 
Neutrophil defensin 2 (HNP-2) 
(HP-2) (HP2)] 
P59666 DEF3 DEFA3 DEF3 Neutrophil defensin 3 (Defensin, 
alpha 3) (HNP-3) (HP-3) (HP3) 
[Cleaved into: HP 3-56; 
Neutrophil defensin 2 (HNP-2) 
(HP-2) (HP2)] 
P12838 DEF4 DEFA4 DEF4 Neutrophil defensin 4 (Defensin, 
alpha 4) (HNP-4) (HP-4) 
Q01523 DEF5 DEFA5 DEF5 Defensin-5 (Defensin, alpha 5) 
(HD5(20-94)) [Cleaved into: 
HD5(23-94); HD5(29-94); 
HD5(56-94); HD5(63-94)] 
Q01524 DEF6 DEFA6 DEF6 Defensin-6 (Defensin, alpha 6) 
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P60022 DEFB1 DEFB1 BD1 HBD1 Beta-defensin 1 (BD-1) (hBD-1) 
(Defensin, beta 1) 
P81534 D103A DEFB103A BD3 DEFB103 
DEFB3; DEFB103B 
Beta-defensin 103 (Beta-defensin 
3) (BD-3) (DEFB-3) (HBD3) 
(hBD-3) (Defensin, beta 103) 
(Defensin-like protein) 
Q8NG35 D105A DEFB105A BD5 DEFB105 
DEFB5; DEFB105B 
Beta-defensin 105 (Beta-defensin 
5) (BD-5) (DEFB-5) (Defensin, 
beta 105) 
Q8IZN7 D107A DEFB107A DEFB107 DEFB7; 
DEFB107B 
Beta-defensin 107 (Beta-defensin 
7) (BD-7) (DEFB-7) (Defensin, 
beta 107) 
Q30KR1 DB109 DEFB109P1 DEFB109 
DEFB109A; DEFB109P1B 
Beta-defensin 109 (Defensin, beta 
109) (Defensin, beta 109, 
pseudogene 1/1B) 
Q30KQ9 DB110 DEFB110 DEFB10 DEFB11 
DEFB111 
Beta-defensin 110 (Beta-defensin 
10) (DEFB-10) (Beta-defensin 11) 
(DEFB-11) (Beta-defensin 111) 
(Defensin, beta 110) (Defensin, 
beta 111) 
Q30KQ7 DB113 DEFB113 DEFB13 Beta-defensin 113 (Beta-defensin 
13) (DEFB-13) (Defensin, beta 
113) 
Q30KQ6 DB114 DEFB114 DEFB14 Beta-defensin 114 (Beta-defensin 
14) (DEFB-14) (Defensin, beta 
114) 
Q30KQ5 DB115 DEFB115 DEFB15 Beta-defensin 115 (Beta-defensin 
15) (DEFB-15) (Defensin, beta 
115) 
Q8N690 DB119 DEFB119 DEFB120 DEFB19 
DEFB20 UNQ2449/PRO5729 
Beta-defensin 119 (Beta-defensin 
120) (Beta-defensin 19) (DEFB-
19) (Beta-defensin 20) (DEFB-20) 
(Defensin, beta 119) (Defensin, 
beta 120) (ESC42-RELA) 
Q5J5C9 DB121 DEFB121 DEFB21 Beta-defensin 121 (Beta-defensin 
21) (DEFB-21) (Defensin, beta 
121) 
Q8N688 DB123 DEFB123 DEFB23 
UNQ1963/PRO4485 
Beta-defensin 123 (Beta-defensin 
23) (DEFB-23) (Defensin, beta 
123) 
Q8NES8 DB124 DEFB124 DEFB24 Beta-defensin 124 (Beta-defensin 
24) (DEFB-24) (Defensin, beta 
124) 
Q9BYW3 DB126 DEFB126 C20orf8 DEFB26 Beta-defensin 126 (Beta-defensin 
26) (DEFB-26) (Defensin, beta 
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126) (Epididymal secretory 
protein 13.2) (ESP13.2) (HBD26) 
Q9H1M4 DB127 DEFB127 C20orf73 DEFB27 
UNQ1956/PRO6071 
Beta-defensin 127 (Beta-defensin 
27) (DEFB-27) (Defensin, beta 
127) 
Q7Z7B8 DB128 DEFB128 DEFB28 Beta-defensin 128 (Beta-defensin 
28) (DEFB-28) (Defensin, beta 
128) 
Q9H1M3 DB129 DEFB129 C20orf87 DEFB29 
UNQ5794/PRO19599 
Beta-defensin 129 (Beta-defensin 
29) (DEFB-29) (Defensin, beta 
129) 
Q30KQ2 DB130 DEFB130 DEFB30; DEFB130L Beta-defensin 130 (Beta-defensin 
30) (DEFB-30) (Defensin, beta 
130) 
P59861 DB131 DEFB131 DEFB31 Beta-defensin 131 (Beta-defensin 
31) (DEFB-31) (Defensin, beta 
131) 
Q7Z7B7 DB132 DEFB132 DEFB32 
UNQ827/PRO1754 
Beta-defensin 132 (Beta-defensin 
32) (BD-32) (DEFB-32) (Defensin 
HEL-75) (Defensin, beta 132) 
Q30KQ1 DB133 DEFB133 Beta-defensin 133 (Defensin, beta 
133) 
Q4QY38 DB134 DEFB134 Beta-defensin 134 (Defensin, beta 
134) 
Q30KP9 DB135 DEFB135 Beta-defensin 135 (Defensin, beta 
135) 
Q30KP8 DB136 DEFB136 Beta-defensin 136 (Defensin, beta 
136) 
O15263 DFB4A DEFB4A DEFB102 DEFB2 
DEFB4; DEFB4B 
Beta-defensin 4A (Beta-defensin 
2) (BD-2) (hBD-2) (Defensin, beta 
2) (Skin-antimicrobial peptide 1) 
(SAP1) 
Q6UX07 DHR13 DHRS13 SDR7C5 
UNQ419/PRO853 
Dehydrogenase/reductase SDR 
family member 13 (EC 1.1.-.-) 
(Short chain 
dehydrogenase/reductase family 
7C member 5) 
Q92874 DNSL2 DNASE1L2 DHP1 DNAS1L2 Deoxyribonuclease-1-like 2 (EC 
3.1.21.-) (DNase I homolog 
protein DHP1) 
(Deoxyribonuclease I-like 2) 
(DNase I-like 2) 
Q9UHL4 DPP2 DPP7 DPP2 QPP Dipeptidyl peptidase 2 (EC 
3.4.14.2) (Dipeptidyl 
aminopeptidase II) (Dipeptidyl 
peptidase 7) (Dipeptidyl peptidase 
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II) (DPP II) (Quiescent cell proline 
dipeptidase) 
Q14213 IL27B EBI3 IL27B Interleukin-27 subunit beta (IL-27 
subunit beta) (IL-27B) (Epstein-
Barr virus-induced gene 3 protein) 
(EBV-induced gene 3 protein) 
P19235 EPOR EPOR Erythropoietin receptor (EPO-R) 
Q7Z5A8 F19A3 FAM19A3 TAFA3 Protein FAM19A3 (Chemokine-
like protein TAFA-3) 
P98173 FAM3A FAM3A 2-19 2.19 Protein FAM3A (Cytokine-like 
protein 2-19) 
P24071 FCAR FCAR CD89 Immunoglobulin alpha Fc receptor 
(IgA Fc receptor) (CD antigen 
CD89) 
P08637 FCG3A FCGR3A CD16A FCG3 
FCGR3 IGFR3 
Low affinity immunoglobulin 
gamma Fc region receptor III-A 
(CD16a antigen) (Fc-gamma RIII-
alpha) (Fc-gamma RIII) (Fc-
gamma RIIIa) (FcRIII) (FcRIIIa) 
(FcR-10) (IgG Fc receptor III-2) 
(CD antigen CD16a) 
O75015 FCG3B FCGR3B CD16B FCG3 FCGR3 
IGFR3 
Low affinity immunoglobulin 
gamma Fc region receptor III-B 
(Fc-gamma RIII-beta) (Fc-gamma 
RIII) (Fc-gamma RIIIb) (FcRIII) 
(FcRIIIb) (FcR-10) (IgG Fc 
receptor III-1) (CD antigen 
CD16b) 
Q6BAA4 FCRLB FCRLB FCRL2 FCRLM2 
FCRY FREB2 
Fc receptor-like B (Fc receptor 
homolog expressed in B-cells 
protein 2) (FREB-2) (Fc receptor-
like and mucin-like protein 2) (Fc 
receptor-like protein 2) (Fc 
receptor-related protein Y) (FcRY) 
Q8NFU4 FDSCP FDCSP C4orf7 
UNQ733/PRO1419 
Follicular dendritic cell secreted 
peptide (FDC secreted protein) 
(FDC-SP) 
O15520 FGF10 FGF10 Fibroblast growth factor 10 (FGF-
10) (Keratinocyte growth factor 2) 
Q14314 FGL2 FGL2 Fibroleukin (Fibrinogen-like 
protein 2) (pT49) 
Q9UK05 GDF2 GDF2 BMP9 Growth/differentiation factor 2 
(GDF-2) (Bone morphogenetic 
protein 9) (BMP-9) 
P55259 GP2 GP2 Pancreatic secretory granule 
membrane major glycoprotein 
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GP2 (Pancreatic zymogen granule 
membrane protein GP-2) (ZAP75) 
P12544 GRAA GZMA CTLA3 HFSP Granzyme A (EC 3.4.21.78) (CTL 
tryptase) (Cytotoxic T-lymphocyte 
proteinase 1) (Fragmentin-1) 
(Granzyme-1) (Hanukkah factor) 
(H factor) (HF) 
P49863 GRAK GZMK TRYP2 Granzyme K (EC 3.4.21.-) 
(Fragmentin-3) (Granzyme-3) 
(NK-tryptase-2) (NK-Tryp-2) 
P51124 GRAM GZMM MET1 Granzyme M (EC 3.4.21.-) (Met-1 
serine protease) (Hu-Met-1) (Met-
ase) (Natural killer cell granular 
protease) 
A8MTL9 HMSD HMSD Serpin-like protein HMSD (Minor 
histocompatibility protein HMSD) 
(Minor histocompatibility serpin 
domain-containing protein) 
P15516 HIS3 HTN3 HIS2 Histatin-3 (Basic histidine-rich 
protein) (Hst) (Histidine-rich 
protein 3) (PB) [Cleaved into: 
Histatin-3; His3-(20-44)-peptide 
(His3 20/44) (His3-(1-25)-peptide) 
(His3 1/25) (Histatin-3 1/25) 
(Histatin-6); His3-(20-43)-peptide 
(His3 20/43) (His3-(1-24)-peptide) 
(His3 1/24) (Histatin-3 1/24) 
(Histatin-5); His3-(20-32)-peptide 
(His3 20/32) (His3-(1-13)-peptide) 
(His3 1/13) (Histatin-3 1/13); 
His3-(20-31)-peptide (His3 20/31) 
(His3-(1-12)-peptide) (His3 1/12) 
(Histatin-3 1/12); His3-(20-30)-
peptide (His3 20/30) (His3-(1-11)-
peptide) (His3 1/11) (Histatin-3 
1/11); His3-(24-32)-peptide (His3 
24/32) (His3-(5-13)-peptide) (His3 
5/13) (Histatin-3 5/13); His3-(24-
31)-peptide (His3 24/31) (His3-(5-
12)-peptide) (His3 5/12) (Histatin-
11) (Histatin-3 5/12); His3-(24-
30)-peptide (His3 24/30) (His3-(5-
11)-peptide) (His3 5/11) (Histatin-
12) (Histatin-3 5/11); His3-(25-
32)-peptide (His3 25/32) (His3-(6-
13)-peptide) (His3 6/13) (Histatin-
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3 6/13); His3-(25-30)-peptide 
(His3 25/30) (His3-(6-11)-peptide) 
(His3 6/11) (Histatin-3 6/11); 
His3-(26-32)-peptide (His3 26/32) 
(His3-(7-13)-peptide) (His3 7/13) 
(Histatin-3 7/13); His3-(26-31)-
peptide (His3 26/31) (His3-(7-12)-
peptide) (His3 7/12) (Histatin-3 
7/12); His3-(26-30)-peptide (His3 
26/30) (His3-(7-11)-peptide) (His3 
7/11) (Histatin-3 7/11); His3-(31-
51)-peptide (His3 31/51) (His3-
(12-32)-peptide) (His3 12/32) 
(Histatin-3 12/32) (Histatin-4); 
His3-(31-44)-peptide (His3 31/44) 
(His3-(12-25)-peptide) (His3 
12/25) (Histatin-3 12/25) 
(Histatin-9); His3-(31-43)-peptide 
(His3 31/43) (His3-(12-24)-
peptide) (His3 12/24) (Histatin-3 
12/24) (Histatin-7); His3-(32-44)-
peptide (His3 32/44) (His3-(13-
25)-peptide) (His3 13/25) 
(Histatin-10) (Histatin-3 13/25); 
His3-(32-43)-peptide (His3 32-43) 
(His3-(13-24)-peptide) (His3 
13/24) (Histatin-3 13/24) 
(Histatin-8); His3-(33-44)-peptide 
(His3 33/44) (His3-(14-25)-
peptide) (His3 14/25) (Histatin-3 
14/25); His3-(33-43)-peptide 
(His3 33/43) (His3-(14-24)-
peptide) (His3 14/24) (Histatin-3 
14/24); His3-(34-44)-peptide 
(His3 34/44) (His3-(15-25)-
peptide) (His3 15/25) (Histatin-3 
15/25); His3-(34-43)-peptide 
(His3 34/43) (His3-(15-24)-
peptide) (His3 15/24) (Histatin-3 
15/24); His3-(45-51)-peptide 
(His3 45/51) (His3-(26-32)-
peptide) (His3 26/32) (Histatin-3 
26/32); His3-(47-51)-peptide 
(His3 47/51) (His3-(28-32)-
peptide) (His3 28/32) (Histatin-3 
28/32); His3-(48-51)-peptide 
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(His3 48/51) (His3-(29-32)-
peptide) (His3 29/32) (Histatin-3 
29/32)] 
Q14773 ICAM4 ICAM4 LW Intercellular adhesion molecule 4 
(ICAM-4) (Landsteiner-Wiener 
blood group glycoprotein) (LW 
blood group protein) (CD antigen 
CD242) 
Q9Y6W8 ICOS ICOS AILIM Inducible T-cell costimulator 
(Activation-inducible lymphocyte 
immunomediatory molecule) (CD 
antigen CD278) 
P13284 GILT IFI30 GILT IP30 Gamma-interferon-inducible 
lysosomal thiol reductase (EC 
1.8.-.-) (Gamma-interferon-
inducible protein IP-30) 
(Legumaturain) 
P01562 IFNA1 IFNA1; IFNA13 Interferon alpha-1/13 (IFN-alpha-
1/13) (Interferon alpha-D) (LeIF 
D) 
P01566 IFN10 IFNA10 Interferon alpha-10 (IFN-alpha-
10) (Interferon alpha-6L) 
(Interferon alpha-C) (LeIF C) 
P01570 IFN14 IFNA14 Interferon alpha-14 (IFN-alpha-
14) (Interferon alpha-H) (LeIF H) 
(Interferon lambda-2-H) 
P05015 IFN16 IFNA16 Interferon alpha-16 (IFN-alpha-
16) (Interferon alpha-WA) 
P01571 IFN17 IFNA17 Interferon alpha-17 (IFN-alpha-
17) (Interferon alpha-88) 
(Interferon alpha-I') (LeIF I) 
(Interferon alpha-T) 
P01563 IFNA2 IFNA2 IFNA2A IFNA2B 
IFNA2C 
Interferon alpha-2 (IFN-alpha-2) 
(Interferon alpha-A) (LeIF A) 
P01568 IFN21 IFNA21 Interferon alpha-21 (IFN-alpha-
21) (Interferon alpha-F) (LeIF F) 
P05014 IFNA4 IFNA4 Interferon alpha-4 (IFN-alpha-4) 
(Interferon alpha-4B) (Interferon 
alpha-76) (Interferon alpha-M1) 
P05013 IFNA6 IFNA6 Interferon alpha-6 (IFN-alpha-6) 
(Interferon alpha-54) (Interferon 
alpha-K) (LeIF K) 
P01567 IFNA7 IFNA7 Interferon alpha-7 (IFN-alpha-7) 
(Interferon alpha-J) (LeIF J) 
(Interferon alpha-J1) (IFN-alpha-
J1) 
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P32881 IFNA8 IFNA8 Interferon alpha-8 (IFN-alpha-8) 
(Interferon alpha-B) (LeIF B) 
(Interferon alpha-B2) 
P48551 INAR2 IFNAR2 IFNABR IFNARB Interferon alpha/beta receptor 2 
(IFN-R-2) (IFN-alpha binding 
protein) (IFN-alpha/beta receptor 
2) (Interferon alpha binding 
protein) (Type I interferon 
receptor 2) 
P01574 IFNB IFNB1 IFB IFNB Interferon beta (IFN-beta) 
(Fibroblast interferon) 
Q86WN2 IFNE IFNE IFNE1 UNQ360/PRO655 Interferon epsilon (IFN-epsilon) 
(Interferon epsilon-1) 
P01579 IFNG IFNG Interferon gamma (IFN-gamma) 
(Immune interferon) 
P05000 IFNW1 IFNW1 Interferon omega-1 (Interferon 
alpha-II-1) 
A6NJS3 IV1U1 IGHV1OR21-1 Putative V-set and 
immunoglobulin domain-
containing-like protein 
IGHV1OR21-1 (Immunoglobulin 
heavy variable 1 orphon 21-1) 
A6NJ16 IV4F8 IGHV4OR15-8 VSIG6 Putative V-set and 
immunoglobulin domain-
containing-like protein 
IGHV4OR15-8 (Immunoglobulin 
heavy variable 4 orphon 15-8) 
(Putative V-set and 
immunoglobulin domain-
containing protein 6) 
A6NJ69 IGIP IGIP C5orf53 IgA-inducing protein homolog 
A6NGN9 IGLO5 IGLON5 IgLON family member 5 
Q96ID5 IGS21 IGSF21 Immunoglobulin superfamily 
member 21 (IgSF21) 
P29459 IL12A IL12A NKSF1 Interleukin-12 subunit alpha (IL-
12A) (Cytotoxic lymphocyte 
maturation factor 35 kDa subunit) 
(CLMF p35) (IL-12 subunit p35) 
(NK cell stimulatory factor chain 
1) (NKSF1) 
P29460 IL12B IL12B NKSF2 Interleukin-12 subunit beta (IL-
12B) (Cytotoxic lymphocyte 
maturation factor 40 kDa subunit) 
(CLMF p40) (IL-12 subunit p40) 
(NK cell stimulatory factor chain 
2) (NKSF2) 
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P35225 IL13 IL13 NC30 Interleukin-13 (IL-13) 
Q16552 IL17 IL17A CTLA8 IL17 Interleukin-17A (IL-17) (IL-17A) 
(Cytotoxic T-lymphocyte-
associated antigen 8) (CTLA-8) 
Q9NRM6 I17RB IL17RB CRL4 EVI27 IL17BR 
UNQ2501/PRO19612 
Interleukin-17 receptor B (IL-17 
receptor B) (IL-17RB) (Cytokine 
receptor-like 4) (IL-17 receptor 
homolog 1) (IL-17Rh1) (IL17Rh1) 
(Interleukin-17B receptor) (IL-
17B receptor) 
O95998 I18BP IL18BP Interleukin-18-binding protein 
(IL-18BP) (Tadekinig-alfa) 
Q9UHD0 IL19 IL19 ZMDA1 Interleukin-19 (IL-19) (Melanoma 
differentiation-associated protein-
like protein) (NG.1) 
P14778 IL1R1 IL1R1 IL1R IL1RA IL1RT1 Interleukin-1 receptor type 1 (IL-
1R-1) (IL-1RT-1) (IL-1RT1) 
(CD121 antigen-like family 
member A) (Interleukin-1 receptor 
alpha) (IL-1R-alpha) (Interleukin-
1 receptor type I) (p80) (CD 
antigen CD121a) [Cleaved into: 
Interleukin-1 receptor type 1, 
membrane form (mIL-1R1) (mIL-
1RI); Interleukin-1 receptor type 
1, soluble form (sIL-1R1) (sIL-
1RI)] 
P27930 IL1R2 IL1R2 IL1RB Interleukin-1 receptor type 2 (IL-
1R-2) (IL-1RT-2) (IL-1RT2) 
(CD121 antigen-like family 
member B) (CDw121b) (IL-1 type 
II receptor) (Interleukin-1 receptor 
beta) (IL-1R-beta) (Interleukin-1 
receptor type II) (CD antigen 
CD121b) [Cleaved into: 
Interleukin-1 receptor type 2, 
membrane form (mIL-1R2) (mIL-
1RII); Interleukin-1 receptor type 
2, soluble form (sIL-1R2) (sIL-
1RII)] 
Q9NPH3 IL1AP IL1RAP C3orf13 IL1R3 Interleukin-1 receptor accessory 
protein (IL-1 receptor accessory 
protein) (IL-1RAcP) (Interleukin-
1 receptor 3) (IL-1R-3) (IL-1R3) 
Q01638 ILRL1 IL1RL1 DER4 ST2 T1 Interleukin-1 receptor-like 1 
(Protein ST2) 
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P18510 IL1RA IL1RN IL1F3 IL1RA Interleukin-1 receptor antagonist 
protein (IL-1RN) (IL-1ra) (IRAP) 
(ICIL-1RA) (IL1 inhibitor) 
(Anakinra) 
P60568 IL2 IL2 Interleukin-2 (IL-2) (T-cell growth 
factor) (TCGF) (Aldesleukin) 
Q9NYY1 IL20 IL20 ZCYTO10 
UNQ852/PRO1801 
Interleukin-20 (IL-20) (Cytokine 
Zcyto10) 
Q9GZX6 IL22 IL22 ILTIF ZCYTO18 
UNQ3099/PRO10096 
Interleukin-22 (IL-22) (Cytokine 
Zcyto18) (IL-10-related T-cell-
derived-inducible factor) (IL-TIF) 
Q9NPF7 IL23A IL23A SGRF 
UNQ2498/PRO5798 
Interleukin-23 subunit alpha (IL-
23 subunit alpha) (IL-23-A) 
(Interleukin-23 subunit p19) (IL-
23p19) 
Q13007 IL24 IL24 MDA7 ST16 Interleukin-24 (IL-24) (Melanoma 
differentiation-associated gene 7 
protein) (MDA-7) (Suppression of 
tumorigenicity 16 protein) 
Q8NEV9 IL27A IL27 IL27A IL30 Interleukin-27 subunit alpha (IL-
27 subunit alpha) (IL-27-A) 
(IL27-A) (Interleukin-30) (p28) 
Q6EBC2 IL31 IL31 Interleukin-31 (IL-31) 
Q6ZMJ4 IL34 IL34 C16orf77 Interleukin-34 (IL-34) 
P05113 IL5 IL5 Interleukin-5 (IL-5) (B-cell 
differentiation factor I) 
(Eosinophil differentiation factor) 
(T-cell replacing factor) (TRF) 
P13232 IL7 IL7 Interleukin-7 (IL-7) 
P16871 IL7RA IL7R Interleukin-7 receptor subunit 
alpha (IL-7 receptor subunit alpha) 
(IL-7R subunit alpha) (IL-7R-
alpha) (IL-7RA) (CDw127) (CD 
antigen CD127) 
P15248 IL9 IL9 Interleukin-9 (IL-9) (Cytokine 
P40) (T-cell growth factor P40) 
Q01113 IL9R IL9R Interleukin-9 receptor (IL-9 
receptor) (IL-9R) (CD antigen 
CD129) 
P08476 INHBA INHBA Inhibin beta A chain (Activin beta-
A chain) (Erythroid differentiation 
protein) (EDF) 
Q8TB96 TIP ITFG1 LNKN-1 TIP CDA08 T-cell immunomodulatory protein 
(Protein TIP) (Integrin-alpha FG-
GAP repeat-containing protein 1) 
(Linkin) 
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Q9BX67 JAM3 JAM3 UNQ859/PRO1868 Junctional adhesion molecule C 
(JAM-C) (JAM-2) (Junctional 
adhesion molecule 3) (JAM-3) 
P01591 IGJ JCHAIN IGCJ IGJ Immunoglobulin J chain (Joining 
chain of multimeric IgA and IgM) 
P21583 SCF KITLG MGF SCF Kit ligand (Mast cell growth 
factor) (MGF) (Stem cell factor) 
(SCF) (c-Kit ligand) [Cleaved 
into: Soluble KIT ligand 
(sKITLG)] 
Q9UEF7 KLOT KL   
P18428 LBP LBP Lipopolysaccharide-binding 
protein (LBP) 
Q08380 LG3BP LGALS3BP M2BP Galectin-3-binding protein 
(Basement membrane autoantigen 
p105) (Lectin galactoside-binding 
soluble 3-binding protein) (Mac-2-
binding protein) (MAC2BP) 
(Mac-2 BP) (Tumor-associated 
antigen 90K) 
P15018 LIF LIF HILDA Leukemia inhibitory factor (LIF) 
(Differentiation-stimulating factor) 
(D factor) (Melanoma-derived 
LPL inhibitor) (MLPLI) 
(Emfilermin) 
Q8N149 LIRA2 LILRA2 ILT1 LIR7 Leukocyte immunoglobulin-like 
receptor subfamily A member 2 
(CD85 antigen-like family 
member H) (Immunoglobulin-like 
transcript 1) (ILT-1) (Leukocyte 
immunoglobulin-like receptor 7) 
(LIR-7) (CD antigen CD85h) 
Q8N6C8 LIRA3 LILRA3 ILT6 LIR4 Leukocyte immunoglobulin-like 
receptor subfamily A member 3 
(CD85 antigen-like family 
member E) (Immunoglobulin-like 
transcript 6) (ILT-6) (Leukocyte 
immunoglobulin-like receptor 4) 
(LIR-4) (Monocyte inhibitory 
receptor HM43/HM31) (CD 
antigen CD85e) 
P01374 TNFB LTA TNFB TNFSF1 Lymphotoxin-alpha (LT-alpha) 
(TNF-beta) (Tumor necrosis factor 
ligand superfamily member 1) 
Q8NDX9 LY65B LY6G5B C6orf19 G5B Lymphocyte antigen 6 complex 
locus protein G5b 
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Q5SRR4 LY65C LY6G5C C6orf20 G5C NG33 Lymphocyte antigen 6 complex 
locus protein G5c 
O95711 LY86 LY86 MD1 Lymphocyte antigen 86 (Ly-86) 
(Protein MD-1) 
Q9Y6Y9 LY96 LY96 ESOP1 MD2 Lymphocyte antigen 96 (Ly-96) 
(ESOP-1) (Protein MD-2) 
Q9BZG9 LYNX1 LYNX1 SLURP2 Ly-6/neurotoxin-like protein 1 
(Secreted Ly-6/uPAR domain-
containing protein 2) (Secreted 
Ly-6/uPAR-related protein 2) 
(SLURP-2) 
Q6UX82 LYPD8 LYPD8 UNQ511/PRO1026 Ly6/PLAUR domain-containing 
protein 8 
Q6UWQ5 LYZL1 LYZL1 LYC2 
UNQ648/PRO1278 
Lysozyme-like protein 1 (EC 
3.2.1.17) 
Q7Z4W2 LYZL2 LYZL2 Lysozyme-like protein 2 
(Lysozyme-2) (EC 3.2.1.17) 
O75951 LYZL6 LYZL6 LYC1 
UNQ754/PRO1485 
Lysozyme-like protein 6 (EC 
3.2.1.17) 
Q95460 HMR1 MR1 Major histocompatibility complex 
class I-related gene protein (MHC 
class I-related gene protein) (Class 
I histocompatibility antigen-like 
protein) 
Q969H8 MYDGF MYDGF C19orf10 IL25 Myeloid-derived growth factor 
(MYDGF) (Interleukin-25) (IL-
25) (Stromal cell-derived growth 
factor SF20) 
P02763 A1AG1 ORM1 AGP1 Alpha-1-acid glycoprotein 1 (AGP 
1) (Orosomucoid-1) (OMD 1) 
P19652 A1AG2 ORM2 AGP2 Alpha-1-acid glycoprotein 2 (AGP 
2) (Orosomucoid-2) (OMD 2) 
Q9BQ51 PD1L2 PDCD1LG2 B7DC CD273 
PDCD1L2 PDL2 
Programmed cell death 1 ligand 2 
(PD-1 ligand 2) (PD-L2) (PDCD1 
ligand 2) (Programmed death 
ligand 2) (Butyrophilin B7-DC) 
(B7-DC) (CD antigen CD273) 
P02776 PLF4 PF4 CXCL4 SCYB4 Platelet factor 4 (PF-4) (C-X-C 
motif chemokine 4) (Iroplact) 
(Oncostatin-A) [Cleaved into: 
Platelet factor 4, short form] 
P10720 PF4V PF4V1 CXCL4V1 SCYB4V1 Platelet factor 4 variant (C-X-C 
motif chemokine 4 variant) 
(CXCL4L1) (PF4alt) (PF4var1) 
[Cleaved into: Platelet factor 4 
variant(4-74); Platelet factor 4 
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variant(5-74); Platelet factor 4 
variant(6-74)] 
Q96LB9 PGRP3 PGLYRP3 PGRPIA Peptidoglycan recognition protein 
3 (Peptidoglycan recognition 
protein I-alpha) (PGLYRPIalpha) 
(PGRP-I-alpha) (Peptidoglycan 
recognition protein intermediate 
alpha) 
Q96LB8 PGRP4 PGLYRP4 PGRPIB SBBI67 Peptidoglycan recognition protein 
4 (Peptidoglycan recognition 
protein I-beta) (PGLYRPIbeta) 
(PGRP-I-beta) (Peptidoglycan 
recognition protein intermediate 
beta) 
P19957 ELAF PI3 WAP3 WFDC14 Elafin (Elastase-specific inhibitor) 
(ESI) (Peptidase inhibitor 3) (PI-3) 
(Protease inhibitor WAP3) (Skin-
derived antileukoproteinase) 
(SKALP) (WAP four-disulfide 
core domain protein 14) 
Q02325 PLGB PLGLB1 PLGL PRGB; 
PLGLB2 PLGP1 
Plasminogen-like protein B 
(Plasminogen-related protein B) 
P14222 PERF PRF1 PFP Perforin-1 (P1) (Cytolysin) 
(Lymphocyte pore-forming 
protein) (PFP) 
P13727 PRG2 PRG2 MBP Bone marrow proteoglycan 
(BMPG) (Proteoglycan 2) 
[Cleaved into: Eosinophil granule 
major basic protein (EMBP) 
(MBP) (Pregnancy-associated 
major basic protein)] 
P01236 PRL PRL Prolactin (PRL) 
Q9HC23 PROK2 PROK2 BV8 Prokineticin-2 (PK2) (Protein Bv8 
homolog) 
P07477 TRY1 PRSS1 TRP1 TRY1 TRYP1 Trypsin-1 (EC 3.4.21.4) (Beta-
trypsin) (Cationic trypsinogen) 
(Serine protease 1) (Trypsin I) 
[Cleaved into: Alpha-trypsin chain 
1; Alpha-trypsin chain 2] 
P11465 PSG2 PSG2 PSBG2 Pregnancy-specific beta-1-
glycoprotein 2 (PS-beta-G-2) 
(PSBG-2) (Pregnancy-specific 
glycoprotein 2) (Pregnancy-
specific beta-1 glycoprotein E) 
(PS-beta-E) 
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Q00888 PSG4 PSG4 CGM4 PSG9 Pregnancy-specific beta-1-
glycoprotein 4 (PS-beta-G-4) 
(PSBG-4) (Pregnancy-specific 
glycoprotein 4) (Pregnancy-
specific beta-1-glycoprotein 9) 
(PS-beta-G-9) (PSBG-9) 
(Pregnancy-specific glycoprotein 
9) 
Q15238 PSG5 PSG5 Pregnancy-specific beta-1-
glycoprotein 5 (PS-beta-G-5) 
(PSBG-5) (Pregnancy-specific 
glycoprotein 5) (Fetal liver non-
specific cross-reactive antigen 3) 
(FL-NCA-3) 
Q96A99 PTX4 PTX4 C16orf38 Pentraxin-4 
Q8TD07 N2DL4 RAET1E LETAL N2DL4 
ULBP4 UNQ1867/PRO4303 
NKG2D ligand 4 (N2DL-4) 
(NKG2DL4) (Lymphocyte 
effector toxicity activation ligand) 
(RAE-1-like transcript 4) (RL-4) 
(Retinoic acid early transcript 1E) 
Q99969 RARR2 RARRES2 TIG2 Retinoic acid receptor responder 
protein 2 (Chemerin) (RAR-
responsive protein TIG2) 
(Tazarotene-induced gene 2 
protein) 
Q06141 REG3A REG3A HIP PAP PAP1 Regenerating islet-derived protein 
3-alpha (REG-3-alpha) 
(Hepatointestinal pancreatic 
protein) (HIP/PAP) (Human 
proislet peptide) (Pancreatitis-
associated protein 1) 
(Regenerating islet-derived protein 
III-alpha) (Reg III-alpha) [Cleaved 
into: Regenerating islet-derived 
protein 3-alpha 16.5 kDa form; 
Regenerating islet-derived protein 
3-alpha 15 kDa form] 
P12724 ECP RNASE3 ECP RNS3 Eosinophil cationic protein (ECP) 
(EC 3.1.27.-) (Ribonuclease 3) 
(RNase 3) 
Q96QR1 SG3A1 SCGB3A1 HIN1 PNSP2 
UGRP2 UNQ629/PRO1245 
Secretoglobin family 3A member 
1 (Cytokine HIN-1) (High in 
normal 1) (Pneumo secretory 
protein 2) (PnSP-2) (Uteroglobin-
related protein 2) 
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Q8WVN6 SCTM1 SECTM1 K12 Secreted and transmembrane 
protein 1 (Protein K-12) 
O95025 SEM3D SEMA3D UNQ760/PRO1491 
P01011 AACT SERPINA3 AACT GIG24 
GIG25 
Alpha-1-antichymotrypsin (ACT) 
(Cell growth-inhibiting gene 24/25 
protein) (Serpin A3) [Cleaved 
into: Alpha-1-antichymotrypsin 
His-Pro-less] 
Q13291 SLAF1 SLAMF1 SLAM Signaling lymphocytic activation 
molecule (CDw150) (IPO-3) 
(SLAM family member 1) (CD 
antigen CD150) 
Q5VX71 SUSD4 SUSD4 UNQ196/PRO222 Sushi domain-containing protein 4 
P61812 TGFB2 TGFB2 Transforming growth factor beta-2 
(TGF-beta-2) (BSC-1 cell growth 
inhibitor) (Cetermin) 
(Glioblastoma-derived T-cell 
suppressor factor) (G-TSF) 
(Polyergin) [Cleaved into: 
Latency-associated peptide (LAP)] 
Q15661 TRYB1 TPSAB1 TPS1 TPS2 TPSB1 Tryptase alpha/beta-1 (Tryptase-1) 
(EC 3.4.21.59) (Tryptase I) 
(Tryptase alpha-1) 
P20231 TRYB2 TPSB2 TPS2 Tryptase beta-2 (Tryptase-2) (EC 
3.4.21.59) (Tryptase II) 
Q9NP99 TREM1 TREM1 Triggering receptor expressed on 
myeloid cells 1 (TREM-1) 
(Triggering receptor expressed on 
monocytes 1) (CD antigen 
CD354) 
Q6UXN2 TRML4 TREML4 TLT4 
UNQ9425/PRO34675 
Trem-like transcript 4 protein 
(TLT-4) (Triggering receptor 
expressed on myeloid cells-like 
protein 4) 
Q969D9 TSLP TSLP Thymic stromal lymphopoietin 
Q96RP3 UCN2 UCN2 SRP URP Urocortin-2 (Stresscopin-related 
peptide) (Urocortin II) (Ucn II) 
(Urocortin-related peptide) 
Q9BZM5 N2DL2 ULBP2 N2DL2 RAET1H 
UNQ463/PRO791 
NKG2D ligand 2 (N2DL-2) 
(NKG2DL2) (ALCAN-alpha) 
(Retinoic acid early transcript 1H) 
(UL16-binding protein 2) 
P01282 VIP VIP VIP peptides [Cleaved into: 
Intestinal peptide PHV-42 
(Peptide histidine valine 42); 
Intestinal peptide PHM-27 
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(Peptide histidine methioninamide 
27); Vasoactive intestinal peptide 
(VIP) (Vasoactive intestinal 
polypeptide)] 
Q8IW00 VSTM4 VSTM4 C10orf72 V-set and transmembrane domain-
containing protein 4 [Cleaved into: 
Peptide Lv] 
P47992 XCL1 XCL1 LTN SCYC1 Lymphotactin (ATAC) (C motif 
chemokine 1) (Cytokine SCM-1) 
(Lymphotaxin) (SCM-1-alpha) 
(Small-inducible cytokine C1) 
(XC chemokine ligand 1) 
Q9UBD3 XCL2 XCL2 SCYC2 Cytokine SCM-1 beta (C motif 
chemokine 2) (XC chemokine 
ligand 2) 
P04217 A1BG A1BG Alpha-1B-glycoprotein (Alpha-1-
B glycoprotein) 
Q86SQ3 AGRE4 ADGRE4P EMR4 EMR4P 
GPR127 PGR16 
Putative adhesion G protein-
coupled receptor E4P (EGF-like 
module receptor 4) (EGF-like 
module-containing mucin-like 
hormone receptor-like 4) (G-
protein coupled receptor 127) (G-
protein coupled receptor PGR16) 
Q92485 ASM3B SMPDL3B ASML3B Acid sphingomyelinase-like 
phosphodiesterase 3b (ASM-like 
phosphodiesterase 3b) (EC 3.1.4.-) 
Proteins functionally related to energy production and metabolism 
Q96PD5 PGRP2 PGLYRP2 PGLYRPL PGRPL 
UNQ3103/PRO10102 
N-acetylmuramoyl-L-alanine 
amidase (EC 3.5.1.28) 
(Peptidoglycan recognition protein 
2) (Peptidoglycan recognition 
protein long) (PGRP-L) 
P01242 SOM2 GH2 Growth hormone variant (GH-V) 
(Growth hormone 2) (Placenta-
specific growth hormone) 
P22303 ACES ACHE Acetylcholinesterase (AChE) (EC 
3.1.1.7) 
Q15848 ADIPO ADIPOQ ACDC ACRP30 
APM1 GBP28 
Adiponectin (30 kDa adipocyte 
complement-related protein) 
(Adipocyte complement-related 30 
kDa protein) (ACRP30) 
(Adipocyte, C1q and collagen 
domain-containing protein) 
(Adipose most abundant gene 
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transcript 1 protein) (apM-1) 
(Gelatin-binding protein) 
Q9BRR6 ADPGK ADPGK PSEC0260 ADP-dependent glucokinase 
(ADP-GK) (ADPGK) (EC 
2.7.1.147) (RbBP-35) 
P43652 AFAM AFM ALB2 ALBA Afamin (Alpha-albumin) (Alpha-
Alb) 
P04745 AMY1 AMY1A AMY1; AMY1B 
AMY1; AMY1C AMY1 
Alpha-amylase 1 (EC 3.2.1.1) 
(1,4-alpha-D-glucan 
glucanohydrolase 1) (Salivary 
alpha-amylase) 
P19961 AMY2B AMY2B Alpha-amylase 2B (EC 3.2.1.1) 
(1,4-alpha-D-glucan 
glucanohydrolase 2B) (Carcinoid 
alpha-amylase) 
P02743 SAMP APCS PTX2 Serum amyloid P-component 
(SAP) (9.5S alpha-1-glycoprotein) 
[Cleaved into: Serum amyloid P-
component(1-203)] 
P02652 APOA2 APOA2 Apolipoprotein A-II (Apo-AII) 
(ApoA-II) (Apolipoprotein A2) 
[Cleaved into: Proapolipoprotein 
A-II (ProapoA-II); Truncated 
apolipoprotein A-II 
(Apolipoprotein A-II(1-76))] 
P04114 APOB APOB   
Q13790 APOF APOF Apolipoprotein F (Apo-F) (Lipid 
transfer inhibitor protein) (LTIP) 
Q9BPW4 APOL4 APOL4 Apolipoprotein L4 
(Apolipoprotein L-IV) (ApoL-IV) 
O95445 APOM APOM G3A NG20 HSPC336 Apolipoprotein M (Apo-M) 
(ApoM) (Protein G3a) 
Q9BUR5 MIC26 APOO FAM121B MIC23 
MIC26 My025 
UNQ1866/PRO4302 
MICOS complex subunit MIC26 
(Apolipoprotein O) (MICOS 
complex subunit MIC23) (Protein 
FAM121B) 
P54793 ARSF ARSF Arylsulfatase F (ASF) (EC 3.1.6.-) 
Q5FYB1 ARSI ARSI Arylsulfatase I (ASI) (EC 3.1.6.-) 
Q5FYB0 ARSJ ARSJ UNQ372/PRO708 Arylsulfatase J (ASJ) (EC 3.1.6.-) 
Q6UWY0 ARSK ARSK TSULF 
UNQ630/PRO1246 
Arylsulfatase K (ASK) (EC 3.1.6.-
) (Telethon sulfatase) 
P06276 CHLE BCHE CHE1 Cholinesterase (EC 3.1.1.8) 
(Acylcholine acylhydrolase) 
(Butyrylcholine esterase) (Choline 
esterase II) (Pseudocholinesterase) 
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P43251 BTD BTD Biotinidase (Biotinase) (EC 
3.5.1.12) 
P23280 CAH6 CA6 Carbonic anhydrase 6 (EC 4.2.1.1) 
(Carbonate dehydratase VI) 
(Carbonic anhydrase VI) (CA-VI) 
(Salivary carbonic anhydrase) 
(Secreted carbonic anhydrase) 
P08218 CEL2B CELA2B ELA2B Chymotrypsin-like elastase family 
member 2B (EC 3.4.21.71) 
(Elastase-2B) 
Q9UKY3 CES1P CES1P1 CES4 Putative inactive carboxylesterase 
4 (Inactive carboxylesterase 1 
pseudogene 1) (Placental 
carboxylesterase 3) (PCE-3) 
Q5XG92 EST4A CES4A CES8 
UNQ440/PRO873 
Carboxylesterase 4A (EC 3.1.1.-) 
P11597 CETP CETP Cholesteryl ester transfer protein 
(Lipid transfer protein I) 
Q92496 FHR4 CFHR4 CFHL4 FHR4 Complement factor H-related 
protein 4 (FHR-4) 
Q9BZP6 CHIA CHIA Acidic mammalian chitinase 
(AMCase) (EC 3.2.1.14) (Lung-
specific protein TSA1902) 
Q6UXF7 CL18B CLEC18B MRLP1 
UNQ306/PRO347 
C-type lectin domain family 18 
member B (Mannose receptor-like 
protein 1) 
Q8NCF0 CL18C CLEC18C MRLP3 C-type lectin domain family 18 
member C (Mannose receptor-like 
protein 3) 
P04118 COL CLPS Colipase 
Q6UWE3 COLL2 CLPSL2 C6orf126 
UNQ3045/PRO9861 
Colipase-like protein 2 
Q96KN2 CNDP1 CNDP1 CN1 CPGL2 
UNQ1915/PRO4380 
Beta-Ala-His dipeptidase (EC 
3.4.13.20) (CNDP dipeptidase 1) 
(Carnosine dipeptidase 1) 
(Glutamate carboxypeptidase-like 
protein 2) (Serum carnosinase) 
P15085 CBPA1 CPA1 CPA Carboxypeptidase A1 (EC 
3.4.17.1) 
P48052 CBPA2 CPA2 Carboxypeptidase A2 (EC 
3.4.17.15) 
Q8N4T0 CBPA6 CPA6 CPAH Carboxypeptidase A6 (EC 3.4.17.-
) 
P15086 CBPB1 CPB1 CPB PCPB Carboxypeptidase B (EC 3.4.17.2) 
(Pancreas-specific protein) 
(PASP) 
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Q96IY4 CBPB2 CPB2 Carboxypeptidase B2 (EC 
3.4.17.20) (Carboxypeptidase U) 
(CPU) (Plasma carboxypeptidase 
B) (pCPB) (Thrombin-activable 
fibrinolysis inhibitor) (TAFI) 
P16870 CBPE CPE Carboxypeptidase E (CPE) (EC 
3.4.17.10) (Carboxypeptidase H) 
(CPH) (Enkephalin convertase) 
(Prohormone-processing 
carboxypeptidase) 
P17538 CTRB1 CTRB1 CTRB Chymotrypsinogen B (EC 
3.4.21.1) [Cleaved into: 
Chymotrypsin B chain A; 
Chymotrypsin B chain B; 
Chymotrypsin B chain C] 
Q6PKH6 DR4L2 DHRS4L2 SDR25C3 Dehydrogenase/reductase SDR 
family member 4-like 2 (EC 1.1.-.-
) (Short chain 
dehydrogenase/reductase family 
25C member 3) 
A6NNS2 DRS7C DHRS7C SDR32C2 Dehydrogenase/reductase SDR 
family member 7C (EC 1.1.-.-) 
(Short-chain 
dehydrogenase/reductase family 
32C member 2) 
Q9UGM3 DMBT1 DMBT1 GP340   
O75356 ENTP5 ENTPD5 CD39L4 PCPH Ectonucleoside triphosphate 
diphosphohydrolase 5 (NTPDase 
5) (EC 3.6.1.6) (CD39 antigen-like 
4) (ER-UDPase) (Guanosine-
diphosphatase ENTPD5) (GDPase 
ENTPD5) (EC 3.6.1.42) 
(Nucleoside diphosphatase) 
(Uridine-diphosphatase ENTPD5) 
(UDPase ENTPD5) 
Q8NAU1 FNDC5 FNDC5 FRCP2 Fibronectin type III domain-
containing protein 5 (Fibronectin 
type III repeat-containing protein 
2) [Cleaved into: Irisin] 
Q92820 GGH GGH Gamma-glutamyl hydrolase (EC 
3.4.19.9) (Conjugase) (GH) 
(Gamma-Glu-X carboxypeptidase) 
P27352 IF GIF IFMH Gastric intrinsic factor (Intrinsic 
factor) (IF) (INF) 
Q6UWU2 GLB1L GLB1L UNQ229/PRO262 Beta-galactosidase-1-like protein 
(EC 3.2.1.-) 
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Q96SL4 GPX7 GPX7 GPX6 UNQ469/PRO828 Glutathione peroxidase 7 (GPx-7) 
(GSHPx-7) (EC 1.11.1.9) (CL683) 
Q16661 GUC2B GUCA2B Guanylate cyclase activator 2B 
[Cleaved into: Guanylate cyclase 
C-activating peptide 2 (Guanylate 
cyclase C-activating peptide II) 
(GCAP-II); Uroguanylin (UGN)] 
P81172 HEPC HAMP HEPC LEAP1 
UNQ487/PRO1003 
Hepcidin (Liver-expressed 
antimicrobial peptide 1) (LEAP-1) 
(Putative liver tumor regressor) 
(PLTR) [Cleaved into: Hepcidin-
25 (Hepc25); Hepcidin-20 
(Hepc20)] 
P10997 IAPP IAPP Islet amyloid polypeptide 
(Amylin) (Diabetes-associated 
peptide) (DAP) (Insulinoma 
amyloid peptide) 
P01569 IFNA5 IFNA5 Interferon alpha-5 (IFN-alpha-5) 
(Interferon alpha-61) (Interferon 
alpha-G) (LeIF G) 
Q6UW32 IGFL1 IGFL1 UNQ644/PRO1274 Insulin growth factor-like family 
member 2 
Q6UWQ7 IGFL2 IGFL2 UNQ645/PRO1275 Insulin growth factor-like family 
member 3 
Q6UXB1 IGFL3 IGFL3 UNQ483/PRO982 
P01308 INS INS Insulin [Cleaved into: Insulin B 
chain; Insulin A chain] 
P04180 LCAT LCAT Phosphatidylcholine-sterol 
acyltransferase (EC 2.3.1.43) 
(Lecithin-cholesterol 
acyltransferase) (Phospholipid-
cholesterol acyltransferase) 
Q6JVE5 LCN12 LCN12 Epididymal-specific lipocalin-12 
Q5VSP4 LC1L1 LCN1P1 LCN1L1 Putative lipocalin 1-like protein 1 
(Lipocalin 1-like pseudogene 1) 
Q8WX39 LCN9 LCN9 Epididymal-specific lipocalin-9 
(MUP-like lipocalin) 
P48357 LEPR LEPR DB OBR   
P11150 LIPC LIPC HTGL Hepatic triacylglycerol lipase (HL) 
(Hepatic lipase) (EC 3.1.1.3) 
(Lipase member C) 
P07098 LIPG LIPF Gastric triacylglycerol lipase (GL) 
(Gastric lipase) (EC 3.1.1.3) 
Q9Y5X9 LIPE LIPG UNQ387/PRO719 Endothelial lipase (EC 3.1.1.3) 
(Endothelial cell-derived lipase) 
(EDL) (EL) 
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Q8WWY
8 
LIPH LIPH LPDLR MPAPLA1 
PLA1B 
Lipase member H (LIPH) (EC 
3.1.1.-) (LPD lipase-related 
protein) (Membrane-associated 
phosphatidic acid-selective 
phospholipase A1-alpha) (mPA-
PLA1 alpha) (Phospholipase A1 
member B) 
Q6XZB0 LIPI LIPI LPDL PRED5 Lipase member I (LIPI) (EC 
3.1.1.-) (Cancer/testis antigen 17) 
(CT17) (LPD lipase) (Membrane-
associated phosphatidic acid-
selective phospholipase A1-beta) 
(mPA-PLA1 beta) 
Q5VXJ0 LIPK LIPK LIPL2 Lipase member K (EC 3.1.1.-) 
(Lipase-like abhydrolase domain-
containing protein 2) 
Q5VYY2 LIPM LIPM LIPL3 Lipase member M (EC 3.1.1.-) 
(Lipase-like abhydrolase domain-
containing protein 3) 
Q5VXI9 LIPN LIPN LIPL4 Lipase member N (EC 3.1.1.-) 
(Lipase-like abhydrolase domain-
containing protein 4) 
P06858 LIPL LPL LIPD Lipoprotein lipase (LPL) (EC 
3.1.1.34) 
Q9Y2E5 MA2B2 MAN2B2 KIAA0935   
Q08431 MFGM MFGE8   
A6NG13 MGT4D MGAT4D Alpha-1,3-mannosyl-glycoprotein 
4-beta-N-
acetylglucosaminyltransferase-like 
protein MGAT4D (EC 2.4.1.-) 
O96009 NAPSA NAPSA NAP1 NAPA Napsin-A (EC 3.4.23.-) (Aspartyl 
protease 4) (ASP4) (Asp 4) 
(Napsin-1) (TA01/TA02) 
P61916 NPC2 NPC2 HE1 Epididymal secretory protein E1 
(Human epididymis-specific 
protein 1) (He1) (Niemann-Pick 
disease type C2 protein) 
P0DJD8 PEPA3 PGA3 Pepsin A-3 (EC 3.4.23.1) 
(Pepsinogen-3) 
P0DJD7 PEPA4 PGA4 Pepsin A-4 (EC 3.4.23.1) 
(Pepsinogen-4) 
P0DJD9 PEPA5 PGA5 Pepsin A-5 (EC 3.4.23.1) 
(Pepsinogen-5) 
P20142 PEPC PGC Gastricsin (EC 3.4.23.3) 
(Pepsinogen C) 
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O43692 PI15 PI15 CRISP8 P25TI Peptidase inhibitor 15 (PI-15) (25 
kDa trypsin inhibitor) (p25TI) 
(Cysteine-rich secretory protein 8) 
(CRISP-8) (SugarCrisp) 
Q53H76 PLA1A PLA1A NMD PSPLA1 Phospholipase A1 member A (EC 
3.1.1.-) (Phosphatidylserine-
specific phospholipase A1) (PS-
PLA1) 
H3BRW4 H3BRW
4 
PLA2G10 hCG_1746186 Phospholipase A(2) (EC 3.1.1.4) 
Q8NCC3 PAG15 PLA2G15 LYPLA3 
UNQ341/PRO540 
Group XV phospholipase A2 (EC 
2.3.1.-) (1-O-acylceramide 
synthase) (ACS) (LCAT-like 
lysophospholipase) (LLPL) 
(Lysophospholipase 3) 
(Lysosomal phospholipase A2) 
(LPLA2) 
P04054 PA21B PLA2G1B PLA2 PLA2A 
PPLA2 
Phospholipase A2 (EC 3.1.1.4) 
(Group IB phospholipase A2) 
(Phosphatidylcholine 2-
acylhydrolase 1B) 
Q5R387 PA2GC PLA2G2C Putative inactive group IIC 
secretory phospholipase A2 
(Phosphatidylcholine 2-
acylhydrolase-like protein GIIC) 
Q13093 PAFA PLA2G7 PAFAH Platelet-activating factor 
acetylhydrolase (PAF 
acetylhydrolase) (EC 3.1.1.47) (1-
alkyl-2-
acetylglycerophosphocholine 
esterase) (2-acetyl-1-
alkylglycerophosphocholine 
esterase) (Group-VIIA 
phospholipase A2) (gVIIA-PLA2) 
(LDL-associated phospholipase 
A2) (LDL-PLA(2)) (PAF 2-
acylhydrolase) 
P55058 PLTP PLTP Phospholipid transfer protein 
(Lipid transfer protein II) 
P16233 LIPP PNLIP Pancreatic triacylglycerol lipase 
(PL) (PTL) (Pancreatic lipase) 
(EC 3.1.1.3) 
P54315 LIPR1 PNLIPRP1 PLRP1 Inactive pancreatic lipase-related 
protein 1 (PL-RP1) 
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P54317 LIPR2 PNLIPRP2 PLRP2 Pancreatic lipase-related protein 2 
(PL-RP2) (EC 3.1.1.26) (EC 
3.1.1.3) (Galactolipase) 
Q17RR3 LIPR3 PNLIPRP3 Pancreatic lipase-related protein 3 
(PL-RP3) (EC 3.1.1.3) 
P27169 PON1 PON1 PON Serum paraoxonase/arylesterase 1 
(PON 1) (EC 3.1.1.2) (EC 
3.1.1.81) (EC 3.1.8.1) (Aromatic 
esterase 1) (A-esterase 1) (K-45) 
(Serum aryldialkylphosphatase 1) 
Q15166 PON3 PON3 Serum paraoxonase/lactonase 3 
(EC 3.1.1.2) (EC 3.1.1.81) (EC 
3.1.8.1) 
Q13162 PRDX4 PRDX4 Peroxiredoxin-4 (EC 1.11.1.15) 
(Antioxidant enzyme AOE372) 
(AOE37-2) (Peroxiredoxin IV) 
(Prx-IV) (Thioredoxin peroxidase 
AO372) (Thioredoxin-dependent 
peroxide reductase A0372) 
P04070 PROC PROC Vitamin K-dependent protein C 
Q9BQR3 PRS27 PRSS27 MPN 
UNQ1884/PRO4327 
Serine protease 27 (EC 3.4.21.-) 
(Marapsin) (Pancreasin) 
P07602 SAP PSAP GLBA SAP1 Prosaposin (Proactivator 
polypeptide) [Cleaved into: 
Saposin-A (Protein A); Saposin-B-
Val; Saposin-B (Cerebroside 
sulfate activator) (CSAct) 
(Dispersin) (Sphingolipid activator 
protein 1) (SAP-1) 
(Sulfatide/GM1 activator); 
Saposin-C (A1 activator) (Co-
beta-glucosidase) 
(Glucosylceramidase activator) 
(Sphingolipid activator protein 2) 
(SAP-2); Saposin-D (Component 
C) (Protein C)] 
Q6NUJ1 SAPL1 PSAPL1 Proactivator polypeptide-like 1 
[Cleaved into: Saposin A-like; 
Saposin B-Val-like; Saposin B-
like; Saposin C-like; Saposin D-
like] 
Q9NRI6 PYY2 PYY2 Putative peptide YY-2 (Putative 
peptide YY2) 
P02753 RET4 RBP4 PRO2222 Retinol-binding protein 4 (Plasma 
retinol-binding protein) (PRBP) 
(RBP) [Cleaved into: Plasma 
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retinol-binding protein(1-182); 
Plasma retinol-binding protein(1-
181); Plasma retinol-binding 
protein(1-179); Plasma retinol-
binding protein(1-176)] 
P05451 REG1A REG1A PSPS PSPS1 REG Lithostathine-1-alpha (Islet cells 
regeneration factor) (ICRF) (Islet 
of Langerhans regenerating 
protein) (REG) (Pancreatic stone 
protein) (PSP) (Pancreatic thread 
protein) (PTP) (Regenerating islet-
derived protein 1-alpha) (REG-1-
alpha) (Regenerating protein I 
alpha) 
P35542 SAA4 SAA4 CSAA Serum amyloid A-4 protein 
(Constitutively expressed serum 
amyloid A protein) (C-SAA) 
Q8IW75 SPA12 SERPINA12 Serpin A12 (OL-64) (Visceral 
adipose tissue-derived serine 
protease inhibitor) (Vaspin) 
(Visceral adipose-specific serpin) 
Q9HAT2 SIAE SIAE YSG2 Sialate O-acetylesterase (EC 
3.1.1.53) (H-Lse) (Sialic acid-
specific 9-O-acetylesterase) 
P17405 ASM SMPD1 ASM Sphingomyelin phosphodiesterase 
(EC 3.1.4.12) (Acid 
sphingomyelinase) (aSMase) 
Q92484 ASM3A SMPDL3A ASML3A Acid sphingomyelinase-like 
phosphodiesterase 3a (ASM-like 
phosphodiesterase 3a) (EC 3.1.4.-) 
P00995 ISK1 SPINK1 PSTI Serine protease inhibitor Kazal-
type 1 (Pancreatic secretory 
trypsin inhibitor) (Tumor-
associated trypsin inhibitor) 
(TATI) 
P20061 TCO1 TCN1 TC1 Transcobalamin-1 (TC-1) 
(Haptocorrin) (HC) (Protein R) 
(Transcobalamin I) (TC I) (TCI) 
P20062 TCO2 TCN2 TC2 Transcobalamin-2 (TC-2) 
(Transcobalamin II) (TC II) (TCII) 
P01222 TSHB TSHB Thyrotropin subunit beta 
(Thyroid-stimulating hormone 
subunit beta) (TSH-B) (TSH-beta) 
(Thyrotropin beta chain) 
(Thyrotropin alfa) 
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P02766 TTHY TTR PALB Transthyretin (ATTR) 
(Prealbumin) (TBPA) 
P55089 UCN1 UCN Urocortin 
O95399 UTS2 UTS2 UNQ525/PRO1068 Urotensin-2 (Urotensin II) (U-II) 
(UII) 
Q765I0 UTS2B UTS2B URP UTS2D Urotensin-2B (Urotensin II-related 
peptide) (Urotensin IIB) (U-IIB) 
(UIIB) (Urotensin-2 domain-
containing protein) 
Q13231 CHIT1 CHIT1 Chitotriosidase-1 (EC 3.2.1.14) 
(Chitinase-1) 
A5D8T8 CL18A CLEC18A MRLP2 C-type lectin domain family 18 
member A (Mannose receptor-like 
protein 2) 
P04746 AMYP AMY2A Pancreatic alpha-amylase (PA) 
(EC 3.2.1.1) (1,4-alpha-D-glucan 
glucanohydrolase) 
P80188 NGAL LCN2 HNL NGAL Neutrophil gelatinase-associated 
lipocalin (NGAL) (25 kDa alpha-
2-microglobulin-related subunit of 
MMP-9) (Lipocalin-2) (Oncogene 
24p3) (Siderocalin LCN2) (p25) 
Q9NZK5 CECR1 CECR1 ADA2 ADGF IDGFL Adenosine deaminase CECR1 (EC 
3.5.4.4) (Cat eye syndrome critical 
region protein 1) 
Proteins of unknown function 
Q6P093 ADCL2 AADACL2 Arylacetamide deacetylase-like 2 
(EC 3.1.1.-) 
Q5VST6 AB17B ABHD17B C9orf77 FAM108B1 
CGI-67 
Protein ABHD17B (EC 3.-.-.-) 
(Alpha/beta hydrolase domain-
containing protein 17B) 
(Abhydrolase domain-containing 
protein 17B) 
O43827 ANGL7 ANGPTL7 CDT6 
UNQ313/PRO356 
Angiopoietin-related protein 7 
(Angiopoietin-like factor) 
(Angiopoietin-like protein 7) 
(Cornea-derived transcript 6 
protein) 
P0DMC3 ELA APELA ELA TDL Apelin receptor early endogenous 
ligand (Protein Elabela) (Protein 
Toddler) 
Q86Y30 BAGE2 BAGE2 B melanoma antigen 2 
(Cancer/testis antigen 2.2) (CT2.2) 
Q86Y29 BAGE3 BAGE3 B melanoma antigen 3 
(Cancer/testis antigen 2.3) (CT2.3) 
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Q86Y28 BAGE4 BAGE4 MLL3P B melanoma antigen 4 
(Cancer/testis antigen 2.4) (CT2.4) 
Q7Z5Y6 BMP8A BMP8A Bone morphogenetic protein 8A 
(BMP-8A) 
P34820 BMP8B BMP8B BMP8 Bone morphogenetic protein 8B 
(BMP-8) (BMP-8B) (Osteogenic 
protein 2) (OP-2) 
Q86YQ2 LATH BPIFA4P BASE LATH Putative BPIFA4P protein (BPI 
fold containing family A, member 
4, pseudogene) (Breast cancer and 
salivary gland-expressed protein) 
(Putative latherin) 
Q8N4F0 BPIB2 BPIFB2 BPIL1 C20orf184 
LPLUNC2 UNQ2489/PRO5776 
BPI fold-containing family B 
member 2 
(Bactericidal/permeability-
increasing protein-like 1) (BPI-
like 1) (Long palate, lung and 
nasal epithelium carcinoma-
associated protein 2) (RYSR) 
P59827 BPIB4 BPIFB4 C20orf186 LPLUNC4 BPI fold-containing family B 
member 4 (Ligand-binding protein 
RY2G5) (Long palate, lung and 
nasal epithelium carcinoma-
associated protein 4) 
Q8NFQ5 BPIB6 BPIFB6 BPIL3 BPI fold-containing family B 
member 6 
(Bactericidal/permeability-
increasing protein-like 3) 
Q8N8R5 CB069 C2orf69 UPF0565 protein C2orf69 
P23435 CBLN1 CBLN1 Cerebellin-1 (Precerebellin) 
[Cleaved into: Cerebellin (CER); 
[des-Ser1]-cerebellin] 
Q6UW01 CBLN3 CBLN3 UNQ755/PRO1486 Cerebellin-3 
Q9NTU7 CBLN4 CBLN4 CBLNL1 
UNQ718/PRO1382 
Cerebellin-4 (Cerebellin-like 
glycoprotein 1) 
Q9H6E4 CC134 CCDC134 Coiled-coil domain-containing 
protein 134 
Q04900 MUC24 CD164 Sialomucin core protein 24 
(MUC-24) (Endolyn) (Multi-
glycosylated core protein 24) 
(MGC-24) (MGC-24v) (CD 
antigen CD164) 
Q5VXM1 CDCP2 CDCP2 CUB domain-containing protein 2 
Q6NT32 EST5A CES5A CES7 Carboxylesterase 5A (EC 3.1.1.1) 
(Carboxylesterase-like urinary 
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excreted protein homolog) 
(Cauxin) 
P01215 GLHA CGA Glycoprotein hormones alpha 
chain (Anterior pituitary 
glycoprotein hormones common 
subunit alpha) 
(Choriogonadotropin alpha chain) 
(Chorionic gonadotrophin subunit 
alpha) (CG-alpha) (Follicle-
stimulating hormone alpha chain) 
(FSH-alpha) (Follitropin alpha 
chain) (Luteinizing hormone alpha 
chain) (LSH-alpha) (Lutropin 
alpha chain) (Thyroid-stimulating 
hormone alpha chain) (TSH-alpha) 
(Thyrotropin alpha chain) 
H9KV56 H9KV56 CGB2 Choriogonadotropin subunit beta 
variant 2 
P0DN87 CGB7 CGB7 Choriogonadotropin subunit beta 7 
Q9BWS9 CHID1 CHID1 GL008 PSEC0104 
SB139 
Chitinase domain-containing 
protein 1 (Stabilin-1-interacting 
chitinase-like protein) (SI-CLP) 
Q9Y6N3 CLCA3 CLCA3P CLCA3 Calcium-activated chloride 
channel regulator family member 
3 (Calcium-activated chloride 
channel family member 3) 
(hCLCA3) 
A2RUU4 COLL1 CLPSL1 C6orf127 Colipase-like protein 1 
Q9UI42 CBPA4 CPA4 CPA3 
UNQ694/PRO1339 
Carboxypeptidase A4 (EC 3.4.17.-
) (Carboxypeptidase A3) 
Q8WXQ8 CBPA5 CPA5 Carboxypeptidase A5 (EC 3.4.17.-
) 
P15169 CBPN CPN1 ACBP Carboxypeptidase N catalytic 
chain (CPN) (EC 3.4.17.3) 
(Anaphylatoxin inactivator) 
(Arginine carboxypeptidase) 
(Carboxypeptidase N polypeptide 
1) (Carboxypeptidase N small 
subunit) (Kininase-1) (Lysine 
carboxypeptidase) (Plasma 
carboxypeptidase B) (Serum 
carboxypeptidase N) (SCPN) 
P22792 CPN2 CPN2 ACBP Carboxypeptidase N subunit 2 
(Carboxypeptidase N 83 kDa 
chain) (Carboxypeptidase N large 
subunit) (Carboxypeptidase N 
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polypeptide 2) (Carboxypeptidase 
N regulatory subunit) 
P24387 CRHBP CRHBP CRFBP Corticotropin-releasing factor-
binding protein (CRF-BP) (CRF-
binding protein) (Corticotropin-
releasing hormone-binding 
protein) (CRH-BP) 
P07498 CASK CSN3 CASK CSN10 CSNK Granulocyte colony-stimulating 
factor (G-CSF) (Pluripoietin) 
(Filgrastim) (Lenograstim) 
P09228 CYTT CST2 Cystatin-SA (Cystatin-2) 
(Cystatin-S5) 
Q5W188 CST9P CST9LP1 Putative cystatin-9-like protein 
CST9LP1 (Cystatin-9-like 
pseudogene 1) 
Q6UWP2 DHR11 DHRS11 SDR24C1 
UNQ836/PRO1774 
Dehydrogenase/reductase SDR 
family member 11 (EC 1.1.-.-) 
(Short-chain 
dehydrogenase/reductase family 
24C member 1) 
P24855 DNAS1 DNASE1 DNL1 DRNI Deoxyribonuclease-1 (EC 
3.1.21.1) (Deoxyribonuclease I) 
(DNase I) (Dornase alfa) 
Q7Z5P4 DHB13 HSD17B13 SCDR9 SDR16C3 
HMFN0376 UNQ497/PRO1014 
17-beta-hydroxysteroid 
dehydrogenase 13 (17-beta-HSD 
13) (EC 1.1.-.-) (Short chain 
dehydrogenase/reductase family 
16C member 3) (Short-chain 
dehydrogenase/reductase 9) 
Q8N0V4 LGI2 LGI2 KIAA1916 LGIL2 Leucine-rich repeat LGI family 
member 2 (LGI1-like protein 2) 
(Leucine-rich glioma-inactivated 
protein 2) 
Q6UXI9 NPNT NPNT EGFL6L POEM 
UNQ295/PRO334 
Nephronectin (Preosteoblast EGF-
like repeat protein with MAM 
domain) (Protein EGFL6-like) 
Q9GZU5 NYX NYX CLRP Nyctalopin 
O95897 NOE2 OLFM2 NOE2 Noelin-2 (Olfactomedin-2) 
Q96PB7 NOE3 OLFM3 NOE3 
UNQ1924/PRO4399 
Noelin-3 (Olfactomedin-3) 
(Optimedin) 
A8MZH6 OOSP1 OOSP1 Putative oocyte-secreted protein 1 
homolog 
Q3ZCN5 OTOGL OTOGL C12orf64   
Q7RTZ1 OVCH2 OVCH2 OVTN Ovochymase-2 (EC 3.4.21.-) 
(Oviductin) 
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Q8WXA2 PATE1 PATE1 PATE Prostate and testis expressed 
protein 1 
Q6UY27 PATE2 PATE2 C11orf38 
UNQ3112/PRO10144 
Prostate and testis expressed 
protein 2 (PATE-like protein M) 
(PATE-M) 
B3GLJ2 PATE3 PATE3 Prostate and testis expressed 
protein 3 (Acrosomal vesicle 
protein HEL-127) (PATE-like 
protein DJ) (PATE-DJ) 
E5RFR1 E5RFR1 PENK Proenkephalin-A (Fragment) 
Q9HBJ0 PLAC1 PLAC1 Placenta-specific protein 1 
Q6GTS8 P20D1 PM20D1 Probable carboxypeptidase 
PM20D1 (EC 3.4.17.-) (Peptidase 
M20 domain-containing protein 1) 
Q9BSG0 PADC1 PRADC1 C2orf7 PAP21 UNQ833/PRO1760 
Q9P1C3 YN010 PRO2829 Putative uncharacterized protein 
PRO2829 
A6NIE9 PRS29 PRSS29P ISP2 Putative serine protease 29 (EC 
3.4.21.-) (Implantation serine 
proteinase 2-like protein) (ISP2-
like protein) 
A4D1T9 PRS37 PRSS37 TRYX2 Probable inactive serine protease 
37 (Probable inactive trypsin-X2) 
A1L453 PRS38 PRSS38 MPN2 Serine protease 38 (EC 3.4.21.-) 
(Marapsin-2) 
Q7Z5A4 PRS42 PRSS42 TESSP2 Serine protease 42 (EC 3.4.21.-) 
(Testis serine protease 2) 
E7EML9 PRS44 PRSS44 TESSP4 Serine protease 44 (EC 3.4.21.-) 
(Testis serine protease 4) (TESSP-
4) 
A8MTI9 PRS47 PRSS47 Putative serine protease 47 (EC 
3.4.21.-) 
Q7RTY5 PRS48 PRSS48 ESSPL Serine protease 48 (EC 3.4.21.-) 
(Epidermis-specific serine 
protease-like protein) 
Q6PEW0 PRS54 PRSS54 KLKBL4 Inactive serine protease 54 
(Cancer/testis antigen 67) (CT67) 
(Plasma kallikrein-like protein 4) 
Q8IYP2 PRS58 PRSS58 TRY1 TRYX3 
UNQ2540/PRO6090 
Serine protease 58 (EC 3.4.21.4) 
(Trypsin-X3) 
Q5JQD4 PYY3 PYY3 Putative peptide YY-3 (Putative 
peptide YY3) (PYY-III) 
P00797 RENI REN Renin (EC 3.4.23.15) 
(Angiotensinogenase) 
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P34096 RNAS4 RNASE4 RNS4 Ribonuclease 4 (RNase 4) (EC 
3.1.27.-) 
P11684 UTER SCGB1A1 CC10 CCSP UGB Uteroglobin (Clara cell 
phospholipid-binding protein) 
(CCPBP) (Clara cells 10 kDa 
secretory protein) (CC10) 
(Secretoglobin family 1A member 
1) (Urinary protein 1) (UP-1) 
(UP1) (Urine protein 1) 
Q8TD33 SG1C1 SCGB1C1 Secretoglobin family 1C member 
1 (Secretoglobin RYD5) 
P0DMR2 SG1C2 SCGB1C2 Secretoglobin family 1C member 
2 
Q9HB40 RISC SCPEP1 RISC SCP1 MSTP034 
UNQ265/PRO302 
Retinoid-inducible serine 
carboxypeptidase (EC 3.4.16.-) 
(Serine carboxypeptidase 1) 
Q9UK55 ZPI SERPINA10 ZPI 
UNQ707/PRO1358 
Protein Z-dependent protease 
inhibitor (PZ-dependent protease 
inhibitor) (PZI) (Serpin A10) 
P08185 CBG SERPINA6 CBG Corticosteroid-binding globulin 
(CBG) (Serpin A6) (Transcortin) 
P05543 THBG SERPINA7 TBG Thyroxine-binding globulin 
(Serpin A7) (T4-binding globulin) 
P05120 PAI2 SERPINB2 PAI2 PLANH2 Plasminogen activator inhibitor 2 
(PAI-2) (Monocyte Arg-serpin) 
(Placental plasminogen activator 
inhibitor) (Serpin B2) (Urokinase 
inhibitor) 
P0C7L1 ISK8 SPINK8 Serine protease inhibitor Kazal-
type 8 
Q5DT21 ISK9 SPINK9 LEKTI2 Serine protease inhibitor Kazal-
type 9 (Lymphoepithelial Kazal-
type-related inhibitor 2) 
P49223 SPIT3 SPINT3 Kunitz-type protease inhibitor 3 
(HKIB9) 
Q6UDR6 SPIT4 SPINT4 C20orf137 Kunitz-type protease inhibitor 4 
P01266 THYG TG   
Q9P2K2 TXD16 TXNDC16 KIAA1344   
P07911 UROM UMOD Uromodulin (Tamm-Horsfall 
urinary glycoprotein) (THP) 
[Cleaved into: Uromodulin, 
secreted form] 
Q6UY13 YB003 UNQ5830/PRO19650/PRO1981
6 
Putative uncharacterized protein 
UNQ5830/PRO19650/PRO19816 
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Q9H1F0 WF10A WFDC10A C20orf146 WAP10 WAP four-disulfide core domain 
protein 10A (Putative protease 
inhibitor WAP10A) 
Q8IUB3 WF10B WFDC10B WAP12 Protein WFDC10B 
Q8NEX5 WFDC9 WFDC9 WAP9 Protein WFDC9 
P60852 ZP1 ZP1 Zona pellucida sperm-binding 
protein 1 (Zona pellucida 
glycoprotein 1) (Zp-1) [Cleaved 
into: Processed zona pellucida 
sperm-binding protein 1] 
 
